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The transcription factor Cdx2 is required for the formation of several developmental 
lineages in the mouse embryo, and is thought to play different roles within the same 
lineage at different stages. The role of Cdx2 in establishing trophoblast fate has been 
extensively studied, but the reason for its continued expression in established 
trophoblast cells is less well understood.  
 
To explore this question, I generated ATAC-seq and RNA-seq libraries from wild-
type and Cdx2 knockdown trophoblast stem cells (TSCs) in vitro. ATAC-seq 
experiments show, as expected, that loss of Cdx2 causes decreased accessibility at 
CDX2 consensus binding sites. However, of the regions showing differential 
chromatin accessibility in Cdx2 knockdown cells, two thirds have increased 
accessibility. These sites are enriched for the TFAP2C consensus motif and footprint; 
Tfap2c is a TSC marker that plays a part in trophoblast differentiation by driving 
genome-wide increases in accessibility.  
 
Gene ontology analysis of sites with increased accessibility in Cdx2 knockdown cells 
suggests that these regulatory regions are associated with trophoblast giant cell 
(TGC) differentiation. Consistent with this observation, continued Cdx2 knockdown 
drives homogenous differentiation of trophoblast stem cells into trophoblast giant 
cells within days. Similarly, homozygous Cdx2 knockout TSCs are unstable and 
spontaneously differentiate into TGCs, although in this context cells appear to retain 
some ability to compensate.  
 
TSC differentiation can also be initiated in vitro by growth factor withdrawal, albeit in 
a heterogeneous manner. However, the sites of increased chromatin accessibility 
observed under these circumstances differ from those observed in Cdx2 knockdown 
cells. Moreover, although RNA-seq analysis shows that 87% of genes whose 
expression changes in Cdx2 knockdown cells are also mis-regulated during 





This work suggests that Cdx2 normally maintains ‘stemness’ in TSCs by preventing 
them from differentiating directly and homogeneously into TGCs. This gatekeeping 
role of Cdx2 differs from its earlier function in repressing pluripotency genes and 
suggests that Cdx2 is repurposed to play different roles within the trophoblast lineage. 
Furthermore, our work may finally provide a plausible mechanism by which half of 
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Chapter 1. Introduction 
The placenta is required for healthy foetal development. Defects in the placenta 
result in its dysfunction and the reduced transfer of nutrients to the foetus. As a result, 
placental insufficiency causes many developmental defects in utero and has also 
been shown to pre-dispose individuals to late-onset disease (reviewed in Gagnon, 
2003). Recent work by Perez-Garcia et al (2018) has shown that placenta 
insufficiency in mouse knockout models causes embryonic developmental defects 
directly and can exacerbate abnormal foetus development (Perez-Garcia et al., 
2018). Loss of many placental genes results in embryonic death, but this can be 
rescued by providing a normal placenta (Perez-Garcia et al., 2018, Guillemot et al., 
1994, Auman et al., 2002). For example, knockout of Caudal related 2 (Cdx2), a 
transcription factor known to by required for healthy placenta development, is 
embryonic lethal at embryonic day 4.5 (E4.5) (Strumpf et al., 2005). Tetraploid 
complementation assays, where Cdx2-null embryos are provided with a wildtype 
placenta, rescues early embryonic lethality (Chawengsaksophak et al., 2004). In the 
first trophoblast (placenta) cells, the trophectoderm, CDX2 is required to antagonise 
pluripotency genes, silencing them to promote placental development (Strumpf et 
al., 2005, Niwa et al., 2005). However, Cdx2 is expressed in trophoblast stem cell 
populations of the placenta long after this role becomes obsolete. What role Cdx2 
plays in trophoblast stems cells after lineage commitment remains unclear.  
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1.1 Early mammalian embryogenesis: making a blastocyst 
The self-organising mouse embryo is a model system used to understand early 
development and lineage commitment. However, mouse and human embryonic 
development differs both in timing and in the underlying transcriptional network. 
Here, I briefly outline what is known about mouse blastocyst formation and some key 
differences between early mouse and human development. 
1.1.1 The first lineage decision: trophectoderm or inner cell mass? 
After fertilisation, the zygote undergoes successive cell divisions (Chazaud and 
Yamanaka, 2016). Historically, all cells of the early morula embryo were thought to 
be identical, but these have since been shown to have a bias for different 
developmental lineages as early as the 4-cell stage (Kelly, 1977, Fujimori et al., 
2003, Tabansky et al., 2013). At the 8-cell stage, tension increases at the embryo 
surface, blastomeres form adherens junctions with one another and filipodia form 
over adjacent cells (De Vries et al., 2004, Fierro-Gonzalez et al., 2013, Maitre et al., 
2015). This process results in a morphological change known as compaction. During 
compaction, embryos become polarised and the outermost cells accumulate the cell 
polarity pathway proteins, PAR3, PAR6 and aPKC, F-actin and microvilli at the apical 
surface (Yamanaka et al., 2006, Plusa et al., 2005, Alarcon, 2010). Conversely, 
another polarity protein, PAR1, accumulates basolaterally at the surfaces of cells 
with high cell-cell contacts (Vinot et al., 2005). Combined, these events lead to the 
formation of outer polarised cells and inner non-polarised cells.  
 
Compacted and polarised 8-cell embryos undergo two further rounds of cell divisions 
(Chazaud and Yamanaka, 2016). Lineage commitment begins at the 16-cell stage 
and is complete by the 32-cell stage, when embryos undergo cavitation to form the 
blastocyst structure (Posfai et al., 2017). During this period, cells commit to one of 
two lineages: the trophectoderm (TE) and the inner cell mass (ICM) (Chazaud and 
Yamanaka, 2016). The outermost polarised cells commit to the TE, which generates 
the foetal proportion of the placenta, and the inner non-polarised cells commit to the 
ICM, which generates all other cell types (Chazaud and Yamanaka, 2016).  
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Commitment to the TE and the ICM is controlled by the differential activation of the 
Hippo signalling pathway in outer and inner cells (Nishioka et al., 2009, Cockburn et 
al., 2013, Hirate et al., 2013, Leung and Zernicka-Goetz, 2013). Briefly, within inner 
cells, phosphorylated AMOT localises to cell-cell adherens junctions, where it forms 
an active complex with NF2 and LATS1/2 (Hirate et al., 2013, Cockburn et al., 2013). 
Active Hippo signalling phosphorylates YAP, sequestering it to the cytoplasm and 
driving inner cells to acquire an ICM fate (Hirate et al., 2013, Leung and Zernicka-
Goetz, 2013). In outer cells, AMOT is localised to the apical surface of outer cells by 
polarity proteins, preventing binding to LATS1/2 and turning Hippo signalling off. This 
enables YAP to translocate to the nucleus and act as a co-factor for TEAD4 (Nishioka 
et al., 2009, Hirate et al., 2013, Leung and Zernicka-Goetz, 2013). Recent work has 
shown that aberrant mid-range Hippo signalling in outer cells results in the ectopic 
expression of the ICM marker SOX2. As a result, such cells are either internalised 
and become inner cells or undergo apoptosis (Frum et al., 2018).  
 
TEAD4 and the co-activator YAP activate the trophectoderm program in outer cells, 
inducing the expression of both Cdx2 and Gata3 (Nishioka et al., 2009, Ralston et 
al., 2010). Without Tead4, outer cells cannot commit to the trophoblast lineage, and 
embryos arrest after compaction (Nishioka et al., 2008, Yagi et al., 2007). Cdx2-null 
embryos can form blastocoel cavities, albeit briefly, and express some TE markers, 
indicating that Cdx2 is not required for lineage segregation (Strumpf et al., 2005, Wu 
et al., 2010). Instead, CDX2 antagonises and represses the expression of core 
pluripotency markers in the trophectoderm (Strumpf et al., 2005, Niwa et al., 2005). 
As a result, Cdx2-null embryos retain Oct4 and Nanog expression in the TE (Strumpf 
et al., 2005). Similarly, Oct4-null embryos express TE marker genes in the ICM 
(Nichols et al., 1998). Therefore, this antagonistic relationship between Cdx2 and 
Oct4 is critical to reinforce commitment to the TE or the ICM.  
1.1.2 Trophoblast lineage segregation in human embryos 
Differences in early mouse and human blastocyst development are numerous and 
have been reviewed in depth (Wamaitha and Niakan, 2018). The timing of 
developmental stages, including embryonic genome activation (EGA) and 
compaction, differs between human and mouse (Flach et al., 1982, Hamatani et al., 
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2004, Braude et al., 1988)(Nikas et al., 1996, Steptoe et al., 1971, Edwards et al., 
1981, Wamaitha and Niakan, 2018). Another critical difference between early mouse 
and human development is the timing of lineage segregation. In the mouse, 
segregation of the TE and ICM predates the decision in the ICM to form either the 
yolk sac primitive endoderm (PrE) or the embryo proper forming epiblast (Epi) 
lineages (reviewed in (Rossant, 2015) and (Chazaud and Yamanaka, 2016)). In 
contrast, formation of these lineages may be concurrent in humans, with all cells of 
the expanded blastocysts able to make TE, PrE and Epi cells (Petropoulos et al., 
2016, De Paepe et al., 2013).  
 
Additionally, the expression of known key lineage markers differs between human 
and mouse development. Whilst orthologs of some mouse TE markers are also 
expressed in human TE, such as GATA3, others are delayed or absent, such as 
CDX2 (Blakeley et al., 2015). Cdx2 is expressed before blastocyst formation in the 
mouse (Strumpf et al., 2005). In humans, CDX2 is only expressed in TE cells post-
cavitation at the 35-cell stage and is co-expressed with OCT4 (Chen et al., 2009a, 
Niakan and Eggan, 2013). This is comparable to the timing of CDX2 expression in 
cow, pig and rabbit embryos (Kuijk et al., 2008, Kobolak et al., 2009, Berg et al., 
2011, Bou et al., 2017). Differences in CDX2/Cdx2 expression between human and 
mouse TE may align with differences in timing of lineage commitment (Rossant, 
2015, Petropoulos et al., 2016). In humans, where lineage commitment occurs later, 
CDX2 and its downstream effectors may still be critical for the repression of OCT4 
expression (Niakan and Eggan, 2013).  
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1.2 Placental development and the trophoblast lineages 
The placenta is a critical interface between mother and foetus, enabling exchange of 
nutrients, waste products and secreting factors to maintain pregnancy (Rossant and 
Cross, 2001). Amniotes, including mammals, birds and reptiles, form four common 
extraembryonic membranes: the amnion, chorion, allantois and yolk sac. Chorio-
allantoic placentas of mammals are formed from both embryonic-derived and  
maternal-derived tissues. The epithelial proportion of chorio-allantoic placentae is 
derived from the trophectoderm (Mess and Ferner, 2010, Ferner and Mess, 2011). 
1.2.1 Mouse placental development 
The mouse has been used extensively as a model for placental development. There 
are multiple review articles that summarise our knowledge of mouse placental 
development to date (Rossant and Cross, 2001, Simmons and Cross, 2005, Watson 
and Cross, 2005, Woods et al., 2018, Rai and Cross, 2014). In this section, I will 
provide a brief overview of placental development and its specialised cell types. 
Figure 1.1b outlines the transition between different cell types and known marker 
genes during placental development.  
1.2.1.1 From one cell layer to functional placenta 
The fate of cells in the trophectoderm is dependent on their position. Those that 
directly overlay the ICM, the polar trophectoderm, receive FGF4 signalling and 
continue to proliferate (Rossant and Cross, 2001). The mural trophectoderm, which 
is not in contact with ICM, does not receive FGF4 signalling queues and ceases to 
proliferate (Gardner et al., 1973, Rossant and Cross, 2001). Mural trophectoderm 
cells differentiate into the first specialised trophoblast subtype: primary parietal 
trophoblast giant cells (p-TGCs). Differentiation to p-TGCs is considered to be the 
default differentiation pathway in the absence of signalling factors (Gardner et al., 
1973). After implantation, the polar trophectoderm continues to receive growth factor 
stimulation from the epiblast, which results in the formation of the stem cell 
compartments: the extraembryonic ectoderm (ExE) and later the chorionic ectoderm 
(Tanaka et al., 1998, Uy et al., 2002). As cells move away from FGF4 and TGF 
signalling in the ExE, they begin to differentiate and form the ectoplacental cone 
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(EPC). The EPC contains a pool of progenitor cells that co-express two antagonistic 
basic helix-hoop-helix (bHLH) transcription factors: Ascl2 and Hand1. Hand1 
expression promotes trophoblast giant cell (TGC) formation, while Ascl2 suppresses 
it (Carney et al., 1993, Scott et al., 2000). Other non-bHLH transcription factors, such 
as Snai1, also inhibits TGC differentiation in the EPC from 7.5 days post coitum 
(embryonic day 7.5 (E7.5)) (Nakayama et al., 1998).  
 
At gastrulation, at approximately E7.5, ExE cells in closest proximity to the embryo 
form the chorion. At E8.5, the chorion fuses with the embryonic mesoderm-derived 
allantois in a process called chorio-allantoic fusion to form an early placenta structure 
(reviewed in Watson and Cross, 2005). As the placenta continues to develop, foetal 
blood vessels invade the allantois and the ectoplacental cone is specified as 
spongiotrophoblast (SpT). At the same time, the chorion differentiates to form the 
labyrinth layer, which sits directly beneath the SpT layer (Figure 1.1a) (Adamson et 
al., 2002, Simmons et al., 2008, Simmons and Cross, 2005). By E14.5, the placenta 
is mature and fully functional. In all, there are three trophoblast layers: an outer p-
TGCs layer in direct contact with the maternal decidua, a SpT containing junctional 
zone and a labyrinth layer in which gas, nutrient and waste exchange occurs 
(Adamson et al., 2002).  
 




Figure 1.1: Cell types and structure of mouse placental development. a) Schematic representing the 
gross anatomical structure of the mouse placenta immediately after chorio-allantoic fusion (E8.5), an 
intermediate placenta time point (E9.5) and the mature placenta (E14.5). TGC = trophoblast giant cell, SpT 
= spongiotrophoblast, EPC = ectoplacental cone. b) An overview of the stem cell (blue), progenitor (purple) 
and specialised subtypes of the mouse placenta. Non-italicised genes are those that were used in qRT-
PCR experiments in this thesis. Red = Syncytiotrophoblast lineage, orange = spongiotrophoblast (SpT), 
Green = trophoblast giant cell (TGC), het = heterogeneous. 
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1.2.1.2 Trophoblast giant cells  
There are several specialised TGC subtypes that play unique roles in the placenta 
(reviewed in (Hemberger, 2008) and (Hu and Cross, 2010)). TGC have different 
functions, but have some universal characteristics. Firstly, all TGCs express the 
transcription factor Hand1, which is required for the formation of every TGC subtype 
(Simmons et al., 2007). Secondly, TGCs are large in size (Bevilacqua and 
Abrahamsohn, 1988). An increase in cell size occurs as TGC undergo successive 
rounds of endoreduplication (DNA replication without mitoses) resulting in up to 1000 
copies of the genome (Geng et al., 2003, Parisi et al., 2003). Lastly, mouse TGCs 
have a single, large nucleus which contains the endoreduplicated DNA (Simmons et 
al., 2007). It is unclear why endoreduplication is critical to TGC function. One 
potential explanation is that polyploidy is advantageous for growth and/or protein 
synthesis (Cross, 2014, Hemberger, 2008). TGCs secrete a diverse range of 
proteins, including cell adhesion molecules, proteinases and extracellular matrix; 
therefore, an increase protein production would be advantageous to cell function 
(Hemberger, 2008, Hu and Cross, 2010, Rai and Cross, 2014). TGCs are known to 
secrete prolactins, which differ between TGC subtypes, and are commonly used as 
a way to identify subgroups of TGCs (Figure 1.1b).  
1.2.1.2.1 Parietal trophoblast giant cells 
The mural trophectoderm differentiates into primary parietal trophoblast giant cells 
(p-TGCs). p-TGCs are thought to be important for attachment, implantation and 
decidua cell differentiation (Gardner et al., 1973, Hu and Cross, 2010). Post-
implantation, secondary p-TGCs are generated from the polar trophectoderm (Cross 
et al., 1994). However, only half of the secondary p-TGCs are derived from Tpbpa-
expressing progenitor cells in the ectoplacental cone (Simmons et al., 2007). p-TGCs 
that differentiate from the EPC uniquely express Prolactin-4a1 (Prl4a1), suggesting 
that this marker could be used to distinguish between progenitor derived p-TGCs 
and non-progenitor derived pTGCs (Ma and Linzer, 2000). In vitro, p-TGCs can also 
be formed by non-Tpbpa expressing precursors in the presence of retinoic acid, but 
these cells express Ascl2 during the derivation process, indicating that they still 
progress through an EPC-like fate (Yan et al., 2001, Simmons et al., 2007). 
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Additionally, p-TGCs are the only TGC subtype to express Prolactin-3d1 (Prl3d1), 
which is expressed until E10.5 in vivo (Simmons et al., 2007, Rawn et al., 2015).  
 
p-TGCs are components of the parietal yolk sac, which is a transient barrier structure 
responsible for the initial gas and nutrient exchange between mother and foetus after 
implantation (Welsh and Enders, 1987, Cross et al., 1994, Nau, 2001). In the 
established chorio-allantoic placenta, p-TGCs form an outer barrier that is in direct 
contact with the maternal decidua (Adamson et al., 2002, Hu and Cross, 2010). In 
all, p-TGCs are thought to be required for a broad range of functions, controlling 
various aspects of maternal placental physiology, such as vasculature, extracellular 
matrix and the hormonal changes required to maintain pregnancy (Hemberger, 2008, 
Hu and Cross, 2010).     
1.2.1.2.2 Spiral artery trophoblast giant cells 
As their name suggests, spiral artery trophoblast giant cells (SpA-TGCs) line 
maternal spiral arteries. Present from E8.5 onwards, this TGC subtype is highly 
invasive and migrates into the maternal decidua. Once migration is complete, the 
SpA-TGCs secrete factors to regulate arterial remodelling and line maternal spinal 
arteries (Adamson et al., 2002, Hu and Cross, 2010). As a result, this TGC subtype 
is critical for facilitating blood flow into the placenta. Lineage tracing studies indicate 
that almost all SpA-TGCs are derived from Tpbpa-positive precursors (Simmons et 
al., 2007). More recent evidence shows that SpA-TGC precursors express Blimp1 
(Mould et al., 2012).   
1.2.1.2.3 Canal trophoblast giant cells  
Canal TGCs (c-TGCs) are structurally important for lining the maternal blood canals, 
(Simmons et al., 2007, Hu and Cross, 2010). The first c-TGCs are specified by E10.5, 
and they are continually generated to cover the increasing surface area of the 
maternal blood canals during development (Mould et al., 2012). The developmental 
origin of c-TGCs is heterogeneous. Whilst half of c-TGCs are derived from Tpbpa 
expressing progenitors in the outer EPC and spongiotrophoblast, the other half are 
derived from non-Tpbpa expressing populations from the inner EPC and chorion 
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(Simmons et al., 2007). More recent data has shown that c-TGCs are derived from 
Blimp1 co-expressing progenitors in the EPC (Mould et al., 2012). 
1.2.1.2.4 Sinusoidal trophoblast giant cells 
Maternal blood pools in sinusoids within the labyrinth layer of the mature placenta. 
The sinusoidal spaces are lined by sinusoidal TGCs (s-TGCs) and are the main 
source of nutrient exchange in the placenta (Rai and Cross, 2014). All s-TGCs come 
from precursor populations that have never expressed Tpbpa (Simmons et al., 2007). 
Instead, s-TGCs are derived from s-TGC precursors in the chorion that are present 
from E8.5 onwards (Simmons et al., 2008). s-TGCs are known to secrete hormones, 
including Prolactin-2c2 (Prl2c2) or other proteins such as Cathepsin Q (Ctsq). Given 
the proximity of s-TGCs to both maternal and foetal circulation, they may play a role 
in modulating growth factor and hormones (Rai and Cross, 2014, Hu and Cross, 
2010).  
1.2.1.2.5 Channel trophoblast giant cells  
Channel TGCs (Ch-TGCs) form channels that help move maternal blood away from 
sinusoids in the labyrinth layer after gas and nutrient exchange. The channels attach 
to p-TGC lined lacunae that are connected to the uterine veins (Rai and Cross, 2014). 
Thought to derive specifically from differentiation in the EPC, Ch-TGCs are one of 
only two TGC subtypes to express the marker Cathepsin Q (Ctsq) and co-express 
Prolactin-2c2 (Prl2c2) (Rai and Cross, 2015).  
1.2.1.3 Junctional zone cell types 
The junctional zone, derived from the ectoplacental cone, sits between the outer p-
TGC layer and inner labyrinth layer (Figure 1.1a) (Adamson et al., 2002, Rai and 
Cross, 2014). This region contains spongiotrophoblast and glycogen cells.  
1.2.1.3.1 Spongiotrophoblast  
Spongiotrophoblast (SpT) cells are heterogeneous in appearance over time. Unlike 
at earlier stages of placental development, E16.5 SpT cells contain extensive 
endoplasmic reticulum (Coan et al., 2005). Such extensive endoplasmic reticulum 
may be required to produce the endocrine factors they secrete (Coan et al., 2005). 
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By E16.5, it is thought that the SpT cells themselves could support the signalling 
needs until the end of gestation (Coan et al., 2006). Therefore, SpT cells probably 
play a functional role in modulating maternal and/or foetal physiology (Coan et al., 
2005). In addition, SpT may provide structural support for sinusoid development in 
the underlying labyrinth zone (Simmons and Cross, 2005). 
1.2.1.3.2 Glycogen trophoblast 
Glycogen trophoblast cell (GTC) progenitors are found in the ectoplacental cone as 
early as E7.5 (Tesser et al., 2010). Glycogen found in GTC progenitors is 
metabolised into glucose to serve as an energy source to the migrating GTCs 
(Tesser et al., 2010). As GTCs mature, the nucleus condenses and glycogen 
granules form (Coan et al., 2005, Coan et al., 2006). By E12 mature GTCs are found 
in the maternal decidua having migrated out to this region from the junctional zone 
(Adamson et al., 2002, Simmons and Cross, 2005). Here, GTCs are thought to be a 
key source of energy when demand is high at the latter stages of gestation (Coan et 
al., 2006). 
1.2.1.4 Labyrinth layer cells 
The labyrinth layer is the site of gas and nutrient exchange in the placenta. Three 
different chorion derivatives form the barrier between maternal sinusoids and the 
foetal circulatory system derived from extraembryonic mesoderm (Cross et al., 
2006). As discussed above, s-TGCs line the maternal sinusoids. s-TGCs are loosely 
attached to the adjacent syncytiotrophoblast layer; syncytiotrophoblast-I (Syn-I) 
(Coan et al., 2005). This allows the Syn-I layer to access maternal blood and 
nutrients. Syn-I are tightly attached to another syncytiotrophoblast layer, Syn-II, 
which is in direct contact with the endothelial cells that line the foetal capillaries 
(Enders, 1965, Hernandez-Verdun, 1974). 
1.2.1.4.1 Syncytiotrophoblast  
Around the time of chorio-allantoic fusion, at E8.5, the chorion becomes organised 
into three distinct cell layers that give rise to each of the labyrinth populations: Syn-
I, Syn-II and s-TGCs (Simmons et al., 2008, Watson et al., 2011). Whether there is 
a single progenitor that can differentiate into both Syn subtypes is unclear. Syn-I and 
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Syn-II express Syna and Synb, respectively, and Syna/b are essential for fusing 
trophoblast cells to produce multi-nucleated Syn cells (Dupressoir et al., 2005).  
1.2.2 Differences in placenta development between mouse and human 
There have been many recent reviews that highlight the differences between mouse 
and human placental development (Soncin et al., 2015, Schmidt et al., 2015, Silva 
and Serakides, 2016). As such, I will only outline a few key differences relevant to 
this thesis.  
 
The chorio-allantoic placenta develops earlier in humans than in mice (Malassine et 
al., 2008, Schmidt et al., 2015). Given this, it is not surprising that mouse and human 
placentas are structured differently. However, it has been suggested that there are 
structurally and/or functionally analogous cells between mouse and human 
placentas (see (Soncin et al., 2015)). Cytotrophoblast cells (CTBs) are thought to be 
the stem cells of the human placenta (Hemberger et al., 2010, Soncin et al., 2018). 
CDX2 expressing CTBs are particularly abundant in early gestation, near the 
chorionic plate and co-express the mouse trophoblast stem cell marker ELF5 
(Hemberger et al., 2010, Soncin et al., 2018). However, CDX2 expression is absent 
from CTBs at other places in the placenta (Soncin et al., 2018).  
 
Beyond CDX2 and ELF5, other key mouse trophoblast stem cell markers, including 
EOMES, are absent (Soncin et al., 2018). This indicates that the transcriptional 
network used to establish and maintain trophoblast stem cells in humans is different 
to that used in mice (Soncin et al., 2018). Despite these differences, many of the 
genes known to be important for TGC formation in mice are conserved in their human 
equivalent: extravillous trophoblast (EVT) (Rawn and Cross, 2008). Given the ethical 
implications of studying human placental development in vivo and the limited in vitro 
tools available, mouse in vivo and in vitro models are useful and necessary 
alternatives.  
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1.3 Derivation and maintenance of in vitro trophoblast stem 
cells  
In 1981, stable in vitro stem cell lines were derived and propagated from early 
embryos for the first time (Evans and Kaufman, 1981, Martin, 1981). These so-called 
mouse embryonic stem cells (mESCs), derived from the ICM, were pluripotent as 
shown in teratoma carcinomas and chimera embryos (Bradley et al., 1984, Evans et 
al., 1985, Beddington and Robertson, 1989). Almost two decades later, Janet 
Rossant and colleagues successfully isolated and maintained self-renewing stem 
cells from both the extraembryonic ectoderm of E6.5 embryos and trophectoderm of 
E3.5 embryos (Tanaka et al., 1998). Subsequent work derived similar cells from E8.5 
chorionic ectoderm (Uy et al., 2002). These isolated cells, known as trophoblast stem 
cells (TSCs), are indistinguishable from each other in both appearance and 
differentiation potential regardless of which stage they are derived from (Tanaka et 
al., 1998, Uy et al., 2002). When the growth factors that maintain trophoblast stem 
cell cultures are removed, proliferation declines and cells differentiate to all 
trophoblast derivatives (Tanaka et al., 1998). When injected into blastocysts, TSCs 
contribute solely to trophoblast lineage derivatives (Tanaka et al., 1998). Further, 
TSCs remodel vessels to form of blood-filled lacunas when they are injected under 
the skin of mice, indicating that TSCs retain their invasiveness and functionality in 
vivo, even outside of the embryo context (Kibschull et al., 2004, Kibschull and 
Winterhager, 2006). 
1.3.1 Signalling pathways that maintain trophoblast stem cells 
Fibroblast growth factor 4 (FGF4) is a key growth factor required to derive and 
maintain TSCs (Tanaka et al., 1998). In vivo, FGF4 is expressed in the ICM and 
Epiblast and FGFR2 is expressed in the TE. The importance of FGF4 signalling is 
confirmed by the observation that Fgf4-null and Fgfr2-null embryos are not viable 
(Tanaka et al., 1998, Feldman et al., 1995, Arman et al., 1998). In the trophectoderm, 
FGF4 activates the RAS/MAPK1 signalling pathway, which is required to maintain 
stemness but is not required for initial lineage segregation (Feldman et al., 1995, 
Arman et al., 1998, Saba-El-Leil et al., 2003, Lu et al., 2008). The other components 
of the original TSC culture medium were less-well defined, containing 20% foetal 
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bovine serum and factors secreted by mouse embryonic fibroblasts (MEFs) (Tanaka 
et al., 1998). Subsequent work established that MEFs provide nodal and/or activin; 
these are both members of the transforming growth factor beta (TGF) superfamily 
and are critical for TSC proliferation and maintenance (Erlebacher et al., 2004, 
Natale et al., 2009, Saba-El-Leil et al., 2003). In recent years, two independent 
groups have optimised defined culture conditions in which TSCs can be derived and 
maintained (Kubaczka et al., 2014, Ohinata and Tsukiyama, 2014). Despite the 
differences between medium composition, both support differentiation into all 
trophoblast derivatives both in vitro and in chimera experiments in vivo.  
1.3.2 Alternative trophoblast stem cell derivation methods 
Work aimed at understanding the reciprocal relationship between Oct4 and Cdx2 
inadvertently discovered that overexpressing Cdx2 or repressing Oct4 in mESCs can 
convert them into TSC-like cells (Niwa et al., 2000, Niwa et al., 2005). Conversely, 
overexpression of Oct4 alone in TSCs can convert them into mESCs, but the 
efficiency of this is increases by overexpressing Oct4 in combination with the other 
core ‘Yamanka’ factors (Wu et al., 2011, Kuckenberg et al., 2011). The importance 
of the Cdx2-Oct4 relationship at an early developmental stage has been confirmed 
by the inability of Cdx2 overexpression to induce trophoblast gene expression in 
stem cells derived from the epiblast (Blij et al., 2015). Overall, the ability to 
‘transdifferentiate’ mESCs to TSC-like cells and vice versa demonstrates the 
importance of the repressive, antagonistic relationship between Oct4 and Cdx2 
(Niwa et al., 2000, Niwa et al., 2005, Strumpf et al., 2005, Wu et al., 2011, 
Kuckenberg et al., 2011).  
 
Overexpression of other trophoblast related transcription factors has been reported 
to convert mESCs to the trophoblast lineage, with varying degrees of success; 
including Eomes, Elf5, Gata3, Tfap2c and Tead4 (Niwa et al., 2005, Ng et al., 2008, 
Ralston et al., 2010, Kuckenberg et al., 2010, Nishioka et al., 2009). TSC-like cells 
can also be generated by overexpressing Ras and, therefore, activating MAPK 
signalling (Lu et al., 2008). The morphological appearance and validation performed 
for each approach is outlined in Table 1.1.  
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Recently, two independent groups successfully reprogrammed mouse embryonic 
fibroblasts (MEFs) into induced-TSCs (iTSCs) by overexpressing a combination of 
transcription factors: Gata3, Eomes and Tfap2c (GET) with either Myc or Ets2 
(Benchetrit et al., 2015, Kubaczka et al., 2015). This process is successful but 
inefficient, with a success rate of only 0.03% (Benchetrit et al., 2015, Kubaczka et 
al., 2015). Interestingly, cells undergoing reprogramming do not express pluripotent 
marker genes, Oct4, Nanog or Sox2, suggesting that they do not progress through 
an ‘mESC-like’ fate. Additionally, Kubaczka et al (2015) found that overexpression 
of GET + Ets2 could not convert mESCs into stable proliferating iTSCs (Kubaczka et 
al., 2015).  
 
TSC-like cells can also be generated by growth factor induced approaches, although 
these are less commonly used (Hayashi et al., 2010, Schenke-Layland et al., 2007, 
He et al., 2008). BMP4-treatment of 1-cell to 8-cell stage mouse embryos induces 
TE markers expression in the nuclei of inner cells pre-compaction and in ICM cells 
of blastocyst embryos (Home et al., 2012). Similarly, BMP4-treatment of mESCs in 
defined culture conditions on laminin has also been shown to drive differentiation 
towards TSC-like cells (Hayashi et al., 2010). Others have shown that Wnt signalling 
or collagen-V can drive also transdifferentiation of mESCs to TSC-like cells 
(Schenke-Layland et al., 2007, He et al., 2008). However, growth factor-induced 
transdifferentiation is heterogeneous, cultures do not resemble TSCs and the 
validation relies solely on the expression of a relatively small panel of genes (Hayashi 
et al., 2010, Schenke-Layland et al., 2007, He et al., 2008). As such, growth factor 
induced TSCs are unlikely to represent bona fide TSCs.  
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1.3.3 Human trophoblast stem cells: to be or not to be? 
For almost two decades, in vitro work on human trophoblast has relied on TSC-like 
cells transdifferentiated from human ESCs using exogenous BMP4 (Xu et al., 2002, 
Das et al., 2007, Li et al., 2013). When exposed to BMP4, human ESCs decrease 
expression of pluripotency genes and increase the expression of TE-genes (Amita 
et al., 2013). However, they cannot be propagated and it has been suggested that 
the cells generated using this method are extraembryonic mesoderm (Bernardo et 
al., 2011). Therefore, whether such cultures represent human trophoblast is 
contentious (Roberts et al., 2014).   
 
Given these problems, others have tried to generate human TSCs from blastocysts 
or placenta directly (Kunath et al., 2014, Okae et al., 2018). Derivation methods used 
for mice do not work for human blastocysts, as only one of 60 blastocysts could be 
cultured for three passages and these cells did not resemble human ESCs nor 
mouse TSCs (Kunath et al., 2014). Okae et al (2018) recently published a method to 
derive self-renewing cells from both human blastocysts and post-implantation villous 
cytotrophoblast (Okae et al., 2018). This approach modulates completely different 
pathways to those targeted in mouse and does not use BMP4. Whilst these cells do 
have gene expression profiles similar to primary trophoblast cells, further validation 
is required to understand what these cells resemble (Okae et al., 2018, Wamaitha 
and Niakan, 2018).  
1.3.4 Validating transdifferentiated and reprogrammed trophoblast stem cells 
The methods used to validate TSC-like or iTSCs vary between publications. In some 
cases, transdifferentiation into TSC-like cells was confirmed by the expression of a 
few trophoblast marker genes (Niwa et al., 2005, Ralston et al., 2010, Nishioka et 
al., 2009). However, the transcription factors used in these studies are expressed in 
various developmental lineages and can, therefore, also induce genes associated 
with these lineages (Ralston et al., 2010, Nishiyama et al., 2009). As such, whether 
transdifferentiation generates stable, bona fide TSCs has been subject to 
controversy. TSC-like cells derived from Cdx2 overexpression or Oct4 knockout are 
homogenous and phenotypically normal in appearance, but do not resemble bona 
fide TSCs transcriptionally nor epigenetically (Cambuli et al., 2014). Currently, other 
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than using the transcriptome, there are two described methods of validating 
transdifferentiation into TSCs: examining contribution to embryos in chimera 
experiments and/or the epigenome. The validation performed for each 
transdifferentiation approach is outlined in Table 1.1.  
1.3.4.1 Using chimera integration 
To validate in vitro TSCs, Tanaka et al (1998) injected cells into blastocysts to 
determine their contribution to the mouse embryo. This assay revealed that TSCs 
only contribute to the placenta (Tanaka et al., 1998). Consequently, 
transdifferentiated TSC-like cells and reprogrammed iTSCs have been validated 
using chimeras (Table 1.1). While some studies determined their long-term 
contribution by transferring embryos to pseudo-pregnant females, others were only 
assessed for the ability to contribute to the trophectoderm ex vivo (Table 1.1). TSC-
like cells can contribute to the placenta, but this contribution is poorer than for bona 
fide TSCs (Cambuli et al., 2014). 
1.3.4.2 Using the epigenome 
TSCs and mESCs have distinct histone modification and DNA methylation profiles 
(Rugg-Gunn et al., 2010, Senner et al., 2012). The importance of these DNA 
methylation profiles is apparent from Dnmt1-null mESCs and embryos. Dnmt1-null 
mESCs and embryos cannot maintain the hypermethylated status of the Elf5 locus, 
resulting in spontaneous TGC-like differentiation in vitro and in the embryo proper in 
vivo (Ng et al., 2008). When tested, several loci that are hypomethylated in TSCs, 
including the key lineage barrier gatekeeping gene Elf5, remain methylated in 
transdifferentiated TSC-like cells (Cambuli et al., 2014). More recently, it has been 
shown that the chromatin landscape of bona fide TSCs and TSC-like cells are highly 
dissimilar (Rhee et al., 2017). 
1.3.4.3 Using the transcriptome 
TSC-like cells transdifferentiated from mESCs are significantly less proliferative than 
bona fide TSCs (Cambuli et al., 2014). TSC-like cells do not express TSC marker 
genes to the same levels as in bona fide TSCs and their expression fluctuates from 
between passages (Cambuli et al., 2014). Multiple RNA-seq studies have confirmed 
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that TSC-like cells do not faithfully recapitulate the bona fide TSC transcriptome 
(Adachi et al., 2013, Aiba et al., 2009). It is known that those transcription factors 
that maintain the TSC gene regulatory network (GRN) are stringently balanced, 
regulating stem cell maintenance and differentiation (Latos et al., 2015b, Nelson et 
al., 2017). As such, fluctuations in stem cell marker genes may be symptomatic of 
an unstable gene regulatory network and reflect incomplete conversion of the cells.  
1.3.4.4 Lineage barriers and their incompatibility  
At the time of writing this thesis, only one study has used more than one of these 
approaches when validating their transdifferentiated mESCs (Wei et al., 2016). Wei 
et al (2016) used a CRISPR-mediated approach to induce endogenous Cdx2 
expression rather than overexpression. Whilst these cells express TSC marker 
genes at similar levels as bona fide TSCs and show altered methylation, no global 
transcriptional nor epigenomic analyses were performed. In contrast, MEF 
reprogramming to iTSCs using GET, with or without Ets2 or Myc, faithfully 
reprograms DNA methylation marks and histone modifications globally (Kubaczka et 
al., 2015, Benchetrit et al., 2015). As such, iTSCs are nearly indistinguishable from 
bona fide TSCs in their transcriptome, morphology and DNA methylation status 
(Benchetrit et al., 2015, Kubaczka et al., 2015). In all, this confirms that TSCs can be 
generated using alternative approaches to embryonic-outgrowths.  
 
Kubaczka et al (2015) offered two potential explanations for this incompatibility in 
generating TSCs from mESCs by overexpression: 1) The DNA methylation status is 
more similar between TSCs and MEFs, resulting in easier conversion between these 
fates; 2) To prevent aberrant differentiation between early developmental lineages in 
the blastocyst, there is tighter regulation of the epigenetic barrier (Kubaczka et al., 
2015). In contrast, Oct4, alone or in combination with other factors, can overcome 
this epigenetic barrier and transdifferentiate TSCs into epigenetically and 
transcriptionally indistinguishable mESCs (Kuckenberg et al., 2011, Wu et al., 2011). 
Thus, it is possible that we have not yet determined the correct conditions to 
overcome the lineage barrier between mESCs and TSCS. 
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1.4 Deciphering the trophoblast stem cell gene regulatory 
network  
When and where the transcription factors that establish and maintain TSCs are 
expressed in early development varies greatly. Some TSC markers are expressed 
in both the TE or ICM, highlighting the importance of context for their functionality. 
Here, I provide an overview of the expression of core TSC marker genes in early 
development (Figure 1.2), their placental knockout phenotype and their known 
functions in trophoblast stem cells.  
 
 
Figure 1.2: A summary of trophoblast stem cell marker gene expression in early placental 
development. The top left schematic represents an E3.5 blastocyst and top right is a E6.5 embryo. ICM = 
inner cell mass, TE = trophectoderm, PrExE = proximal extraembryonic ectoderm, DiExE = distal 
extraembryonic ectoderm, EPC = ecoplacental cone, TGC = trophoblast giant cell, T = Transcript, P = 
protein.  




Cdx2 is first expressed at the 8- to 16-cell stage in mice. CDX2 protein is present in 
the outer cells of the 16-cell embryo and subsequently in the trophectoderm of the 
blastocyst (Beck et al., 1995, Guo et al., 2010, Strumpf et al., 2005). Peri-
implantation, at approximately E4.5, CDX2 expression is downregulated in the mural 
trophectoderm (Strumpf et al., 2005, Frias-Aldeguer et al., 2019). In the polar 
trophectoderm and its stem cell derivatives, the extraembryonic ectoderm and 
subsequently the chorionic ectoderm, CDX2 expression is maintained (Beck et al., 
1995). Later, at E7.5-8.5, Cdx2 expression is present in ectoplacental glycogen cells 
and at E9.5 in the spongiotrophoblast (Beck et al., 1995, van Nes et al., 2006). 
Although Cdx2-null embryos can form blastocysts, they cannot maintain epithelial 
integrity. As a result, their blastocoel cavity collapses and embryos die before 
implantation (Strumpf et al., 2005). CDX2 antagonises Nanog and Oct4 expression 
by binding and repressing their promoters (Niwa et al., 2005, Chen et al., 2009b). As 
such, both Nanog and Oct4 are expressed in all cells of Cdx2-null embryos (Strumpf 
et al., 2005). 
 
Cdx2 expression is driven by different enhancers at different developmental stages 
(Rayon et al., 2016). As outlined in Chapter 1.1.1, Cdx2 expression is activated by 
TEAD4 downstream of Hippo signalling (Nishioka et al., 2009). Recently, it has been 
shown that Notch signalling, which is specifically active in outer cells of the 
compacting blastocyst, also induces Cdx2 expression (Rayon et al., 2014). Hippo 
(via YAP) and Notch (via RBPJ) signalling pathways converge on the TE-specific 
enhancer (TEE) which is bound by TEAD4 and co-activate Cdx2 expression (Rayon 
et al., 2014, Rayon et al., 2016). Activation of the TEE enhancer is also dependent 
on the chromatin factor SBNO1, which is thought to be required to recruit the histone 
chaperone FACT (Watanabe et al., 2017). After implantation and in in vitro TSC 
cultures, the TEE enhancer is inactive. Instead, Cdx2 expression is controlled using 
other enhancers that may also be active in the blastocyst (Rayon et al., 2016). 
Although it is not directly involved in activating the TEE, the TSC transcription factor 
Tfap2c is also important for Hippo signalling, suppressing its activity via the cell 
polarity protein PARD6B (Cao et al., 2015). Independent of this, TFAP2C is also 
responsible for regulating Cdx2 activity from an enhancer in intron 1 of Cdx2 (Cao et 
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al., 2015). Additionally, it has been suggested that Cdx2 can also autoregulate its 
own expression (Niwa et al., 2005).  
 
Although Cdx2 function is now known to be downstream of initial TE commitment, it 
is still essential for TSC self-renewal (Ralston and Rossant, 2008, Wu et al., 2010). 
Trophoblast outgrowths cannot be generated from Cdx2-null embryos, which never 
express trophectoderm markers nor markers of trophoblast differentiation (Strumpf 
et al., 2005). TSC-like cells cannot be maintained without Cdx2, instead upregulating 
differentiation markers and subsequently terminally differentiating (Niwa et al., 2005, 
Kuckenberg et al., 2010). Similarly, Cdx2 knockdown in TSCs downregulates TSC 
marker genes and upregulates the TGC and Syn-I markers Prl3d1 and Syna, 
respectively (Table 1.2) (Latos et al., 2015b). This is unsurprising as Cdx2 is 
downregulated during TSC differentiation in vitro and in vivo (Beck et al., 1995, 
Tanaka et al., 1998).  
 
The role of CDX2 in the trophoblast gene regulatory network is unclear. CDX2 is 
known to directly interact with other TSC marker genes, including TEAD4 and 
EOMES (Latos et al., 2015a). As such, it has been speculated that these might 
represent CDX2 co-factors within the trophoblast context (Huang et al., 2017). 
Others have shown that CDX2 binds endogenous retroviruses, known to be core 
enhancers that drive placental evolution and divergence between species, in 
conjunction with EOMES and ELF5 (Chuong et al., 2013). In addition to these TSC 
specific roles, it has been suggested that CDX2 can drive the expression of Bmp4 
from the ExE that is required to maintain the epiblast (Murohashi et al., 2010).  
1.4.2 Elf5 
ETS transcription factor family member Elf5 is first expressed in the trophectoderm 
of pre-implantation embryos, but ELF5 protein is not detected at these stages 
(Donnison et al., 2005, Ng et al., 2008). Post-implantation, Elf5 is expressed in the 
proximal and distal extraembryonic ectoderm (ExE) and chorionic ectoderm 
(Donnison et al., 2005, Latos et al., 2015b, Ng et al., 2008). Elf5 expression levels 
are critical for early embryonic development. Whilst Cdx2 is expressed normally in 
pre-implantation Elf5-null embryos, post-implantation embryos develop smaller ExE 
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compartments that do not express Cdx2. As a result, Elf5-null embryos die before 
E10.5 due to placental defects (Donnison et al., 2005). Elf5 overexpression in vivo 
reduces the number of Tpbpa-positive spongiotrophoblast precursors and induces a 
vast overabundance of TGCs, resulting in embryo reabsorption by E10.5 (Latos et 
al., 2015b). This suggests that Elf5 expression must be tightly regulated. 
 
In agreement with the in vivo phenotype, trophoblast outgrowths from Elf5-null 
embryos only contain cells resembling TGCs (Donnison et al., 2005). Similarly, 
knockdown of Elf5 in TSCs downregulates stem cell markers such as Eomes and 
Cdx2 and upregulates TGC and Syn markers (Latos et al., 2015b). However, neither 
Eomes nor Cdx2 are direct targets of Elf5, with only Sox2 expression downregulated 
24-hours post Elf5 knockdown (Table 1.2) (Pearton et al., 2014). Elf5 overexpression 
in mESCs drives them to differentiate towards the trophoblast lineage, but these 
TSC-like cells do not self-renew (Ng et al., 2008). Likewise, TSCs overexpressing 
Elf5 can be maintained, but these cultures are unstable and show an increased 
propensity to differentiate into TGCs (Latos et al., 2015b). Therefore, the requirement 
for exact Elf5 expression levels in vivo are also replicated in in vitro cultures. 
 
One potential explanation for these phenotypes is that ELF5 interacts with different 
proteins depending on its expression level. In TSCs, ELF5 preferentially interacts 
with EOMES, but also interacts with TFAP2C. All three transcription factors co-bind 
and activate key TSC marker genes, including themselves and Cdx2 (Latos et al., 
2015b, Ng et al., 2008). During in vitro differentiation, Elf5 is briefly upregulated 
before it is downregulated (Donnison et al., 2015, Latos et al., 2015b). In 
differentiation, ELF5 preferentially interacts with TFAP2C and binds around genes 
associated with trophoblast differentiation (Latos et al., 2015a). In combination, this 
explains why TSCs cannot be maintained with too much or too little Elf5 expressed.  
1.4.3 Eomesodermin (Eomes) 
A T-Box transcription factor, Eomes is expressed in the trophectoderm and persists 
in the ExE of post-implantation embryos (Ciruna and Rossant, 1999, Hancock et al., 
1999, Russ et al., 2000, Arnold et al., 2009). Although Eomes-null embryos implant, 
they remain blastocyst-like in appearance, suggesting that trophoblast differentiation 
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is compromised (Russ et al., 2000, Strumpf et al., 2005). Unsurprisingly, TSC 
cultures cannot be generated ex vivo from Eomes-null embryos as they remain as 
blastocyst-like structures and do not generate trophoblast outgrowths (Russ et al., 
2000, Strumpf et al., 2005). Whilst Cdx2 is not required to initiate Eomes expression, 
it cannot be upregulated in the absence of Cdx2, indicating that Eomes is 
downstream of Cdx2 in TE establishment (Strumpf et al., 2005). 
 
Eomes is a core member of the TSC GRN, forming interactions with a number of 
other transcription factors. Eomes knockdown in TSCs results in differentiation 
towards the trophoblast giant cell (TGC) and syncytiotrophoblast lineages (Kidder 
and Palmer, 2010, Latos et al., 2015b). Sox2 is downregulated two days after Eomes 
is knocked-down and is likely a direct target of its expression. Downregulation of 
Cdx2 and Elf5 only occurs six days after Eomes expression is knocked-down, 
showing that their dysregulation is an indirect effect of Eomes loss (Table 1.2) 
(Kidder and Palmer, 2010, Latos et al., 2015b). As discussed above, stoichiometric 
ratios between Eomes, Elf5 and Tfap2c regulate the maintenance or differentiation 
of TSCs (Latos et al., 2015b). Together, these transcription factors bind a number of 
TSC marker gene promoters including the Eomes promoter, suggesting that EOMES 
autoregulates itself (Kidder and Palmer, 2010, Latos et al., 2015b).  
1.4.4 Esrrb 
Esrrb is highly expressed in all cells of the embryo up to the 16-cell stage. 
Subsequently, Esrrb expression is restricted to the ICM of the mid-blastocyst and 
epiblast of the late-blastocyst but is absent from the TE (Guo et al., 2010, Adachi et 
al., 2013, Boroviak et al., 2014). As in the ICM, Esrrb is expressed in mESCs, 
induced by the GSK3 (Glycogen Synthase Kinase-3) signalling pathway, and is both 
necessary and sufficient to stabilise a naïve pluripotent state (Martello et al., 2012). 
In this context, ESRRB, facilitated by OCT4, binds the promoter regions of other core 
pluripotency genes including Nanog (van den Berg et al., 2008, Festuccia et al., 
2012). Esrrb knockdown or knockout in in vitro mESCs results in a reduction in mESC 
self-renewing capacity (Ivanova et al., 2006, Festuccia et al., 2012). Despite this 
essential role in maintaining pluripotency in vitro, Esrrb-null embryos survive in utero 
until approximately E10.5 (Luo et al., 1997).  




Post-implantation, Esrrb is expressed in the proximal extraembryonic ectoderm from 
E5.5 and later in the chorionic ectoderm (Luo et al., 1997, Adachi et al., 2013). Esrrb-
null embryos show severe placental abnormalities, including a gross expansion of 
secondary TGCs at the expense of other trophoblast lineages and a failure of chorio-
allantoic fusion (Luo et al., 1997). Esrrb is expressed in TSCs and is essential to TSC 
maintenance (Tanaka et al., 1998). Addition of the oestrogen-related receptor 
antagonist Diethylstilbestrol (DES) or Esrrb knockdown in TSC cultures drives 
differentiation specifically towards the TGC lineage as observed in vivo (Tremblay et 
al., 2001, Latos et al., 2015a, Gao et al., 2019). Short-term interference of ESRRB 
activity downregulates several key TSC marker genes, including Eomes, Elf5 and 
Sox2, suggesting that Esrrb directly regulates them (Table 1.2) (Latos et al., 2015a). 
In keeping with this, ESRRB binds the promoter-TSS of key TSC maintenance genes 
and drives their expression (Adachi et al., 2013, Latos et al., 2015a). However, short-
term Esrrb perturbation minimally affects Cdx2 expression suggesting it is not a 
direct target of Esrrb in TSC maintenance (Latos et al., 2015a).  
 
Esrrb expression is required for transdifferentiation of MEFs into induced TSCs 
(iTSCS), and can replace Eomes in the cocktail of factors required for this process 
(Gao et al., 2019). In TSCs, Esrrb expression is downstream of FGF/ERK signalling 
and, when overexpressed alone (Gao et al., 2019), or with Sox2 (Adachi et al., 2013), 
it can substitute for exogenous FGF4. This suggests that Esrrb is an effector of 
FGF/ERK signalling, controlling the expression of other key TSC marker genes 
(Latos et al., 2015a). Unlike in mESCs, ESRRB interacts with Kdm1a in TSCs. This 
is a histone demethylase that regulates the onset of trophoblast differentiation and 
co-binds many ESRRB binding sites (Zhu et al., 2014, Latos et al., 2015a).  
1.4.5 Ets2 
The ETS transcription factor family member Ets2 is expressed in the ExE and EPC. 
Ets2 expression increases in both of these lineages from E5 to E6.75, and then is 
downregulated from E7.75 (Georgiades and Rossant, 2006, Yamamoto et al., 1998). 
Despite its short temporal expression, loss of Ets2 causes embryos to die at E8.5-
9.5. Death of Ets2-null embryos occurs as a result of a defective placenta because 
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tetraploid aggregations can rescue this phenotype (Georgiades and Rossant, 2006, 
Yamamoto et al., 1998). Ets2-null embryos fall into two categories depending on 
phenotype: Type-I and Type-II. Type-I embryos contain no ExE and a small region 
resembling the EPC. In contrast, Type-II embryos possess an EPC and an ExE-like 
domain, expressing associated marker genes Cdx2, Eomes, Esrrb and Sox2 for a 
short period of time (Georgiades and Rossant, 2006, Polydorou and Georgiades, 
2013).  
 
In line with in vivo data, Ets2 knockdown or knockout in TSCs downregulates a small 
number of genes including Cdx2, Eomes and Esrrb (Odiatis and Georgiades, 2010, 
Wen et al., 2007). This observed downregulation of Cdx2 is likely driven by the loss 
of ETS2 binding at a functional binding site in the distal Cdx2 promoter region (Wen 
et al., 2007). Ets2 expression in TSCs is required to promote self-renewal, maintain 
TSC fate and allow for differentiation towards the TGC and spongiotrophoblast 
lineages (Odiatis and Georgiades, 2010, Wen et al., 2007). As Cdx2 overexpression 
cannot rescue the self-renewal phenotype, Ets2 has other roles in TSCs than simply 
maintaining Cdx2 expression (Wen et al., 2007). In Ets2 knockout TSCs, Hand1 is 
not upregulated even in the absence of growth factors and TSCs show increased 
propensity to differentiate towards labyrinth trophoblast (Odiatis and Georgiades, 
2010, Wen et al., 2007). In contrast, short-term knockdown of Ets2 expression does 
not affect Elf5 nor Fgfr2 expression (Wen et al., 2007). Beyond these TSC-specific 
roles, Ets2 expression in the ExE is also essential for the production of Bmp4, which 
is required for gastrulation (Polydorou and Georgiades, 2013).  
1.4.6 Gata3 
Gata3 is first expressed in the 4-cell stage embryo and GATA3 protein in the 8-cell 
stage embryo. Subsequently, Gata3 becomes restricted to the outer cells and then 
trophectoderm of the blastocyst (Home et al., 2009, Ralston et al., 2010). Gata3 
expression is downstream of TEAD4 and the Hippo signalling pathway and is 
activated in parallel with Cdx2 (Ralston et al., 2010). Similar to Cdx2, Gata3 is also 
repressed in the ICM by OCT4 (Ralston et al., 2010). After implantation, GATA3 is 
expressed in the extraembryonic ectoderm, ectoplacental cone and the trophoblast 
giant cells that surrounds the embryonic cavity (George et al., 1994, Ralston et al., 
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2010, Ma et al., 1997). There is contradictory evidence on the importance of Gata3 
to blastocyst formation. Gata3-null embryos develop normally until E9.5 but die at 
approximately E12 as a result of haematopoietic defects (Pandolfi et al., 1995). 
However, approximately 65% of embryos in which Gata3 was knocked-down at the 
2-cell stage did not mature to the blastocyst stage (Home et al., 2009). GATA3 
directly represses Gata2 expression in TSCs (Ray et al., 2009). As Gata2/3 double 
knockout embryos undergo cavitation but do not implant (Home et al., 2017), 
perhaps Gata2 compensates for Gata3 under knockout, but not knockdown, 
conditions. 
 
At later stages of development, both Gata3 and Gata2 are expressed in TGCs and 
drive associated Prolactin gene expression (Ng et al., 1994). Accordingly, although 
Gata3-null placentas do not show an obvious placenta phenotype at E10.5, both 
Prl3d1 and Prl2c2 are downregulated (Ma et al., 1997).  
 
Gata3 is expressed in, and essential to, TSCs (Home et al., 2009). In TSCs, GATA3 
binds a small number of active promoters (Kidder and Palmer, 2010), as well as a 
conserved GATA motif in intron 1 of Cdx2 from which it regulates Cdx2 expression 
in both TSCs and TE (Home et al., 2009). Gata3 is upregulated during differentiation 
and is important for TGC formation, as shown by the increase in TGCs when Gata3 
is overexpressed (Table 1.2) (Ralston et al., 2010). Therefore, the level of Gata3 
determines whether stem cells are maintained or differentiate (Ralston et al., 2010). 
In agreement with the tight requirement of Gata3 expression, self-renewing TSC-like 
cells cannot be generated by overexpressing Gata3 in mESCs (Ralston et al., 2010).  
1.4.7 Sox2  
Sox2 is initially maternally expressed, but rapidly declines with blastocyst cell 
divisions (Avilion et al., 2003, Guo et al., 2010). Published data on SOX2 dynamics 
in early mouse embryonic development is contradictory. Whilst some papers suggest 
that SOX2 expression is constant and universal, others suggest SOX2 is uniquely 
upregulated in ICM precursors at the 16-cell stage and patterned in parallel with 
Cdx2 (Avilion et al., 2003, Keramari et al., 2010, Guo et al., 2010, Wicklow et al., 
2014). In blastocysts, SOX2 expression remains nuclear and restricted to the ICM 
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(Wicklow et al., 2014). Post-implantation, Sox2 is expressed in a narrow band in the 
ExE at the embryonic/extraembryonic boundary and later in the extraembryonic 
ectoderm proportion of the chorion (Avilion et al., 2003, Adachi et al., 2013). Sox2-
null embryos die shortly after implantation without an ExE or epiblast. Injection of 
wild-type mESCs into Sox2-null blastocysts does not rescue this phenotype, 
confirming that Sox2 expression is critical to the trophoblast lineage (Avilion et al., 
2003).  
 
Sox2-null blastocysts can form trophoblast outgrowths, but these cannot be 
maintained and differentiate into trophoblast derivatives (Avilion et al., 2003). In 
established TSCs, Sox2 is a primary target of FGF signalling (Latos et al., 2015a, 
Adachi et al., 2013). Combined overexpression of Sox2 and Esrrb can maintain TSC 
self-renewal and trophoblast identity in the absence of FGF4 signalling (Adachi et 
al., 2013). Sox2 expression is also rapidly downregulated after Elf5 knockdown, 
suggesting Sox2 is a direct target of Elf5 (Table 1.2) (Pearton et al., 2014). 
 
In all, this suggests that Sox2 initially represses trophectoderm establishment but is 
later essential for maintaining the established trophoblast stem cell fate. This change 
in Sox2 behaviour has been confirmed by experiments in mESCs. When Sox2 is 
knocked-down in mESCs, trophoblast marker genes such as Hand1, Eomes, Ascl2 
and Prl3d1 are upregulated. However, this is heterogeneous as Sox2 knockdown 
also upregulates markers of other embryonic and extraembryonic lineages (Ivanova 
et al., 2006, Masui et al., 2007). In contrast, if Sox2 expression is blocked during 
mESCs conversion to TSC-like cells by Cdx2 overexpression, few TSC markers 
genes are expressed. Instead, genes associated with trophoblast differentiation are 
upregulated (Adachi et al., 2013). To understand how Sox2 plays opposite roles in 
these contexts, Adachi et al (2013) generated SOX2 ChIP-seq libraries during the 
conversion of mESCs into TSC-like cells by Oct4-repression (Adachi et al., 2013). 
These libraries suggest that SOX2 binding is different between mESCs and TSCs. 
Whilst SOX2 binding sites are enriched for OCT-SOX motifs in mESCs, those in 
TSC-like cells are enriched for canonical SOX and AP2 motifs. As such, TFAP2C 
appears to be a core co-factor for SOX2 binding in the trophoblast fate (Adachi et 
al., 2013).   




Tead4, a TEAD family member, is first upregulated at the 4-cell stage and persists 
in all cells of the pre-implantation embryo. TEAD4 expression is detected in both the 
TE and ICM of blastocysts (Nishioka et al., 2008, Yagi et al., 2007). There is 
conflicting data for the subcellular localisation of TEAD4 in the ICM of mice (Nishioka 
et al., 2008, Home et al., 2012), but it is cytoplasmic in other species such as human, 
cattle, rats and rhesus monkeys (Home et al., 2012). Post-implantation, Tead4 is 
expressed in the extraembryonic ectoderm, ectoplacental cone, chorion and 
trophoblast giant cells (Yagi et al., 2007). As discussed in Chapter 1.1.1, TEAD4 and 
the Hippo signalling pathway regulate Cdx2 and Gata3 expression during 
trophectoderm specification (Nishioka et al., 2009, Ralston et al., 2010). Tead4-null 
embryos are morphologically indistinguishable from wild-type embryos until 
compaction, polarising and forming normal adherens junction. However, Tead4-null 
embryos do not form a blastocoel cavity and express minimal, if any, trophectoderm 
marker genes (Nishioka et al., 2008, Yagi et al., 2007). Instead, all cells in Tead4-
null embryos express pluripotency markers OCT4 and NANOG, suggesting that they 
have all been specified as ICM (Nishioka et al., 2008).  
 
As expected given the in vivo phenotype, Tead4-null embryos cannot form 
trophoblast outgrowths (Nishioka et al., 2008, Yagi et al., 2007). Tead4 is expressed 
in both TSCs, where it autoregulates its own expression, and differentiated subtypes 
such as TGCs (Home et al., 2012). In TSCs, Tead4 knockdown downregulates 
multiple trophoblast stem cell marker genes, including Cdx2, Gata3, Elf5 and Eomes 
(Home et al., 2012). TEAD4 binding sites are found near all of these downregulated 
genes in both TSCs and blastocysts (Home et al., 2012). TEAD4 binding sites in 
TSCs are also enriched for the CDX2, EOMES, TFAP2C and SOX2 consensus 
binding motifs, suggesting that they may be TEAD4 co-factors (Home et al., 2012). 
Beyond its importance in regulating TSC marker genes, recent reports suggest that 
TEAD4 is critical for binding and regulating mitochondrial DNA transcription; 
regulating energy homeostasis in both TSCs and pre-implantation mouse embryos 
(Kumar et al., 2018, Kaneko and DePamphilis, 2013).   
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1.4.9 Tfap2c  
Tfap2c is expressed in all cells of the preimplantation embryo but is restricted to the 
ExE, EPC and TGCs after implantation (Auman et al., 2002, Werling and Schorle, 
2002). Pre-implantation, Tfap2c is critical for blastocyst formation, regulating cell 
polarity, proliferation, fluid accumulation and tight junction gene expression and 
organisation (Choi et al., 2012). Despite this, Tfap2c-null embryos undergo 
compaction and cavitation normally and are able to implant. This lack of phenotype 
is likely due to functional redundancy with Tfap2a given that double Tfap2a/c mutants 
die earlier than Tfap2c mutants (Winger et al., 2006). After implantation, Tfap2c-null 
embryo placentas have fewer TGCs and no labyrinth layer, resulting in severe growth 
defects and death by E9.5 (Auman et al., 2002, Werling and Schorle, 2002). The 
embryonic phenotype caused by Tfap2c knockout is rescued by tetraploid 
aggregation, indicating that embryonic defects occur as a result of the observed 
placental defects (Auman et al., 2002). Tfap2c-null placental defects are likely 
caused by their ExE, which is either absent or does not express the key TSC markers 
Cdx2 and Eomes (Auman et al., 2002). Tfap2c expression levels are critical to 
trophoblast development as 60% of Tfap2c-heterozygotes are lost after E14.5. 
Heterozygote embryos have altered placental morphology, decreased expression of 
trophoblast stem cell and spongiotrophoblast markers and a shifted fate towards s-
TGCs (Kaiser et al., 2015).  
 
In vitro, Tfap2c-null embryos have the capacity to form trophoblast outgrowths, but 
these are smaller, have abnormal cell morphology and contain fewer TGCs than 
those derived from wild-type embryos (Auman et al., 2002, Kuckenberg et al., 2010, 
Werling and Schorle, 2002). In addition, Tfap2c-null or heterozygous trophoblast 
outgrowths are lost within 10 passages (Kuckenberg et al., 2010). Similarly, Tfap2c 
knockdown in TSCs decreases trophoblast stem cell marker gene expression, 
changing TSC colony morphology and increasing differentiation (Kidder and Palmer, 
2010, Adachi et al., 2013). This is likely caused by changes to the stoichiometric 
ratios of Elf5, Eomes and Tfap2c that are required to maintain TSCs. Other than 
maintaining TSCs, Tfap2c is also upregulated during trophoblast differentiation 
(Latos et al., 2015b). Under these conditions, TFAP2C and ELF5 drive a global 
increased chromatin accessibility, binding around genes involved in differentiation 
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(Latos et al., 2015b, Nelson et al., 2017). Thus, maintaining Tfap2c expression is 
critical for both TSC maintenance and differentiation.  
 
TFAP2C binds to the promoters of a number of marker genes in TSCs, including 
Tfap2c, Cdx2, Elf5, Eomes, and Gata3 (Kidder and Palmer, 2010, Kuckenberg et al., 
2010). Whilst TFAP2C binding can activate its own and Cdx2 expression, it has little 
effect on Eomes and Elf5 expression (Kidder and Palmer, 2010, Kuckenberg et al., 
2010). In agreement with this, Tfap2c overexpression in mESCs transdifferentiates 
cells into TSC-like cells and induces Cdx2 expression and Tfap2c knockdown 
downregulates Cdx2 (Table 1.2) (Kuckenberg et al., 2010). Furthermore, Tfap2c 
overexpression can transdifferentiate Cdx2-null mESCs into a trophoblast-like fate, 
but Eomes and Elf5 expression is low and these cells cannot be maintained 
(Kuckenberg et al., 2010). In part, this may be due to a downregulation of Oct4 during 
this process and re-distribution of Sox2 to its TSC-binding targets (Adachi et al., 
2013).  
1.4.10 A summary of transcription factor interplay in trophoblast stem cell 
maintenance 
To generate a network map that displays the interplay between different TSC marker 
genes accurately would be difficult. Instead, I have made a table that summarises 
the reported effects of upregulating or downregulating each of these marker genes 
in TSCs (Table 1.2). Many of these studies only provide information on the effects of 
TSC marker perturbation after several days. As such, it is difficult to know if observed 
effects are direct or indirect. Nonetheless, changes to Cdx2 expression are reported 
when the expression of every transcription factor listed in Table 1.2 is perturbed. 
Therefore, Cdx2 expression is highly dependent on the expression of other TSC 
maker genes, although this is probably an indirect effect in some cases. Furthermore, 
changes to almost any component of the core TSC gene regulatory network 
dysregulates it and drives TSCs to upregulate markers of differentiation (Table 1.2).  
 





Table 1.2: Summary of experiments that have altered stem cell marker gene expression in TSCs. This 
table summarises the timeframe, affected genes and morphology after downregulating (yellow) or 
upregulating (purple) known TSC marker genes. When outlined times contain a ‘?’, the timeframe has been 
inferred from figures rather than outlined in the text. 
  
TF Approach Time Affected genes Morphology Comment Reference
Cdx2 shRNA knockdown 5 days
↓ Elf5, Eomes, Esrrb, Fgfr2 
↑ Prl3d1, Syna
No comment N/A
Latos et al., 
2015
shRNA knockdown 6 weeks ?
↓ Cdx2, Eomes 
↑ TGC markers, Syna, Synb
No comment RNA-seq performed (no gene list provided) 
Latos et al., 
2015
shRNA knockdown
24 hours and 48 
hours
↓ Sox2 










↑ Cdx2 and TGC markers inconsistent 
between figures
↑ Eomes, Tfap2c, Hand1, Ascl2
↓  Gcm1, Synb
Increased 
differentiation 
RNA-seq performed (no gene list provided) 
Latos et al., 
2015
shRNA knockdown 6 weeks ?
↓ Elf5 
↑ TGC markers, Syna, Synb
No comment
RNA-seq performed (no gene list provided) 
Similar to differentiation 
Latos et al., 
2015
siRNA knockdown 
(day D0, D2 and D4)
Collected at days 
D2, D4 and D6
D2: ↓ Sox2
D6: ↓ Cdx2, Elf5, Sox2, Tfap2c 
Loss of TS 
morphology 




Most similar to TSCs.
Slight downregulation of Cdx2 and Spry4
Normal TSC 
morphology 
RNA-seq performed (no gene list provided) 















↓ Elf5, Eomes, Sox2
↑ Prl3d1and other Prl genes and Syna
No comment
RNA-seq performed at 24 hours and 4 days 
post-treatment. Gene lists provided
shRNA knockdown 5 days
↓ Cdx2, Elf5, Eomes, Sox2





shRNA knockdown Stable transfection





Gao et al., 
2019
knockout 1 day and 3 days ↓ Cdx2, Esrrb, Elf5 No comment
Colony formation affected. 
RNA-seq performed (no gene list provided) 






Loss of TS 
morphology and 
TGC formation
~75% reduction in Ets2 expression
Odiatis et al., 
2010
shRNA knockdown
5 days total 























Lower doses do not induce differentiation









Gao et al., 
2019
Tead4 shRNA knockdown 3 days
↓ Cdx2, Gata3, Bmp4, Elf5, Eomes, 
Fgfr2, JunB
No comment N/A
Home et al., 
2012
siRNA knockdown 
(day D0, D2 and D4)
Collected at days 
D2, D4 and D6
D2: ↓ Cdx2 lost by D4
D6: ↓ Cdx2, Ets2, Sox2 
Loss of TS 
morphology 















↑ Cdx2 and TGC markers ↓ Syna, Synb - 
inconsistent between figures
↑ Eomes, Tfap2c, Hand1





RNA-seq performed (no gene list provided) 







Latos et al., 
2015
Ets2
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1.5 In vitro differentiation into trophoblast lineages 
TSC marker genes are only co-expressed post-implantation, indicating that the in 
vivo equivalents of TSCs are trophoblast stem cells in the ExE of post-implantation 
embryos (Figure 1.2). However, this has been challenged by recent work suggesting 
that TSCs are heterogeneous populations, containing cells that represent different 
developmental stages: from polar trophectoderm to ExE and differentiating cells 
(Frias-Aldeguer et al., 2019). In vitro, TSCs differentiate when key growth factors 
(FGF4 and TGF) that maintain trophoblast stemness are removed (Tanaka et al., 
1998). The absence of FGF4 and TGF in vitro results in spontaneous differentiation 
to all trophoblast lineages, but is biased towards the TGC lineage and away from 
Syn populations (Hughes et al., 2004, Latos and Hemberger, 2016). In vivo, both 
NODAL and FGF4 are secreted from the epiblast and are critical for maintaining 
extraembryonic ectoderm identity (Guzman-Ayala et al., 2004). FGF4 also represses 
ectoplacental cone identity (Guzman-Ayala et al., 2004). If the ExE is removed from 
NODAL and FGF4 signalling, this stem cell population differentiates into TGCs 
(Guzman-Ayala et al., 2004). Therefore, in vivo ExE and in vitro TSCs primarily 
differentiate through an EPC-like fate and subsequently into the two EPC derivatives: 
the spongiotrophoblast and TGCs.  
 
In vitro, increased differentiation into Syn derivatives can be driven by removing 
FGF4 and TGF and supplementing with activin (Natale et al., 2009). In addition, 
generation of Syn derivatives can also be increased by changing components of the 
extracellular matrix or reducing histone deacetylase (Hdac) activity alongside growth 
factor withdrawal (Choi et al., 2013, Maltepe et al., 2005). Recent work by Murray et 
al (2016) found that the relative expression of the cell surface protein PLET1 is 
indicative of cell fate during differentiation. Trophoblast cells that express high levels 
of PLET1 on the surface preferentially differentiate into TGCs.  Low or absent PLET1 
is indicative that cells will differentiate into Syn derivatives.  As a cell surface protein, 
the differential expression of PLET1 could be used in future experiments to enrich 
for EPC-like TGC progenitors or chorion/labyrinth-like Syn progenitors (Murray et al., 
2016).   
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1.6 Beyond the placenta: Cdx2 in mouse embryogenesis 
In addition to the trophoblast lineage, Cdx2 is required for the normal development 
of multiple other embryonic lineages. The role that Cdx2 plays in other lineages has 
been extensively studied. Understanding how Cdx2 behaves in different lineages 
may help to understand the role of Cdx2 in the trophoblast lineage and/or may 
uncover universal roles of Cdx2 across tissues.  
 
Cdx2 is one of three mouse paralogues of the Drosophila gene caudal (cad): Cdx1 
(Duprey et al., 1988), Cdx2 (James and Kazenwadel, 1991) and Cdx4 (Gamer and 
Wright, 1993). All Cdx genes are members of the ParaHox homeobox gene family 
(Ferrier et al., 2005). Unlike Cdx2, Cdx1 and Cdx4 are not expressed in 
preimplantation embryos or the trophoblast lineage (Meyer and Gruss, 1993, Gamer 
and Wright, 1993, Beck et al., 1995, Strumpf et al., 2005).  
 
All Cdx genes are expressed in the three germ layers of the late primitive streak at 
E7.2-7.5, and both Cdx2 and Cdx4 are expressed in the allantois (Meyer and Gruss, 
1993, Beck et al., 1995, Gamer and Wright, 1993). Cdx2 expression in the allantois 
is essential to its function as tetraploid aggregation rescued Cdx2-null embryos die 
at E11.5 due to failed chorio-allantoic fusion (Chawengsaksophak et al., 2004). By 
E8.5, Cdx1, 2 and 4 are expressed in the neural tube, mesoderm of the tail bud and 
the neuromesodermal progenitor population that drives axial elongation (Tsakiridis 
et al., 2014, Gouti et al., 2017). Additionally, Cdx2 and Cdx4 are expressed in the 
presomitic mesoderm (Beck et al., 1995, Gamer and Wright, 1993).  
 
Cdx4-null embryos are viable and show no phenotype (van Nes et al., 2006). Cdx1-
null embryos, although viable and fertile, show defects in the anterior cervical 
vertebrae (Subramanian et al., 1995). In contrast, rescued Cdx2-null embryos are 
severely truncated, generating a maximum of 17 posteriorly deformed somites 
(Chawengsaksophak et al., 2004). Not only is Cdx2 expression important for axial 
elongation, but it also needs to be present at wild-type levels as Cdx2-heterozygote 
mice show anterior deformities and shortened tails (Chawengsaksophak et al., 
1997). Double knockout Cdx2/4 embryos are more severely affected than Cdx2-null 
embryos (Young et al., 2009). Cdx1/2/4 triple knockout embryos are more severely 
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affected still, failing to generate any post-occipital tissue (van Rooijen et al., 2012). 
In all, this suggests that Cdx genes can compensate for one another to a certain 
extent, but Cdx1 and Cdx4 are poorer at compensating for Cdx2 than vice versa.  
 
After birth, the only tissues Cdx2 is expressed in are the small and large intestine, 
where Cdx1 is also expressed (Duprey et al., 1988, James and Kazenwadel, 1991, 
Beck et al., 1995). All three Cdx genes are expressed in the developing hindgut 
(Meyer and Gruss, 1993, Beck et al., 1995, Gamer and Wright, 1993). Whilst neither 
Cdx1-null nor Cdx4-null mice show intestinal defects, the caecum of Cdx2-
heterozygotes has regions that are incorrectly specified (Chawengsaksophak et al., 
1997). Similarly, if Cdx2 is deleted before the intestine is specified, the intestinal 
epithelium undergoes an oesophageal-like conversion (Gao et al., 2009). In contrast, 
if Cdx2 expression is lost after the intestine is specified, this compromises intestinal 
proliferation, differentiation and overall function (Verzi et al., 2010, San Roman et al., 
2015).  
 
These phenotypic differences are likely caused by CDX2 binding and activating 
different target genes at different stages of intestinal development (Kumar et al., 
2019). Those sites that CDX2 binds to at these different intestinal stages are already 
accessible when CDX2 binds there, indicating that CDX2 responds to chromatin 
changes rather than establishing them (Kumar et al., 2019). Similarly, when 
overexpressed in various cell types, CDX2 binds to regions of accessible chromatin 
rather than altering the chromatin landscape (Mahony et al., 2014). This is in direct 
contrast to recent work investigating neural progenitor commitment during axis 
elongation. Metzis et al (2018) instead suggest that CDX transcription factors are 








To date, the literature indicates that Cdx2 has independent roles in different lineages. 
In addition, Cdx2 has also been shown to have multiple roles in the same lineage at 
different developmental stages. It is well established that Cdx2 is important in the 
early trophoblast context for repressing the pluripotency network during 
trophectoderm establishment. However, Cdx2 expression is required in trophoblast 
stem cell populations long after this role becomes obsolete. What, if any, is its direct 
function later in this lineage?  
 
The aim of this thesis is to establish both the immediate and long-term effects of 
Cdx2 loss on the established trophoblast fate. This work will provide new insights 
into the differential roles Cdx2 may play at different trophoblast developmental 
stages. Furthermore, this analysis will unpick the role of Cdx2 in the gene regulatory 
network that maintains the trophoblast fate.  
 
• In Chapter 3, I will determine CDX2 binding sites in established trophoblast 
stem cells and address the possibility that CDX2 binding differs before and 
after trophoblast fate is established.  
 
• In Chapter 4, I will examine the effect of transient Cdx2 loss on the 
transcriptome and the chromatin landscape of TSCs.  
 
• In Chapter 5, I will define the effect of sustained Cdx2 loss on the TSC fate. 
In addition, I will validate unique enhancers that may be responsible for 
observed phenotypes.  
 
• In Chapter 6, I will further validate the phenotype caused by long-term Cdx2 
loss and its effect on the TSC gene regulatory network by deleting Cdx2 using 
CRISPR-Cas9 genome editing.  
 




Chapter 2. Materials & Methods 
For all data in this thesis, except those generated during bioinformatic analyses (see 
2.5), data was analysed in Microsoft Excel (Microsoft: Washington, USA) and graphs 
generated and statistical analyses performed by Prism8 (Graphpad: La Jolla, USA). 
2.1 Cell Culture 
All cell culture was performed on Costar® plastic (Corning, USA).  
2.1.1 Mouse trophoblast stem cells 
Three mouse trophoblast stem cell (TSC) lines were used in this thesis. INX and 
XYO cell lines were derived by Daniel Snell (Turner Lab, The Francis Crick Institute, 
UK). Rossant-GFP TSCs were a gift from Janet Rossant (Hospital for Sick Children, 
Canada). 
2.1.1.1 Cell maintenance 
Cells were maintained as previously described (Tanaka et al., 1998, Hayakawa et 
al., 2015). Briefly, cultures were maintained in TSC maintenance medium (TSCMM) 
(Appendix A) and incubated at 37C in 5% CO2. TSCs were passaged as follows: 
cells were washed briefly in PBS, incubated in TrypLE (12604013, Gibco) at 37C 
for five minutes, disaggregated by pipetting and quenched with 1.5 mL TSCM 
(Appendix A). Cells were passaged 1:20 approximately every four days with medium 
changes every two days. For cell density experiments, cells were plated at 1.05 x 
104 cells per cm2. Cell counting was performed using an EVE Automatic Cell Counter 
(NanoEnTek Inc., Korea). For ChIP-seq experiments, TSCs were plated in 100 mm 
dishes and harvested at approximately 70% confluency. Cells were subjected to in-
house Mycoplasma screening every two months (Cell Services Science Technology 
Platform, The Francis Crick Institute). 
2.1.1.2 Transfection 
Multiple reagents, vector concentration and incubation times were trialled when 
optimising transfection efficiency. As previously shown, jetPRIME was the most 




efficient reagent (Hayakawa et al., 2015) and the maximum transfection efficiency 
was approximately 30%.  
 
The transfection reagent jetPRIME (114-07, Polyplus-transfection®) was used to 
deliver the vectors for shRNA knockdown, CRISPR-Cas9 genome editing and 
enhancer validation experiments. For shRNA and CRISPR-Cas9 experiments, cells 
were passaged as described above (see 2.1.1.1), plated at 7 x 104 cells per 6 well 
plate well in 1.5 mL TSCMM (Appendix A) and left to adhere overnight 
(approximately 16 hours). For each 6 well plate well transfected, 6 µg of plasmid was 
diluted in 400 µL of jetPRIME buffer. Subsequently, 15 µL of jetPRIME reagent was 
added, mixed briefly and incubated for 10 minutes at room temperature. The 
transfection mix was added to the existing medium on the cells and incubated four 
hours; after which the medium was aspirated and fresh TSCMM was added. For 
shRNA knockdown experiments, cells were co-transfected with 2 µg each for three 
vectors (see 2.2.7.2). For CRISPR-Cas9 co-transfections using two vectors, 3 µg of 
each vector (see 2.2.7.4) was used. 
 
For dual-luciferase assay experiments, 1.75 x 104 cells were plated per 24 well plate 
well in 300 µL TSCMM (Appendix A) and incubated for 16 hours to adhere. The 
activity of enhancer constructs (see 2.2.7.3) was assayed in both the presence (+GF) 
and absence (-GF) of growth factors. For this, six 24 well plate wells were plated per 
enhancer construct per experiment: three biological replicates for +GF and -GF, 
respectively. Immediately before transfection, the medium on -GF wells was replaced 
with fresh TSCM only (Appendix A). A total of 1080 ng of firefly luciferase construct 
and 120 ng of pRL Renilla Luciferase Control Reporter Vector (E2231, Promega) 
was diluted in 100 µL jetPRIME buffer and 3 µL jetPRIME reagent added for each 
24 well plate well. The transfection mix was vortexed, incubated at room temperature 
for ten minutes, added to cells and incubated for four hours. Subsequently, the 
medium was changed to TSCMM and TSCM for +GF and -GF conditions, 
respectively.  




2.1.1.3 Drug selection for transfected cells 
To select for positively transfected cells, 0.7µg/mL puromycin (A1113803, Thermo 
Fisher Scientific) was added to TSCMM (Appendix A) and used to replace the 
medium on cells 48 hours post-transfection. Cells were incubated in puromycin for 
32 hours, before the medium was aspirated. Cells were washed in PBS and cultured 
thereafter in TSCMM.  
2.1.1.4 Differentiation 
To induce spontaneous differentiation in TSCs, cells were plated at 1 x 104 cells per 
6 well plate well in TSCMM (Appendix A) for 16 hours. Concurrent with the start of 
transfection experiments, the medium was changed to TSCM only (Appendix A) 
which is devoid of any growth factors. Cells were collected for immunofluorescence 
(see 2.3.1) and RNA isolation (see 2.2.2) in parallel with transfection experiments.  
2.1.1.5 Fluorescence-activated cell sorting (FACS) 
For shRNA knockdown and CRISPR-Cas9 genome editing experiments, 
constitutively active fluorescent protein cassettes were used to visualise and isolate 
transfected cells. Cells were isolated in bulk for both knockdown and genome editing 
experiments. For CRISPR-Cas9 genome editing, single-cell sorting was also 
performed to generate clonal cell lines. Due to high demand, a range of cell sorting 
machines available in the Flow Cytometry Science Technology Platform at The 
Francis Crick Institute were used, including: MoFlo XDP (Beckman Coulter, USA), 
BD FACSAriaTM Fusion (BD Biosciences, USA) and Avalon (Bio-Rad Laboratories, 
USA) cell sorters. Cells were dissociated as described (see 2.1.1.1), pushed through 
cell strainer lids (352235, Corning, Fisher Scientific) on polypropylene 5 mL FACS 
tubes (352063, Corning, Fisher Scientific) and centrifuged for three minutes at 200x 
g. The supernatant was then aspirated and the pellet re-suspended in approximately 
100 µL PBS containing 1% foetal bovine serum (FBS, 16000044, Thermo Fisher 
Scientific) per 6 well plate well. Tube were kept on ice for the entire sort. For ATAC-
seq, 50,000 cells were collected in 1.5 mL tubes (0030108051, Eppendorf) 
containing PBS. For collections to isolate RNA, cells were sorted directly into TRIzol 
(15596018, Thermo Fisher Scientific). 





TSCs were frozen in TSCM (Appendix A) containing 10% dimethyl sulfoxide (DMSO, 
D2650, Merck). Approximately six cyrovials (363401, Thermo Fisher Scientific) 
containing 1 mL of cells each was obtained from a 6 well plate well. Vials were placed 
at -80C overnight in a cell freezing container and were subsequently transferred to 
permanent storage in liquid nitrogen. 
2.1.2 Mouse embryonic fibroblasts 
Vials of frozen P0 MF1 mouse embryonic fibroblasts (MEFs) (1 x confluent T175) 
were supplied by the Human and Embryo Stem Cell Unit (HESCU, The Francis Crick 
Institute). 
2.1.2.1 Production of conditioned medium for TSCs 
Cells were thawed into a 150 mm dishes and cultured in MEF medium (Appendix A) 
at 37C in 5% CO2. For passaging, cells were dissociated using trypsin-EDTA 
(25300054, Gibco, Thermo Fisher Scientific) and were expanded for three passages 
to generate in excess of 10 x 107 cells. After dissociation, cells were exposed to an 
approximate 35 Gy dose of radiation using a caesium source. Thereafter, cells were 
counted and plated at 6 x 106 cells per 150 mm plate in 27 mL TSCM (Appendix A). 
Every three days, for a total of five collections, conditioned medium (CM) was 
collected, frozen and replaced with fresh TSCM. Once all collections were 
completed, batches were pooled, centrifuged and filtered to remove any MEF cell 
debris. Filtered conditioned medium was stored at -20C. 
2.2 Molecular Biology 
Primers were either obtained from published work or designed using Primer3 
(Untergasser et al., 2007). Primer specificity was confirmed using primer-BLAST (Ye 
et al., 2012). The sequences of all oligonucleotides used within this thesis are 
provided in Appendix B (ordered from Sigma-Aldrich/Merck, USA).  




2.2.1 Genomic DNA extraction 
Genomic DNA (gDNA) was extracted from TSCs for PCR amplification of enhancer 
constructs and to genotype CRISPR-Cas9 genome edited TSCs. After dissociation, 
(see 2.1.1.1) cells were centrifuged at 200x g for three minutes. Pellets were 
resuspended in KT buffer (Appendix A) according to the number of cells isolated 
(approximately 10 µL per 1 x 104 cells) and incubated at 55°C for 60 minutes and at 
95°C for 15 minutes. Lysates were stored at -20°C.  
2.2.2 RNA extraction 
For CRISPR-Cas9 genome edited clones, RNA was extracted using the RNeasy® 
Mini Kit (74106, QIAGEN) according to manufacturer’s instructions (Genomics 
Equipment Park, The Francis Crick Institute). RNA was isolated for RNA-seq and 
shRNA knockdown experiments as follows: cells were washed in PBS, 500 µL TRIzol 
was added (15596018, Thermo Fisher Scientific) and transferred to 1.5 mL LoBind 
Eppendorf tubes (0030108051, Eppendorf). Tubes were snap-frozen and stored at -
80°C. After thawing on ice, 100 µL chloroform (C2432, Sigma-Aldrich, Merck) was 
added per 500 µL TRIzol, mixed and transferred to pre-spun phase-lock tubes (733-
2478, Quanta Bio, VWR). Samples were centrifuged at 12,000 rpm for 30 minutes at 
4°C. The upper aqueous phase containing RNA was transferred to a new RNase-
free tube (0030108051, Eppendorf) and an equal volume of 70% ethanol added 
((32221, Sigma-Aldrich, Merck), diluted in DNase-free water). Samples were 
incubated for 10 minutes at room temperature, transferred to RNeasy MinElute Spin 
Columns (74034, QIAGEN) and centrifuged for 30 seconds at 10,000 rpm. Buffer 
RW1, Buffer RPE and 80% ethanol ((32221, Sigma-Aldrich, Merck), diluted in 
DNase-free water) were applied in subsequent wash steps, centrifuged and 
discarded. After re-centrifugation to remove any residual wash buffer, RNA was 
eluted in 14 µL RNase-free water. RNA concentration was quantified using a 
Nanodrop spectrophotometer (Thermo Fisher: Waltham, USA). 
2.2.3 cDNA synthesis 
RNA was isolated as described (2.2.2) and converted to cDNA using the Maxima 
First Strand cDNA Synthesis Kit according to the manufacturer’s protocol (K1672, 
Thermo Scientific). For each cDNA synthesis reaction, between 250 ng and 1 µg 




total RNA was used.  cDNA dilutions were calculated as 0.6x RNA concentration (ng) 
of dH2O (µL) minus the total final volume of the cDNA synthesis reaction (20µL). 
Minus reverse transcription controls were generated to detect the presence of any 
contaminating genomic DNA.  
2.2.4 Polymerase chain reaction (PCR) 
For all cloning, sequencing and MiSeq genotyping reactions, a high-fidelity 
polymerase was used (M0493S, NEB) as per the manufacturer’s protocol. For PCR 
primer validation, colony PCR and TA cloning, KAPA2G Fast ReadyMix was used 
(KK5103, Kapa Biosystems) according to the manufacturer’s protocol. All PCR 
reactions used an appropriate volume of DNA relative to its concentration. Primers 
were used at a final concentration of 0.2 µM (Sigma-Aldrich/Merck, USA). Standard 
PCR reaction volumes were between 20 µL and 50 µL depending on the intended 
subsequent use. PCR reactions were performed in a thermocycler (T100 Thermal 
Cycler, BioRad). To visualise DNA fragment lengths, PCR products were loaded onto 
an 1-2% agarose/TAE gel (16500500, Invitrogen) containing 1:50,000 RedSafe 
(21141, Ecogen) with an appropriately sized DNA ladder (NEB). Gel electrophoresis 
was performed at around 100 V for an appropriate length of time to resolve bands 
and images were acquired on the ChemiDocTM XRS+ Imaging System (Bio-Rad 
Laboratories, USA) using proprietary Quantity One software (Bio-Rad Laboratories, 
USA).   
2.2.5 Quantitative real-time PCR (qRT-PCR) 
All primers were tested for their specificity using PCR on cDNA followed by gel 
electrophoresis to assess the fragment length and number of products. qRT-PCR 
analysis was performed using the established 2^(-delta delta CT) method (Livak and 
Schmittgen, 2001). As such, primers were tested using standard curve analysis. If 
their efficiency was 2  0.1, this was deemed to be sufficient. RNA was extracted 
(see 2.2.2) and converted to cDNA (see 2.2.3) as described. As per the 
manufacturer’s instruction, 384 plates (4ti-0380/C, 4titude) were prepared with 
Lightcycler 480 SYBR Green I master mix (04887352001, Roche). Each biological 
replicated was plated in technical triplicate and run on the Lightcycler 480 II thermal 




cycler (Roche, Switzerland). Data were exported from proprietary Roche software 
and processed in Excel (Microsoft, USA).  
2.2.6 Solid phase reverse immobilisation (SPRI) bead purification 
SPRI beads were generated and validated in-house by Rita Monteiro (Smith Lab, 
The Francis Crick Institute). For ATAC-seq and MiSeq, beads were applied at ratios 
of 1:1.5 and 1:1 per volume of DNA, respectively, in a 96 well microplate (4ti-0117, 
4titude). Bead-DNA samples were left to incubate for five minutes and then placed 
on a magnetic stand (AM10027, Invitrogen, Thermo Fisher Scientific) for five 
minutes, allowing beads to separate. Bead-DNA complexes were washed twice in 
80% ethanol ((32221, Sigma-Aldrich, Merck), diluted in DNase-free water) and the 
supernatant discarded. Microplates were sealed using an adhesive PCR film (4ti-
0500, 4titude) and centrifuged at 200x g for one minute. Microplates were replaced 
on the magnetic stand and all remaining supernatant removed. After airdrying on the 
magnetic stand, microplates were removed from this stand and beads were re-
suspended in 20 µL 10 mM Tris-HCl to elute DNA. After a five-minute incubation, the 
microplate was re-placed on the magnetic stand, the eluate collected and stored at -
20°C.  
2.2.7 Cloning of vectors 
Once cloning of each vector was confirmed, large quantities of plasmids were 
generated using ZymoPURE II Plasmid Maxiprep Kits (D4202, Zymo Research).   
2.2.7.1 Colony PCR 
Individual colonies were isolated in 50 µL Buffer TE (Media Preparation, The Francis 
Crick Institute). PCR reactions were performed using 2 µL of colony in TE, 0.2 µM 
final concentration of primers and 12 µL 2X KAPA2G Fast ReadyMix (KK5103, KAPA 
Biosystems, Roche). PCR conditions were as follows: pre-incubation at 98°C for 3 
minutes, 35 cycles of; 98°C for 15 seconds, 60°C for 15 seconds, 72°C for 1 minute; 
final extension at 72°C for 2 minutes. Extension time (72°C) within the cycles varied 
depending on the size of the intended fragment from 15 seconds to two minutes. 20 
µL PCR product was used to visualise and verify fragment size in 1-2% agarose/TAE 
gel containing 1:50,000 RedSafe (21141, Ecogen). Positive bacterial clones 




containing the desired size insert were subsequently used to generate mini preps, 
extracted using the QIAprep Spin Miniprep Kit (27106, QIAGEN), and the insert was 
sequenced by sanger sequencing (Genomics Equipment Park, The Francis Crick 
Institute).  
2.2.7.2 pLKO.1-mCherry-IRES-puromycin 
Five TRC (The RNAi Consortium) Lentiviral shRNA vectors that target Cdx2 were 
purchased from Dharmacon-GE (Horizon, UK) (Table 2.1).  
 
Table 2.1: Purchased shRNA vectors targeting Cdx2.  
 
Existing puromycin cassettes in pLKO.1 vectors were replaced by nuclear mCherry-
IRES-puromycin (mCIP) amplified from pBRY-nuclear mCherry-IRES-PURO 
(primers in Appendix B, Merck). pBRY-nuclear mCherry-IRES-PURO was a gift from 
Jacob Hanna (Addgene plasmid # 52409 ; http://n2t.net/addgene:52409 ; 
RRID:Addgene_52409). PCR conditions were as follows: pre-incubation at 98°C for 
3 minutes, 35 cycles of; 98°C for 20 seconds, 68°C for 30 seconds, 72°C for 150 
seconds; final extension at 72°C for 2 minutes (see 2.2.4). pLKO.1 vectors were 
linearised using KnpI-HF (R3142S, NEB) and BamHI-HF (R3136S, NEB) in 
CutSmart® Buffer at 37°C for one hour. Linearised pLKO.1 vectors and mCIP PCR 
products were resolved by gel electrophoresis, the correct band cut out and purified 
using the QIAquick Gel Extraction Kit (28706, QIAGEN) as per the manufacturer’s 
protocol. mCIP PCR products were cloned in to each pLKO.1 vector using In-
Fusion® HD Cloning Kit (638920, Takara Bio) according to the manufacturer’s 
protocol. Ligated plasmids were transformed into TOP10 competent bacteria 
(C4040-06, Thermo Fisher Scientific), plated on agar infused with ampicillin (Media 
Preparation, The Francis Crick Institute) and incubated at 37°C overnight. Colony 
PCR was performed on 6-8 colonies as described (see 2.2.7.1) using mCIP_F and 
mCIP_R primers (Appendix B).  
TRC Clone ID Thesis name Target Sequence Vector
TRCN0000055393 shRNA1 GTTTCACTTTAGTCGATACAT pLKO.1
TRCN0000055394 shRNA2 GCTCTCCGAGAGGCAGGTTAA pLKO.1
TRCN0000055395 shRNA3 CCGCATCATCACCCGCACCAT pLKO.1
TRCN0000055396 shRNA4 CGGGTGGTGTACACAGACCAT pLKO.1
TRCN0000055397 shRNA5 GCGAAACCTGTGCGAGTGGAT pLKO.1
N/A SCR CCTAAGGTTAAGTCGCCCTCG pLKO.1




2.2.7.3 Enhancer validation constructs (pGL3-basic) 
Several genomic regions shown to increase in accessibility under Cdx2 knockdown 
conditions around the Hand1 locus were assessed for their enhancer activity on the 
Hand1 promoter. To perform enhancer validation experiments, pGL3 Luciferase 
Reporter vectors (E1751/E1771/E1761, Promega) containing a modified firefly 
luciferase gene were used in a dual luciferase assay.  
 
Three Hand1 promoters of differing lengths (209bp, 283bp and 673bp, see Figure 
5.11a) were tested for their efficiency (primers in Appendix B). These were PCR 
amplified from INX gDNA (see 2.2.1) using Q5® High-Fidelity DNA Polymerase 
(M0493S, NEB) according to the manufacturers protocol. PCR conditions were as 
follows: pre-incubation at 98°C for three minutes, 40 cycles of; 98°C for 15 seconds, 
60°C for 15 seconds, 72°C for 30 seconds; final extension at 72°C for 1 minutes. 
Fragments were purified using the QIAquick PCR purification kit (28104, QIAGEN) 
as per the manufacturer’s protocol. Restriction digest reactions were performed for 
each promoter fragment, the pGL3-basic vector (E1751, Promega) and the pGL3-
enhancer vector (E1771, Promega) using XhoI (R0146S, NEB) and HindIII-HF 
(R3104S, NEB) in CutSmart® buffer at 37°C for one hour. Linearised pGL3-basic 
vector (500ng) were dephosphorylated and the ligation of PCR fragments and 
vectors performed using the Rapid DNA Dephosphorylation & Ligation Kit (04-898-
125-001, Roche) as per the manufacturer’s protocol. Ligated plasmids were 
transformed into TOP10 competent bacteria (C4040-06, Thermo Fisher Scientific) 
and selected on ampicillin-infused agar plates. Colony PCR was performed on 6-8 
colonies (see 2.2.7.1) using pGL2-Basic_F and LucNrev primers (Appendix B). 
Three clones with the desired insert were sanger sequenced for each new vector. 
Any deviations in sequence from the reference GRCm38.p6 Ensembl genome had 
to be consistent between pGL3-basic and pGL3-enhancer and are highlighted in 
Appendix C 
 
Although all three promoters tested are active and respond to the SV40 enhancer, 
the 283bp promoter had the most similar baseline activity to the SV40 promoter only 
control vector (E1761, Promega). As such, this promoter was chosen to assay the 
enhancer capabilities of six (Region A-F) differentially accessible regions found 




around the Hand1 locus under shRNA knockdown conditions. Two control regions, 
C1 and C2, representing inaccessible and non-changing accessible regions, 
respectively, were also cloned into the 283bp Hand1 promoter pGL3-basic vector. 
Primers were ordered with SalI restriction sites added to the 5’ end of both 
oligonucleotides (Appendix B, Merck). Each enhancer region was amplified and PCR 
purified using the same protocol as described for the promoter regions above. 
Restriction digest reactions for SalI-HF (R3138S, NEB) were performed on all 
amplicons and the 283bp Hand1 promoter pGL3-basic vector according the 
manufacturer’s protocol. The linearised plasmid was dephosphorylated and ligated 
with the enhancer constructs using the Rapid DNA Dephosphorylation & Ligation Kit 
(04-898-125-001, Roche) following the manufacturer’s protocol and transformed into 
TOP10 bacteria (C4040-06, Thermo Fisher Scientific). As only one restriction 
enzyme was used, the enhancer regions could insert in two directions. Colony PCR 
was performed for eight colonies on ampicillin-infused agar plates as described (see 
2.2.7.1) using RVprimer4 and specific forward primers to the respective enhancer 
(Appendix B), enabling the selection of colonies that contained the insert in the 
desired orientation. 
 
Enhancer B and D proved difficult to clone by conventional cloning. As such, both 
were cloned into dephosphorylated SalI-linearised plasmids (primers in Appendix B) 
using the In-Fusion® HD Cloning Kit (638920, Takara Bio) according to the 
manufacturer’s protocol. In-Fusion® products were transformed into TOP10 bacteria 
(C4040-06, Thermo Fisher Scientific) and several colonies on ampicillin-infused agar 
plates were subject to colony PCR (see 2.2.7.1).  
 
Sanger sequencing (Genomics Equipment Park, The Francis Crick Institute) was 
performed on three colonies with the desired orientation for all enhancers to validate 
the sequence and characterise any deviations from the reference GRCm38.p6 
Ensembl genome. Plasmids showing minimal number of deviations from this 
reference genome were selected for dual luciferase assays. Any characterised 
deviations in sequence from the reference genome are outlined in Appendix C.  




2.2.7.4 px330-mCherry-gRNA  
Guide RNA (gRNA) sequences were designed using the MIT CRISPR Designer tool 
(Cong et al., 2013, Ran et al., 2013). BbsI restriction sites were added to the 5’ end 
of each oligonucleotide for the six chosen gRNAs (G2a-f, Merck, Appendix B). 
Oligonucleotide pairs were annealed and cloned into the px330-mCherry plasmid, a 
gift from Jinsong Li (Addgene plasmid # 98750; http://n2t.net/addgene:98750; 
RRID:Addgene_98750), using an established digestion-ligation protocol (Cong et al., 
2013). Each ligation reaction was transformed into TOP10 competent bacteria 
(C4040-06, Thermo Fisher Scientific), plated on agar infused with ampicillin (Media 
preparation, The Francis Crick Institute) and incubated at 37°C overnight. Colony 
PCR (see 2.2.7.1) was performed on six clones for each gRNA inserted using hU6 
and the reverse oligonucleotide for each G2a-f gRNA (primers in Appendix B) and 
visualised on a 1.5% agarose/TAE gel containing 1:50,000 RedSafe (21141, 
Ecogen). Three clones per gRNA were used to generate mini preps and eluted using 
the QIAprep Spin Miniprep Kit (27106, QIAGEN) as per the manufacturer’s protocol. 
Correct orientation and sequence were confirmed by sanger sequencing using the 
hU6 primer (Appendix B) (Genomics Equipment Park, The Francis Crick Institute).  
2.2.7.5 TA cloning 
To validate the genotype of Cdx2 clones, full-length Cdx2 transcripts were PCR 
amplified using 5to3_Cdx2 primers (Appendix B) using 2X KAPA2G Fast ReadyMix 
(KK5103, KAPA Biosystems, Roche) according to the manufacturer’s protocol (see 
2.2.4). PCR products, purified using the QIAquick PCR purification kit (28104, 
QIAGEN) as per the manufacturer’s instructions, were TA cloned into the pGEM®-T 
Easy Vector System (A1360, Promega). TOP10 competent bacteria (C4040-06, 
Thermo Fisher Scientific) were transformed and plated on ampicillin infused agar 
plates. Mini preps were generated for up to 15 colonies and the vectors purified and 
sanger sequenced using the 5to3_Cdx2 primers by the Genomics Equipment Park 
at The Francis Crick Institute.  
2.2.8 Flow cytometry  
Flow cytometry was performed to quantify the expression of CDX2, GATA3, HAND1 
and TFAP2C in wild-type, shRNA knockdown and CRISPR-Cas9 genome editing 




experiments. Cells were dissociated as described (see 2.1.1.1), filtered using cell 
strainers on FACS tube (352235, Corning, Fisher Scientific) and pelleted for three 
minutes at 200x g. Pellets were re-suspended in cold 4% PFA (28908, Thermo 
Fisher Scientific) whilst vortexing cells to reduce cell clumping. Cells were fixed for 
15 minutes on a rotator. To wash cells, tubes were filled with PBS, centrifuged at 
250x g for three minutes and the supernatant discarded three times. To permeabilise 
and block, cells were pelleted for three minutes at 300x g and re-suspended in 
blocking buffer (1% BSA (A9647, Sigma-Aldrich, Merck), 0.5% Tween-20 (NAT1082, 
Scientific Laboratory Supplies)) and incubated for one hour at room temperature. 
Cells were counted using the EVE automatic cell counter (NanoEnTek Inc, Korea).  
 
For staining, antibodies were diluted in blocking buffer as follows: 1:5 anti-CDX2 
(560395, BD Biosciences), 1:5 anti-GATA3 (560405, BD Biosciences), 1:75 anti-
HAND1 (AF3168, R&D Systems) and 1:50 anti-TFAP2C (AF5059, R&D Systems). 
In all cases, 10 μL antibody suspension was added per 1 x 105 cells up to a maximum 
total of 1 x 106 cells (equivalent to 100 μL antibody). Antibody-cell suspensions were 
incubated for 30 minutes at room temperature in the dark. Unstained and single 
antibody stained cells were generated for each antibody in every experiment. Cells 
were washed in three times in PBS, centrifuging at 250x g for three minutes. For the 
unconjugated anti-HAND1 and anti-TFAP2C antibodies, cells were stained with 
donkey anti-goat Alexa fluor 647 (A-21447, Invitrogen, Thermo Fisher Scientific) 
diluted 1:500 in blocking buffer. As with the primary antibodies, 10 μL antibody 
suspension was added per 1 x 105 cells and incubated for 30 minutes at room 
temperature. Cells were washed three times in PBS by filling the tube, centrifuging 
for three minutes at 200x g and discarding the supernatant. Cell pellets were 
resuspended in 200 μL PBS per condition and 10 μL of 250 μg/μL DAPI (DAPI 
(40011, Biotium), diluted to 5 mg/mL in PBS) were added to each experimental 
condition and DAPI only controls.  
 
Flow cytometry analysis was performed on one of the BD LSR Fortessa or BD LSR 
II (BD Biosciences, USA) machines available in the Flow Cytometry Science 
Technology Platform (The Francis Crick Institute). Analysis of flow cytometry data 
was performed on FlowJoTM 10.3 (BD Biosciences, USA).   




2.2.9 Dual luciferase assay for enhancer validation  
All enhancer validation assays were performed in TSCs. Transfections were 
performed as described (see 2.1.1.2). Dual luciferase assay was performed using 
the Dual-Luciferase® Reporter Assay System (E1910, Promega). Luciferase 
Reagent (LARII) and Stop & Glo® reagents were diluted as per the manufacturer’s 
recommendations and then 1:10 with dH2O. LARII and Stop & Glo® reagents were 
stored at -20°C. At approximately 24-hours post-transfection, wells were washed in 
PBS and lysed in 150 μL 1 x passive lysis buffer (PLB) for 30 minutes at room 
temperature in the dark on a shaking plate. 5 μL lysate was transferred per sample 
in technical duplicate and measured one at a time on the microplate luminometer 
(Centro XS3 LB960, Berthold Technologies) using the following conditions: 100 μL 
of LARII was added to a well, there was a delay of two seconds and the luminometer 
measured firefly (pGL3) activity. Subsequently, the luminometer added 100 μL of 
Stop & Glo® reagent, delayed for two seconds and measured Renilla luciferase 
(pRL) activity. MikroWin software (Labsis, Germany) was used to generate ratios 
between firefly and Renilla luciferase and data was exported and processed in Excel 
(Microsoft, USA). 
2.2.10 Clustered regularly interspaced short palindromic repeats (CRISPR) 
mutation analysis 
Six gRNAs (G2a-f) were cloned into the px330-mCherry vector (Wu et al., 2013) (see 
2.2.7.4) and transfected into TSCs alone or in pairs (see 2.1.1.2). Positively 
transfected cells were isolated by their mCherry expression in bulk or as single-cells 
(see 2.1.1.5). Genotyping of clonal and polyclonal populations was performed by one 
of two methods.  
2.2.10.1 MiSeq  
Three primer sets were designed to generate PCR fragments of 360-380bp around 
the targeted region (Chapter 6, Figure 6-6a). Overhang adapter sequences required 
for further library preparation were added to the 5’ end of forward and reverse 
oligonucleotides (ordered from Merck, Appendix B). gDNA was extracted as 
described (see 2.2.1) and PCR amplified using Q5® High-Fidelity DNA Polymerase 
(M0493S, NEB). PCR conditions were as follows: pre-incubation at 98°C for 3 




minutes, 30 cycles of; 98°C for 20 seconds, 61.4°C for 20 seconds, 72°C for 30 
seconds; final extension at 72°C for 1 minutes. Presence of PCR amplicons was 
confirmed by running a small aliquot on a 2% agarose/TAE gel with 1:50,000 
RedSafe (21141, Ecogen). Amplicons were subsequently purified using a SPRI bead 
purification (see 2.2.6) and eluted in 20μL 10 mM Tris-HCl. For single-cell clonal 
analysis, amplicons were generated with one of the three MiSeq primer sets with an 
amplicon for each primer set pooled together to internally multiplex each sample. 
Further library preparation using Illumina TruSeq indexing primers (Illumina) and 
DNA quantification were performed by Matthew Winder (Genetic Modification 
Service, The Francis Crick Institute). Samples were submitted for sequencing to the 
Advanced Sequencing Facility (ASF) at The Francis Crick Institute. Following various 
quality control assessments, libraries were sequenced on the Illumina MiSeq 
platform and generated 250bp paired-end reads. 
 
For bulk sample analyses, mutations and their frequencies were determined using 
Cas-Analyzer using the WT marker analysis parameter (Park et al., 2017). Tables 
were downloaded and subdivided into one of four categories: wild-type and/or 
substitution (WT/SUB), frameshift, small in-frame or large in-frame mutations using 
Excel (Microsoft, USA).  
 
For single-cell clonal analysis, paired-end reads were analysed as single-end reads 
to compare genotypes between reads. Clonal genotyping analysis was performed by 
Harshil Patel (Bioinformatics, The Francis Crick Institute). Briefly, fastq files were 
mapped to the mm10 genome independently using bbmap (version 37.00) (Bushnell, 
2016) with the parameters “in=<FASTQ_FILE> outm<SAM_FILE> ref=<INDEX> 
vslow=t maxindel=2000 ambig=toss sam=1.3 mdtag=t nhtag=t xmtag=t amtag=t 
nmtag=t idtag=t scoretag=t”. Custom scripts using pysam (version 0.9.0) 
(https://github.com/pysam-developers/pysam) were written to split the mapped reads 
by the original primer sequence and to calculate indel frequencies. Individual clone 
genotypes were then inferred using the proportions of reads for each variant within 
that sample and validated as the same for both paired-end reads.  




2.2.10.2 CRISPR cassette screening 
Initial screening of single-cell clones was performed by sanger sequencing, but the 
prevalence of multiple mutations reduced its usefulness. Briefly, gDNA was PCR 
amplified using the MiSeq primers (P1, Appendix B) and conditions outlined in 
2.2.10.1. The presence of amplicons were confirmed by gel electrophoresis. PCR 
reactions were enzymatically purified using ExoSAP-ITTM PCR Product Cleanup 
Reagent (78200.200.UL, Thermo Fisher Scientific) as per the manufacturers 
protocol by Maria Greco (Genomics Equipment Park, The Francis Crick Institute). 
Sanger sequencing was performed for each PCR amplicon using the MiSeq primer 
without the adapter sequence (Genomics Equipment Park, The Francis Crick 
Institute).  
2.3 Microscopy 
Images were analysed using FIJI (ImageJ, version 2.0.0). 
2.3.1 Immunofluorescence (IF) staining 
TSCs were cultured as described (see 2.1.1.1) on sterilised circular coverslips 
(Media Preparation, The Francis Crick Institute). Once cells had reached the desired 
confluency or time point, cell medium was aspirated and cells fixed in ice cold 4% 
formaldehyde (28908, Thermo Fisher Scientific, diluted in PBS) for 10 minutes at 
room temperature on a shaking plate. Fixative was removed and wells were washed 
three times in PBS. Coverslips were stored for up to three months in PBS at 4°C. To 
permeabilise cells, coverslips were incubated in PBST (0.1% Triton X100 (X100, 
Merck) diluted in PBS) for 10 minutes at room temperature. To minimise non-specific 
binding, cells were blocked in blocking buffer (5% donkey serum (34762907, Abcam) 
diluted in PBST) for one hour at room temperature. Primary antibodies and dilutions 
used were as follows: rabbit anti-CDX2 1:200 (A300-691A, Bethyl Laboratories), 
mouse anti-CDX2 1:100 (ab157524, Abcam), anti-TBR2/Eomes 1:250 (ab23345, 
Abcam), goat anti-HAND1 1:150 (AF3168, R&D Systems), goat anti-TFAP2C 1:150 
(AF5059, R&D Systems), goat anti-GATA3 1:200 (AF2605, R&D Systems). All 
primary antibodies were diluted in blocking buffer and incubated at 4°C overnight in 
a humidified chamber. Coverslips were washed in PBST for five minutes three times 




and subsequently stained with an appropriate AlexaFluor conjugated secondary 
antibody (Invitrogen, Thermo Fisher Scientific) diluted in blocking buffer at room 
temperature for one hour. Coverslips were subsequently washed three times with 
PBST. For long-term Cdx2 knockdown and Cdx2 clonal analysis experiments, 
coverslips were stained for 20 minutes at room temperature with 1:100 Alexa Fluor 
Phalloidin 488 (A12379, Thermo Fisher Scientific) and 1:10,000 4’,6-Diamidino-2-
Phenylindole, dihydrochloride (DAPI (40011, Biotium), diluted to 5mg/mL in PBS) 
diluted in blocking buffer. For all experiments, coverslips were washed in PBST for 
five minutes three times and mounted onto microscope slides (J1840AMNT, Thermo 
Fisher Scientific) in VECTASHIELD® Mounting Medium with DAPI (H-1200, Vector 
Laboratories). High quality images were acquired on the LSM 710 Zeiss Confocal 
Laser Scanning Microscope using proprietary Zeiss software (Zeiss, Germany).  
2.3.2 Live cell imaging 
Trophoblast stem cells were transfected with SCR or KD (see 2.1.1.2) and selected 
for using puromycin (see 2.1.1.3). Immediately after, TSCs were placed in an 
incubator (Okolab, Italy) at 37°C and 5% CO2 on the Nikon Eclipse Ti2 inverted 
microscope (Nikon, USA). An image was taken at each position every five minutes 
for 48 hours using Micro-Manager software (version 1.4) (Edelstein et al., 2014).  
2.4 Next generation sequencing 
All quality control metrics and sequencing were performed by the Advanced 
Sequencing Facility (ASF) at The Francis Crick Institute. Library preparation for all 
biological replicate samples was performed in parallel to mitigate batch effects. 
2.4.1 Chromatin immunoprecipitation with massively parallel DNA 
sequencing (ChIP-seq) 
The protocol described below is adapted from a published ChIP-seq protocol 
optimised in the Smith Lab for early Xenopus embryos (Gentsch and Smith, 2017). 
2.4.1.1 Chromatin immunoprecipitation (ChIP) 
INX and XYO TSCs were cultured as described above (section 2.1.1.1) in 3 x 100 
mm dishes per ChIP. At approximately 70% confluency, cell medium was aspirated 




and adherent cells fixed in fixing buffer (1% formaldehyde (F8775, Merck, diluted in 
PBS)) for nine minutes on a shaking plate at room temperature. The fixative was 
aspirated off and cells were washed in ice-cold PBS (Media Preparation, The Francis 
Crick Institute) containing protease inhibitors (88266, Thermo Fisher Scientific) three 
times. To detach adherent fixed cells, a cell scrapper was used to isolate cells into 4 
mL ice-cold PBS containing protease inhibitors per 100 mm dish. Cells were pelleted 
at 250x g for five minutes at 4°C, snap frozen in liquid nitrogen and stored at -80°C 
until processing.  
 
To isolate nuclei, pellets were resuspended in 10 mL ice-cold cell lysis buffer 
(Appendix A) containing protease inhibitors (88666, Thermo Fisher Scientific) and 
centrifuged at 300x g for three minutes. The supernatant was aspirated and pellets 
resuspended in 5 mL ice-cold CEWB1 (Appendix A) containing protease inhibitors. 
Cells were homogenised by pipetting and pelleted at 600x g for four minutes at 4°C. 
Pellets were resuspended in 3 mL CEWB1 containing protease inhibitors and 
incubated for 25 minutes on ice. During this incubation, cells were homogenised by 
pipetting every 5-7 minutes. Approximately 1 mL of homogenate was transferred to 
milliTUBE 1 ml AFA Fibre vessels (520135, Covaris) at a time. A Covaris S220 
Focused-ultrasonicator (500217, Covaris) was used to sonicate samples using the 
following settings: duty cycle = 5%, intensity = 4, cycles/burst = 200, procedure time 
= 420 seconds, temperature = <8°C. Sonicated samples were transferred to 1.5 mL 
DNA LoBind Tubes (0030108051, Eppendorf) on ice. To remove cellular and nuclear 
debris, sonicated DNA was centrifuged at 12,000 rpm for 10 minutes at 4°C. The 
supernatant containing crosslinked DNA transferred to new 1.5 mL DNA LoBind 
tubes (0030108051, Eppendorf) and stored for up to two days at 4°C. Sonication 
efficiency was determined before proceeding to chromatin precipitation. For this, 50 
μL crosslinked sheared chromatin was added to 50 μL SDS Elution buffer (Appendix 
A), 5 μL 5M NaCl and 1 μL 20mg/mL Proteinase K (AM2546, Thermo Fisher 
Scientific) and incubated 65°C for 8-16 hours. De-crosslinked DNA was purified 
using the QIAquick PCR purification kit (28104, QIAGEN) as per the manufacturer’s 
instructions, eluting twice in 11 μL Buffer EB. After treatment with 0.4 μL RNase A 
(Invitrogen, 12091-039), fragment sizes were visualised by gel electrophoresis using 
a 1.4% agarose/TAE gel containing 1:50,000 RedSafe (21141, Ecogen) alongside 
1kb (N3232L, NEB) and 100bp (N3231L, NEB) ladders. Shearing was deemed to be 




successful if the DNA fragments are distributed between 100-1000bp, with the 
majority of fragments sized between 300-500bp. Sonication was repeated for 100-
200 seconds if shearing was unsuccessful at generating such sized fragments.  
 
Prior to chromatin immunoprecipitation (ChIP) on successfully sonicated samples, 
approximately 1% of total sheared chromatin volume was transferred to a new DNA 
lo-bind tube (0030108051, Eppendorf) and stored at 4°C until all ChIP samples were 
to be de-crosslinked. This sample represents the ChIP input. For this thesis, 
immunoprecipitation was performed for using a rabbit anti-CDX2 ChIP-grade 
antibody (A300-691A, Bethyl Laboratories). In total, three x 100 mm dishes were 
used to generate every library with each 100 mm dish immunoprecipitated using 1.5 
μg antibody and incubated overnight on a rotator at 4°C. To wash the ChIP, 60 μL 
Dynabead Protein G (10003D, Invitrogen) were washed in 1 mL CEWB1 for five 
minutes on a rotator at 4°C and resuspended in 60 μL CEWB1. In total, 45 μL of 
washed beads were added to the ChIP sample to account for 4.5 μg total antibody 
used and incubated for four hours on a rotator at 4°C. To remove unbound and non-
specific bound anti-CDX2 antibody, beads were washed ten times with 1 mL pre-
chilled RIPA buffer (Appendix A) and once with pre-chilled TEN buffer (Appendix A) 
for five minutes each. All beads corresponding to a single ChIP experiment were 
pooled together, centrifuged at 1000x g for one minute and placed in a magnetic rack 
where as much supernatant was removed as possible. Beads were re-suspended in 
100 μL SDS elution buffer (Appendix A), incubated at 65°C in a continually vortexing 
thermomixer for 15 minutes, centrifuged at 15,000g for 30 seconds and the eluate-
containing supernatant transferred to a new LoBind Tubes (0030108051, 
Eppendorf). This step was repeated and the eluates combined.  
 
Input sample volumes were adjusted by adding 180 μL SDS elution buffer to ensure 
equivalent volumes in both ChIP and input samples for chromatin reverse cross-
linking. Both samples were supplemented with 10 μL 5M NaCl, and incubated 
overnight at 65°C in a hybridisation buffer. After adding 210 μL of TE buffer and 4.2 
μL RNase A (Invitrogen, 12091-039), samples were incubated at 37°C for one hour. 
Subsequently, 4.2 μL 20mg/mL Proteinase K (AM2546, Thermo Fisher Scientific) 
was added to each sample and incubated at 55°C for two hours. ChIP and input 
samples were purified using QIAquick PCR purification kit (28104, QIAGEN) as per 




the manufacturer’s protocol and eluted in 30 μL dH2O. DNA concentration of ChIP 
and input samples was determined using the QubitTM dsDNA HS Assay (Q32851, 
Invitrogen, Thermo Fisher Scientific).  
2.4.1.2 Paired-end library preparation 
In total, 10 ng DNA was used to generate each ChIP and Input library using the KAPA 
Hyper Prep kit (KK8502, Roche). This was performed as per manufacturer’s protocol 
except for the following; Firstly, approximately 1.67 μM of TruSeq DNA adapters 
(15μM) were used per 10 ng library for Adapter Ligation. Secondly, to convert Y-
shaped Illumina adapters to dsDNA, allowing for efficient migration through the 
agarose gel and reducing the number of adapter dimers, a pre-amplification PCR 
cycle step was added: 5 cycles of; 98°C for 15 seconds, 60°C for 30 seconds, 72°C 
for 30 seconds. Finally, after pre-amplification, reactions were cleaned up using 1x 
volume of SPRI beads and following the protocol outlined in section 2.2.6.  
 
Next, libraries were size selected using an electrophoresis-based method. For this, 
libraries were run on an E-gel® EX 2% agarose gel (G402002, Thermo Fisher 
Scientific) using an E-gel® iBaseTM Power System (11531226, Fisher Scientific) and 
DNA between 250-450bp in size cut from the gel. DNA was subsequently purified 
using the MinElute Gel Extraction Kit (28606, QIAGEN) as per the manufacturer’s 
protocol. Using the HyperPrep kit, DNA was amplified for an appropriate number of 
cycles in a thermocycler and cleaned-up post-amplification according to the 
manufacturer’s instructions. Library concentration and DNA fragment integrity were 
determined by QubitTM dsDNA HS Assay (Q32851, Invitrogen, Thermo Fisher 
Scientific) and Agilent 2100 Bioanalyzer (Agilent, USA), respectively (Advanced 
Sequencing Facility, The Francis Crick Institute). ChIP-seq samples were sequenced 
on the Illumina HiSeq 2500 platform (Advanced Sequencing Facility, The Francis 
Crick Institute) and generated 101bp paired-end reads.  
2.4.2 Assay for Transposase Accessible Chromatin with high-throughput 
sequencing (ATAC-seq) 
ATAC-seq libraries were generated using a well-established protocol (Buenrostro et 
al., 2013, Buenrostro et al., 2015). Briefly, TSCs were cultured and transfected as 




described (sections 2.1.1.1 and 2.1.1.2, respectively). For each library generated, 
50,000 cells were isolated by FACS (section 2.1.1.5) and maintained on ice. Cells 
were pelleted at 500x g for five minutes at 4°C, re-suspended in 50 μL ice-cold ATAC 
cell lysis buffer (Appendix A) and homogenised by pipetting. Nuclei extracts, 
obtained by pelleting cells at 500x g for 10 minutes at 4°C, were resuspend in 50 μL 
transposition reaction mix (Nextera DNA library prep kit, FC-121-1030, Illumina) and 
incubated at 37°C for one hour. Transposed DNA was purified using QIAquick PCR 
purification kit (28104, QIAGEN) according to the manufacturer’s protocol and eluted 
10 μL Buffer EB.  
 
PCR reactions were cleaned-up by SPRI bead purification (section 2.2.6). Prior to 
sequencing, library concentration and DNA fragment sizes were determined by 
QubitTM dsDNA HS Assay (Q32851, Invitrogen, Thermo Fisher Scientific) and Agilent 
2100 Bioanalyzer (Agilent, USA), respectively. Sequencing was performed on the 
Illumina HiSeq 2500 platform (Advanced Sequencing Facility, The Francis Crick 
Institute) and typically generated ~55 million 51bp paired-end reads per library.  
2.4.3 RNA-seq  
Total RNA was extracted as described (section 2.2.2). A minimum of 500 ng was 
submitted to the Advanced Sequencing Facility at The Francis Crick Institute 
whereby samples underwent RNA integrity (RIN) quality control assessment using 
Caliper LabChip GX (Perkin Elmer, USA). Libraries were generated by the Advanced 
Sequencing Facility at The Francis Crick Institute from samples that were determined 
to have a RIN of nine and above using the TruSeq Stranded mRNA Library Prep Kit 
as per manufacturer’s protocol (Illumina, USA). RNA sequencing was carried out on 
the Illumina HiSeq 4000 platform (Advanced Sequencing Facility, The Francis Crick 
Institute) and typically generated ~35 million 76bp strand-specific single-end reads 
per sample.  
2.5 Bioinformatic analysis 
Alignment, generation of visual files, peak calling and differential analysis were 
performed by Harshil Patel (Bioinformatics, The Francis Crick Institute). Any other 
work performed by Harshil Patel is indicated.  




2.5.1 Acquisition of published datasets 
Several published datasets were integrated into analyses. All published ATAC-seq 
data used were downloaded as processed files (Table 2.2). As such, the analysis 
pipeline for these libraries can be found within the corresponding paper and is distinct 
from the pipeline used to process in-house generated ATAC-seq data (see 2.5.2). 
Where ‘.wig’ files were downloaded, I converted these to smaller files called ‘.bigwig’ 
(‘.bw’) using the wigToBigWig binary available from the UCSC (Kent et al., 2010).  
 
 
Table 2.2: Processed ATAC-seq libraries used throughout this thesis. 
 
All published ChIP-seq and RNA-seq libraries were downloaded as raw fastq files 
(Table 2.3) by Harshil Patel. RNA-seq analysis were processed using the same 
pipeline as outlined (see 2.5.4). ChIP-seq libraries were analysed in-line with the 
methods outlined (see 2.5.3) with minor alterations to accommodate for single-end 
reads.  
 
Published Name Thesis Name Respository Accession number File Description Chapters Used
TS_ATAC.wig.gz Visual file 3, 4 and 5
TS_ATAC_DARs.bed.gz Differential access peakset 4 and 5
TS_ATAC_total_peaks.bed.gz Total accessible regions 4
d2diff_ATAC.wig.gz Visual file 4 and 5
d2diff_ATAC_DARs.bed.gz Differential access peakset 4 and 5
d2diff_ATAC_total_peaks.bed.gz Total accessible regions 4








TS "TS RL" GEO GSE94694
d2diff "-GF RL" GEO GSE94694





Table 2.3: Summary of published ChIP-seq and RNA-seq libraries used in this thesis. Datasets were 
downloaded as raw files and processed using the same pipelines as in-house generated data by Harshil 
Patel.  
2.5.2 ATAC-seq analyses 
Raw reads from each sample were adapter-trimmed using cutadapt (version 1.9.1) 
(Martin, 2011) with parameters “-a CTGTCTCTTATA -A CTGTCTCTTATA --
minimum-length=25 –quality-cutoff=20”. BWA (version 0.6.2) (Li and Durbin, 2010)  
with default parameters was used to perform genome-wide mapping of the adapter-
trimmed reads to the mouse mm10 genome assembly downloaded from the UCSC 
(Karolchik et al., 2004). Read group addition, duplicate marking and insert size 
assessment was performed using the picard tools AddOrReplaceReadGroups, 
MarkDuplicates and CollectMultipleMetrics, respectively (version 2.1.1) 
(http://broadinstitute.github.io/picard/). Reads mapped to mitochondrial DNA were 
removed using the pairToBed command from BEDTools (version 2.26.0-foss-2016b) 
(Quinlan and Hall, 2010). Additional filtering was performed to only include uniquely 
mapped, properly-paired reads with insert size <= 1kb, and mismatches <= 1 in both 
Description Library Type Respository Accession number Sample Identifier Paired End / Single End Chapters Used
ADACHI CDX2 ChIP-seq GEO GSE51511 GSM1246724 Single End 3 and 4
ADACHI Input ChIP-seq GEO GSE51511 GSM1246726 Single End 3 and 4
CHUONG CDX2 ChIP-seq GEO GSE42207 GSM1035392 Single End 3
CHUONG Input ChIP-seq GEO GSE42207 GSM1035393 Single End 3
GSE42207 GSM1035380 Single End 4 and 5
GSE42207 GSM1035381 Paired End 4 and 5
H3K4me3 ChIP-seq GEO GSE42207 GSM1035382 Single End 4 and 5
GSE42207 GSM1035383 Single End 4 and 5
GSE42207 GSM1035384 Paired End 4 and 5
H3K4me1 ChIP-Seq GEO GSE42207 GSM1035385 Single End 4 and 5
GSE42207 GSM1035386 Single End 4 and 5
GSE42207 GSM1035387 Paired End 4 and 5
GSE42207 GSM1035393 Single End 4 and 5
GSE42207 GSM1035394 Paired End 4 and 5
TFAP2C in TSCs ChIP-seq ENA PRJNA298763 SRR2913350 Single End 4 and 5
TFAP2C in DD1 ChIP-seq ENA PRJNA298763 SRR2913306 Single End 4 and 5
TFAP2C Input ChIP-seq ENA PRJNA298763 SRR2913307 Single End 4 and 5
TSC Rep 1 RNA-seq ENA PRJNA298763 SRR2895339 Single End 4 and 5
TSC Rep 2 RNA-seq ENA PRJNA298763 SRR2895340 Single End 4 and 5
TSC Rep 3 RNA-seq ENA PRJNA298763 SRR2895341 Single End 4 and 5
TSC Rep 4 RNA-seq ENA PRJNA298763 SRR2895342 Single End 4 and 5
TSC Rep 5 RNA-seq ENA PRJNA298763 SRR2895317 Single End 4 and 5
DD1 Rep 1 RNA-seq ENA PRJNA298763 SRR2895318 Single End 4 and 5
DD1 Rep 2 RNA-seq ENA PRJNA298763 SRR2895319 Single End 4 and 5
DD1 Rep 3 RNA-seq ENA PRJNA298763 SRR2895320 Single End 4 and 5
DD3 Rep 1 RNA-seq ENA PRJNA298763 SRR2895321 Single End 4 and 5
DD3 Rep 2 RNA-seq ENA PRJNA298763 SRR2895322 Single End 4 and 5












reads. SAMtools (version 1.3.1) (Li et al., 2009) was used for bam file sorting and 
indexing. 
 
Three biological replicate libraries were generated per condition (Untransfected – UT, 
Scrambled mCherry negative – SCR NEG, Scrambled mCherry positive - SCR, Cdx2 
knockdown mCherry positive – KD). To generate sufficient numbers of reads, each 
biological replicate library was sequenced more than once. The filtered alignments 
from the technical replicates were merged for each biological replicate library at both 
the replicate level (per biological replicate) and sample level (per condition) using the 
picard MergeSamFiles command (http://broadinstitute.github.io/picard/). Duplicate 
marking and removal were reperformed on the merged alignments. BedGraph 
coverage tracks representing the accessibility signal per million mapped paired-
reads were generated using BEDTools genomeCoverageBed with the parameters “-
bg -pc -scale <SCALE_FACTOR>” for each biological replicate and for each 
condition (merged biological replicates). BedGraph files were converted to bigWig 
using the wigToBigWig binary available from the UCSC with the "-clip" parameter 
(Kent et al., 2010). Histogram of insert size frequency obtained from picard 
CollectMultipleMetrics and plotted using ggplot (version 2.2.1) within the R 
programming environment (version 3.3.1). 
 
On both the biological replicates and condition replicates, regions of chromatin 
accessibility were identified genome-wide using MACS2 callpeak (version 
2.1.1.20160309) (Zhang et al., 2008) with the parameters “--gsize=mm --keep-dup 
all –f BAMPE --nomodel --broad”. A union set of intervals were obtained by merging 
the regions identified across all INX samples to generate a peak file containing all 
accessible regions called “merged all INX”. 
2.5.2.1 Differential accessibility analysis  
Fragment-level BED files were derived from those created using the BEDTools 
(Quinlan and Hall, 2010) bamToBed command with the option “-bedpe”. Differential 
chromatin accessibility sites between conditions were obtained using diffReps 
(version 1.55.4) (Shen et al., 2013) with the parameter “—frag 0”. Differential sites 
that intersected with the union set of accessibility sites and had an FDR <= 0.01 and 




fold-change >= 2 were kept for further analysis. The annotatePeaks.pl program from 
HOMER (version 4.8) (Heinz et al., 2010) was used to annotate the differential sites 
relative to mm10 RefSeq features downloaded from the UCSC on 19 th February 2016. 
2.5.2.2 Footprinting Analysis 
Harshil Patel performed differential footprinting analysis on KD versus SCR and UT 
condition replicates using BaGFoot using default parameters (Baek et al., 2017). 
Bagplots (Rousseeuw and Ruts, 1997) were generated using a default factor of 3 
(Baek et al., 2017).  
2.5.3 ChIP-seq analyses 
Raw reads from each sample were adapter-trimmed using cutadapt (version 1.9.1) 
(Martin, 2011) with parameters “-a CTGTCTCTTATA -A CTGTCTCTTATA --
minimum-length=25 –quality-cutoff=20”. BWA (version 0.6.2) (Li and Durbin, 2010) 
with default parameters was used to perform genome-wide mapping of the adapter-
trimmed reads to the mouse mm10 genome. Duplicate marking was performed using 
the picard tool MarkDuplicates (version 2.1.1) (http://broadinstitute.github.io/picard/). 
Further filtering was performed to exclude read pairs that were duplicates, discordant, 
mapped to different chromosomes, ambiguously mapped, insert size >1kb, and had 
a mismatch >1 in any read. 
 
Genome-wide peak calling was performed with  MACS2 callpeak (version 
2.1.1.20160309) (Zhang et al., 2008) with the parameters  “--format BAMPE --
gsize=hs --keep-dup all --cutoff-analysis --broad --broad 0.1”. The annotatePeaks.pl 
program from HOMER (version 4.8) (Heinz et al., 2010) was used to annotate peaks 
relative to mm10 RefSeq features downloaded from the UCSC on 19th February 
2016. 
 
BedGraph coverage tracks representing the accessibility signal per million mapped 
paired-reads were generated using BEDTools (Quinlan and Hall, 2010) 
genomeCoverageBed with the parameters “-bg -pc -scale <SCALE_FACTOR>”. 
BedGraph files were converted to bigWig using the wigToBigWig binary available 
from the UCSC with the "-clip" parameter (Kent et al., 2010). 




2.5.4 RNA-seq analyses 
Adapter trimming was performed with cutadapt (version 1.9.1) (Martin, 2011) with 
parameters “--minimum-length=25 --quality-cutoff=20 -a AGATCGGAAGAGC”. The 
RSEM package (version 1.3.0) (Li and Dewey, 2011) in conjunction with the STAR 
alignment algorithm (version 2.5.2a) (Dobin et al., 2013) was used for the mapping 
and subsequent gene-level counting of the sequenced reads with respect to mm10 
RefSeq genes downloaded from the UCSC Table Browser (Karolchik et al., 2004) 
on 19th February 2016. The parameters used were “--star-output-genome-bam --
forward-prob 0”.  
2.5.4.1 Differential expression analysis 
Differential expression analysis was performed with the DESeq2 package (version 
1.12.3) (Love et al., 2014) within the R programming environment (version 3.3.1). An 
adjusted p-value of <= 0.05 was used as the significance threshold for the 
identification of differentially expressed genes. Gene set enrichment analysis for 
differentially expressed genes was performed by Gene Ontology Pathway and 
Biological processes using GeneGo MetaCore (https://portal.genego.com/).  
2.5.5 Data visualisation and functional analyses 
The Interactive Genomics Viewer (IGV) (version 2.4.8) (Robinson et al., 2011, 
Thorvaldsdottir et al., 2013) was used to visually explore ATAC-seq and ChIP-seq 
datasets and positioning of peaksets. From IGV, images of genomic regions were 
outputted as .svg files and cropped in Adobe Illustrator 22.1 (Adobe, USA).  
2.5.5.1 Motif analysis 
To find motifs within differential peaksets, motif calling analysis was performed using 
the findMotifsGenome.pl program in HOMER (version 4.8) (Heinz et al., 2010). 
Unless otherwise stated, this was performed using the inherent size of individual 
peaks using the parameter “-size given”. All motif analysis was performed over 
“merged all INX” file described (see 2.5.2.1) as a background file set using “-bg” 
parameter. Visual motif files were generated using the ggseqlogo package (Wagih, 
2017) in RStudio (version 1.0.136).  




2.5.5.2 Intersecting peaks 
To directly overlap peaksets, the mergePeaks.pl program was used from HOMER 
(version 4.8) (Heinz et al., 2010). Unless stated otherwise, peaks were directly 
overlapped with the parameter “-d given” and a file containing the number of 
overlapping peaks output using “-venn”. Overlapping peaks were either visualised 
using Venn diagrams or UpSetR plots in RStudio (version 1.0.136). Venn diagrams 
were generated using the Vennerable package (version 1.0). UpSetR plots were 
generated using the UpSetR package (version 1.3.3) (Conway et al., 2017).  
2.5.5.3 GO analysis on ATAC-seq and ChIP-seq peaksets 
Gene ontology (GO) analysis on peaksets derived from ATAC-seq and ChIP-seq 
analyses was performed using Genomic Regions Enrichment of Annotations Tool 
(GREAT) (Version 3.0.0) (McLean et al., 2010). This tool assigns meaning to non-
coding regions based on the genes closest to them. For this, the Association rule 
settings were set as the “Single nearest gene” to each peak. To provide contextual 
significance, all GREAT analysis was performed over the “merged all INX” file 
described (see 2.5.2.1) as a background file.  
2.5.5.4 DeepTools Visualisation 
All global visualisation of ATAC-seq and ChIP-seq libraries was performed using the 
tool suite deepTools (Ramirez et al., 2016). 
 
To generate Pearson correlation heatmaps at (-bs) 5,000bp intervals for ChIP-seq 
libraries and (-bs) 10,000bp intervals for ATAC-seq libraries:  
multiBamSummary bins --bamfiles <.bam> <> -o <result.npz> -bs #, 
plotCorrelation --corData <result.npz> -c pearson -p heatmap -o 
<Heatmap.pdf> --plotNumbers --colorMap YlGnBu -min # 
 
To generate read coverage heatmaps displaying the average normalised read 
density at individual sites:  
computeMatrix reference-point -S <.bw> <> -R <.bed> <> -a 800 -b 800 -bs 
50 --samplesLabel <Label_1> <> -o <matrix.ma.gz> --referencePoint center, 




plotHeatmap -m <matrix.ma.gz> -o <Heatmap.pdf> --refPointLabel center --
kmeans # --outFileSortedRegions <ClusterOutput.bed> --colorMap Greens --
heatmapHeight # --heatmapWidth # 
 
To generate plotProfiles to show the average read density across all peaks in a given 
peakset, matrices were generated as described for read coverage heatmaps and 
subsequently used in the plotProfile tool with default settings.    




Chapter 3. Profiling Cdx2 expression dynamics and 
binding sites in trophoblast stem cells 
E3.5 blastocysts and E6.5 extraembryonic ectoderm outgrowths can be cultured in 
the presence of critical growth factors to form stable trophoblast stem cell (TSC) lines 
(Tanaka et al., 1998). These lines express core markers of extraembryonic 
ectoderm, including Cdx2, and can be used to model the maintenance of trophoblast 
in vitro. Loss of Cdx2 causes mouse embryos to die at approximately E4.5 (Strumpf 
et al., 2005). Null embryos have ectopic expression of pluripotency genes in the 
trophectoderm and defects in epithelial integrity, followed by the collapse of the 
blastocoel cavity (Strumpf et al., 2005). Cdx2-null embryos are unable to form any 
trophoblast outgrowth in vitro at E3.5 indicating Cdx2 plays a role in TSC 
establishment and differentiation (Strumpf et al., 2005). Consistent with this 
suggestion, overexpression of Cdx2 in mouse embryonic stem cells (mESCs) causes 
them to transdifferentiate into TSC-like cells (Niwa et al., 2005). 
 
It is possible to overcome the immediate requirement for Cdx2 for generating TSC-
like cells from mESCs, either by repressing Oct4 expression or by overexpressing 
other TSC marker genes that subsequently activate Cdx2 expression (Niwa et al., 
2005, Ralston et al., 2010, Kuckenberg et al., 2010, Rhee et al., 2014). However, 
TSC-like cells transdifferentiated in this way cannot self-renew in the absence of 
Cdx2 expression. Instead, loss of Cdx2 causes trophoblast stem cell markers such 
as Eomes to become down-regulated, and differentiation markers such as Ascl2 to 
increase their levels of expression (Niwa et al., 2005). This suggests that Cdx2 is a 
critical component of the gene regulatory network (GRN) that maintains trophoblast 
stemness and that this independent of its role in reinforcing the TSC fate. 
 
Although much is known about its role in trophoblast lineage commitment, less is 
known about how Cdx2 exerts its function in established TSCs. One approach, 
bearing in mind that CDX2 is a transcription factor, is to determine its genomic 
binding sites in established TSCs. Several CDX2 TSC ChIP-seq libraries have been 
published but these vary in quality, complexity and cell origin (Adachi et al., 2013, 
Chuong et al., 2013). In this chapter, I therefore characterise three embryo-derived 




trophoblast stem cell lines that were subsequently used to generate CDX2 ChIP-seq 
libraries. 
  




3.1 Characterisation of trophoblast stem cell lines 
Three trophoblast stem cell (TSC) lines were characterised for their morphological 
appearance, stem cell marker gene expression, and rates of spontaneous 
differentiation. The INX and XYO cell lines were derived by Daniel Snell (The Francis 
Crick Institute), and the Rossant-GFP line was generated and kindly provided by 
Janet Rossant (Hospital for Sick Children, Canada). 
 
 
Figure 3.1: Validation of TSC lines. a) Bright-field images of the INX, XYO and Rossant-GFP TSC lines. 
b-c) qRT-PCR analysis of TSC and differentiation markers in all cell lines. Data plotted is gene expression 
normalised to Gapdh. Three biological replicates were used per cell line. Error bars display standard 
deviation (SD). d) Immunofluorescence for CDX2 and EOMES in three TSC lines.  




All three cell lines share the morphological characteristics of TSCs, with cobblestone-
like colonies and defined edges (Figure 3.1a). Expression of the TSC marker genes 
Cdx2, Elf5, Eomes, Gata3 and Tfap2c was high in all three lines, although expression 
of the TSC marker gene Esrrb was low (Figure 3.1b). Consistent with this 
observation, expression of the differentiation genes Ascl2, Tpbpa and Snai1 was low 
in each line, although expression of the trophoblast giant cell marker Hand1 was high 
(Figure 3.1c). Expression of CDX2 and EOMES was confirmed by 
immunofluorescence, which suggested that CDX2 expression was higher at the 
edges of colonies (Figure 3.1d). 
  




3.2 CDX2 is dynamically expressed in TSCs 
I went on to examine CDX2 expression in colonies over time. Cells were plated at 
1.05 x 104 cells per cm2 and sampled at 24-, 48- and 72-hours. Immunofluorescence 
showed that CDX2 protein is highly expressed at 24-hours in all three cell lines, but 
declined at 48- and 72-hours. CDX2 expression was higher in cells at the colony 
edge than in the centre at 48-hours in all three cell lines (Figure 3.2). This indicates 
that reduced CDX2 and a change in CDX2 distribution in colonies is a common 
feature of TSCs. There are three possible explanations for this decline in CDX2 
expression: that it might depend on time of culture, cell density, or perhaps some 
sort of colony edge-effect. My experiments do not address which of these 
explanations is correct. 
















































































































































To further investigate the decline in CDX2 expression over time, I performed flow 
cytometry. CDX2 expression in single cells was determined using the gating strategy 
indicated in Figure 3.3a. As shown in Figure 3.3b, CDX2 expression levels were 
higher in cells at G2/M than in cells in G1. Some proteins, including C-MYC, are 
regulated by the cell cycle and increase from G1 to S to G2/M (Gookin et al., 2017), 
and although I have not assayed for a direct relationship between CDX2 and the cell 
cycle, it is possible that there is one (Figure 3.3b). Beyond this, I confirmed that CDX2 
expression decreased significantly in all cell lines from 24- to 72-hours post-plating 
(Figure 3.3c-d). As with CDX2 protein, Cdx2 transcripts show a decreased 
expression trend at each time point in all TSC lines (Figure 3.3e). When the TSC cell 
lines replicates are combined, Cdx2 transcript decreased significantly between 24-
hours and 72-hours post plating (Figure 3.3f).  
 
To ask whether increased confluency resulted in cell cycle arrest, cells were 
classified into G1, S and G2/M phases using the ‘biology tool’ in FlowJo (Figure 3.3g). 
The proportion of cells in each cell cycle stage did not change between time points, 
suggesting that the cell cycle is not altered by time/cell density/edge (Figure 3.3h). 
Thus, the decrease in CDX2 expression between 24-hours and 72-hours post-plating 
is not due to cell cycle arrest in G1. 
 
I next asked whether the decline in CDX2 expression is peculiar to a specific stage 
of the cell cycle or whether it occurs across all stages. To this end, I calculated the 
fold change in mean CDX2 expression at each cell cycle stage over the mean 
expression in the total sample (Figure 3.3i). This revealed that neither cell cycle 
arrest nor a decline of CDX2 at a given stage of the cell cycle causes the decline in 
CDX2 expression over time. 
 





Figure 3.3: Downregulation of Cdx2 at the protein and transcript level with increased cell density. 
Dot plots showing gating strategy used for flow cytometry analyses. SSC-A and FSC-A were used to identify 
the intact cell population. Singlet discrimination was completed using DAPI-A and DAPI-H. Nuclei size 
(DAPI-H) is proportional to its area (DAPI-A). Thus, if the area doubles relative to height, cells are excluded 
from the analysis. b) Example dot plot showing CDX2 expression throughout the cell cycle (indicated by 
DAPI). Diploid cells (2N) sit at 50K in G1. The DNA is replicated during S phase, resulting in 4N cells (100K) 
at G2/M. The concentration of antibody was adjusted based on cell number so that the ratio between cell to 
antibody was the same between time points and biological replicates. c-d) Fold change in geometric mean 
CDX2 expression normalised to the geometric mean at 24 hours for individual cell lines (c) and in all cell 
lines combined (d) (n=3 for INX, n=2 for XYO, n=2 for Rossant-GFP). Significance determined by one-way 
ANOVA statistical test: **** = <0.0001. Error bars display SD. e-f) Normalised relative Cdx2 expression in 
INX, YXO and Rossant-GFP at 24- 48- and 72-hours post-plating for individual cell lines (e) and in all cell 
lines combined (f) (n=3 per cell line). Error bars display SD. Statistical significance was determined using 
one-way ANOVA: * = 0.0146, *** = 0.0003. g) Example cell cycle histograms performed using the ‘cell cycle 
biology tool’ in FlowJo. h) Proportion of cells in each cell cycle stage. Error bars display SD. i) Fold change 
of average geometric mean for each cell cycle stage normalised to the total geometric mean CDX2 
expression. Error bars display SD.  
 




qRT-PCR was performed for other TSC markers to determine whether their 
expression also decreased over time. Like Cdx2, Eomes and Gata3 expression 
decreased from 24- to 72-hours after plating (Figure 3.4a-b). This decline was 
confirmed for GATA3 protein (Figure 3.4f). Levels of Esrrb also showed a small 
decrease, but this was not significant (Figure 3.4c). In contrast, Elf5 and Tfap2c gene 
expression remained the same at all timepoints (Figure 3.4d-e). Together, these 
observations reveal that some, but not all, TSC marker genes expression decreased 
in TSC cultures over time. 
 
 
Figure 3.4: TSC markers have different expression dynamics relative to cell density. a-e) qRT-PCR 
analysis of TSC marker genes at 24-, 48- and 72-hours post-cell plating. Data are normalised to Gapdh 
individual cell line (left) and for combined TSCs (right) (n=3 biological replicates per cell line). Significance 
determined by one-way ANOVA statistical test: * = <0.0332, ** = <0.0021, *** = <0.0002, **** = <0.0001. 
Error bars display SD in both combined and separate graphs.  f) Individual (left) and combined (right) fold 
change in geometric mean GATA3 expression relative to 24 hours (INX n=3, XYO n=2, Rossant-GFP n=2). 
Significance determined by one-way ANOVA statistical test: * = 0.0175, ** = 0.005, **** = <0.0001. Error 
bars display SD.  
  




3.3 Determining CDX2 binding sites in TSCs 
In an effort to decipher the role Cdx2 plays within the established trophoblast lineage, 
I determined its binding targets. Several CDX2 ChIP-seq datasets have been 
published for TSCs (Table 3.1). As shown in Table 3.1, I generated new CDX2 ChIP-
seq libraries for both the INX and XYO cell lines. For this, I re-validated a previously 
published ChIP-grade anti-CDX2 antibody (A300-691A, Bethyl laboratories) in 
accordance with ENCODE guidelines (Landt et al., 2012) using immunofluorescence 
(Figure 3.2) and immunoprecipitation/western blot (data not shown). 
 
In Chapter 3.2, I showed that CDX2 expression declines in TSCs the longer they are 
in culture. TSCs were therefore collected at approximately 60-70% confluency as a 
compromise between cell number and CDX2 expression. Two independent ChIP-
seq libraries were generated for the INX and XYO cell lines on two separate 
occasions (yellow, Table 3.1). Two published datasets were downloaded for 
incorporation into analyses: a Rossant-derived TSC line dataset (Chuong et al., 
2013) and a dataset from a transdifferentiated TSC line generated using the tet-
inducible Oct3/4-knockout cell line ZHBTc4 (Adachi et al., 2013) (blue, Table 3.1).  
 
 
Table 3.1: CDX2 ChIP-seq dataset alignment statistics. Summary of alignment figures during subsequent 
filtering steps for in-house generate (yellow) and published (blue) Cdx2 ChIP-seq libraries analysed. 
 
All libraries were aligned to the mm10 genome, filtered and normalised using the 
approach outlined in Materials and Methods (Chapter 2.5.3). Table 3.1 summarises 
alignment efficacy and the number of peaks called for each ChIP library over the 
relevant input library using MACS2. This analysis revealed that the CHUONG CDX2 
ChIP-seq dataset is of particularly low complexity, with >61% of total starting reads 
attributed to PCR duplicates. After quality filtering and duplicate removal, only 20% 
of the total reads remained in this library. With so few reads remaining, read coverage 
Name Type Antibody GEO Series Total Input Pairs % Mapped %Duplication Filtered Total Reads NarrowPeaks
INX_R1 Cdx2 ChIP A300-691A, Bethyl - 50025598 96.41% 8.50% 33249212 (66.77%) 31895
INX_R2 Cdx2 ChIP A300-691A, Bethyl - 41850024 96.16% 7.59% 28127039 (67.53%) 26220
INX_INPUT Input - - 56984844 96.73% 5.19% 39592108 (69.96%) -
XYO_R1 Cdx2 ChIP A300-691A, Bethyl - 25695989 96.35% 7.17% 17510914 (68.51%) 2891
XYO_R2 Cdx2 ChIP A300-691A, Bethyl - 69423294 96.77% 8.62% 43974816 (63.64%) 23886
XYO_INPUT Input - - 55532306 96.72% 5.98% 33055761 (63.90%) -
ADACHI Cdx2 ChIP CDX2-88, BioGenex GSE51511 25776163 97.41% 9.19% 19558086 (76.24%) 103992
ADACHI_INPUT Input - GSE51511 26451066 97.14% 9.63% 19761785 (74.77%) -
CHUONG Cdx2 ChIP A300-691A, Bethyl GSE42207 16534562 85.61% 61.20% 3272500 (20.07%) 1171
CHUONG_INPUT Input - GSE42207 69336966 92.54% 35.86% 29469243 (44.06%) -




was poor, leading to poor clustering with the other datasets, absence of called and 
visible peaks on IGV tracks, and minimal read density enrichment across total called 
peaks (Figure 3.5a-c). This library was therefore omitted from further analyses. 
 
INX and XYO TSC libraries correlated with well one another. However, correlation is 
weaker for XYO_R1, perhaps because this library contained almost half the number 
of reads as other in-house generated libraries (Figure 3.5a, Table 3.1). The effect of 
the reduced number of reads in XYO_R1 was that it produced a lower signal-to-noise 
ratio. This lower ratio does not change the position of CDX2 binding sites between 
libraries, but does change how many normalised reads are found in each peak within 
the XYO_R1 library (Figure 3.5b-c). Overall, the INX and XYO CDX2 ChIP-seq 
libraries confirm that CDX2 binds at the same binding sites between cell lines.   
 





































































































































































































































































































































































































































The ADACHI library correlates poorly with the INX and XYO libraries, instead 
clustering separately with the discarded CHUONG library (Figure 3.5a). As with the 
XYO_R1 library, this library contains a reduced number of total reads. In contrast to 
the XYO_R1 library, over 100,000 CDX2 binding peaks were called in the ADACHI 
library indicating that it has a good signal-to-noise ratio (Table 3.1), although about 
89% of ADACHI peaks are unique (Figure 3.6a). These differences in CDX2 binding 
sites between the ADACHI and INX/XYO libraries were confirmed by the different 
position and height of peaks between their tracks (Figure 3.5c).  
 
Therefore, I next performed motif analysis on the ADACHI, INX and XYO libraries to 
confirm that CDX2 is binding its consensus motif in all of these libraries (Heinz et al., 
2010). CDX2 contains a helix-turn-helix (HTH) homeodomain which recognises a 
consensus motif sequence that is similar to, and shared with, other HTH 
homeodomain family members (Burglin and Affolter, 2016, Catron et al., 1993, 
Mathelier et al., 2016). Whilst 90.6% of the ADACHI peaks contained the CDX2 
consensus motif, fewer than half of INX peaks contained this motif (Figure 3.6b). 
 
To examine the relationships between all the peaks called across these five libraries, 
K-means clustering was performed for read density heatmaps. This best separated 
the data into three clusters: C1, C2 and C3. In contrast to the high enrichment of the 
INX and XYO libraries in clusters 1 and 2, the ADACHI library showed low read 
density enrichment in clusters 1 and 2, but was high in cluster 3 (Figure 3.5b). 
Therefore, Cluster 1 (C1) contained ‘universal’ peaks, whilst cluster 2 (C2) and 
cluster 3 (C3) contained mainly INX/XYO (Embryo-derived TSC-specific peaks) and 
ADACHI (Transdifferentiated TSC-like-specific peaks), respectively (Figure 3.5b). 
 
There are two possible explanations for these differences in CDX2 binding and motif 
enrichment between the ADACHI and the INX/XYO libraries. Firstly, these libraries 
are generated from TSCs cells that were derived using different methods and the 
differences may, therefore, be biological in nature. Whilst the INX and XYO TSC lines 
are derived from embryo outgrowths, ADACHI cells were TSC-like cells that 
transdifferentiated from mESCs by repressing Oct4 expression. Although these 
transdifferentiated cells were said to be stable cell lines, how closely they resemble 




bona fide TSCs is unknown (Adachi et al., 2013). Alternatively, differences in CDX2 
binding and motif enrichment may be an artefact of the different antibodies used to 
make libraries (Table 3.1).  
 
 
Figure 3.6: Embryo-derived and transdifferentiated CDX2 binding sites are different in location and 
motif enrichment. a) Plot generated by UpSetR showing the number of overlapping peaks between 
individual narrowPeak peak files. b) Percentage of peaks per ChIP-seq library containing the consensus 
Cdx2 and Cdx4 motifs called using HOMER.  
  




3.4 CDX2 has different roles in trophoblast stem cells 
depending on their origin 
The ability of a transcription factor to bind a genomic region depends on many factors. 
Transcription factors bind to consensus sequence motifs (Khan et al., 2018). Whilst 
there many consensus sequences across the genome, only a small proportion are 
typically occupied in vivo at any given time (Carr and Biggin, 1999, Iyer et al., 2001, 
Joseph et al., 2010). Factors that influence binding include the accessibility of given 
chromatin regions, the histone modifications present and the occupancy of other 
factors in the vicinity (Pique-Regi et al., 2011, Kumar and Bucher, 2016, Jolma et al., 
2015). These factors can be assayed using next-generation sequencing techniques; 
whilst ChIP-seq determines the distribution of a transcription factor or histone mark 
across the genome, FAIRE-Seq, DNase-Seq and ATAC-seq assess whether or not 
chromatin is accessible (Solomon et al., 1988, Giresi et al., 2007, Crawford et al., 
2006, Buenrostro et al., 2013). From these analyses, it is possible to work out which 
binding sites are likely to be used within a given cell type. 
 
So-called pioneer factors are exceptions to the rules that govern transcription factor 
binding. These pioneer factors are able to bind to condensed chromatin regions and 
cause these regions to open. Their binding precedes that of other factors and can be 
either passive or active: while passive binding recruits other factors that open 
chromatin regions, active binding opens chromatin itself and allow other factors to 
subsequently bind (Cirillo et al., 2002, Zaret and Carroll, 2011).  
 
There is conflicting evidence on whether CDX2 is a pioneer factor (McPherson et al., 
1993, Mahony et al., 2014, Kumar et al., 2019, Verzi et al., 2013, Rhee et al., 2017). 
If Cdx2 is overexpressed in different cell types, CDX2 binds to its consensus motif in 
chromatin that is already accessible, which results in distinct CDX2 binding between 
conditions (Mahony et al., 2014, Rhee et al., 2017). This suggests that CDX2 has 
minimal pioneer capacity when overexpressed in non-CDX2 expressing cell types.  
 
TSCs are an established, robust in vitro cell line (Tanaka., 1998). Therefore, I next 
asked whether CDX2 binding sites in INX, XYO and ADACHI binding sites are 
accessible in TSCs. For this, I generated a read density heatmap at the previously 




determined CDX2 binding site clusters (C1, C2 and C3, Figure 3.5b) in two wild-type 
TSC libraries: the untransfected INX ATAC-seq library generated for this thesis (data 
further discussed in Chapter 4) and a published TSC ATAC-seq library (‘TS RL’) 
(Nelson et al., 2017) (Figure 3.7a).  
 
 
Figure 3.7: Deciphering the accessibility of distinct CDX2 binding sites. a) Heatmap of ATAC-seq read 
density in Untransfected (UT) INX TSCs and published TSCs called ‘TS RL’ at clusters from Figure 3.5b. 
The methods used to process and normalise libraries can change the scale used to visualise libraries, 
although this has no bearing on library quality, nor on enrichment. The ‘TS RL’ ATAC-seq data was 
downloaded as aligned visualisation files (.wig) and so it is on a different scale to the INX data (Nelson et 
al., 2017). b) Percentage of peaks per cluster containing the consensus Cdx2 and Cdx4 motifs determined 
using HOMER. C1 – cluster 1, C2 – cluster 2, C3 – cluster 3.  
 
Cluster C1 sites were bound in all CDX2 ChIP-seq libraries and were considered to 
be universal CDX2 binding sites. In contrast, sites in cluster C2 are bound by CDX2 
in both INX and XYO TSCs, but not ADACHI cells and so represent embryo-derived 
TSC-specific CDX2 binding sites. As C3 binding sites are only bound in ADACHI 
cells, they represent transdifferentiated TSC-like cell-specific peaks (Figure 3.5b).  
 
Whilst most peaks in clusters C1 and C2 are accessible in INX and/or ‘TS RL’, all 
cluster C3 sites are inaccessible in both (Figure 3.7a). Although cluster C3 sites are 
highly enriched for the CDX2 consensus motif, it is unlikely that CDX2 binds 99,177 
inaccessible regions of chromatin in bona fide TSCs (Figure 3.7b). Instead, C3 may 
represent accessible regions in mESCs that CDX2 binds when expressed, 
suggesting that the differences in CDX2 binding are biological.  



























































































































































































































































To assess potential functional differences between peaks contained in each cluster, 
gene ontology (GO) analysis was performed using GREAT (McLean et al., 2010). In 
setting the parameters for this, I found the single nearest gene for each peak within 
each cluster. The enrichment was performed over a background file containing all 
regions deemed accessible in TSCs ATAC-seq data (Chapter 2.5.2).  
 
Cluster 1 peaks are enriched around genes associated with abnormalities in the 
trophoblast lineage, including abnormal trophoblast giant cells (MP:0005033), 
abnormal mural trophectoderm morphology (MP:0012057) and abnormal trophoblast 
layer morphology (MP:0005031) (Figure 3.8a-b). Similarly, cluster 2 sites are 
enriched around genes related to absent trophoblast lineages, including absent 
trophectoderm (MP:0012102) and absent trophoblast giant cells (MP:0001714), as 
well as various abnormal trophoblast lineage morphology. Further, the most enriched 
biological process term found in cluster 2 was trophectodermal cell differentiation 
(GO:0001829), reflecting a potentially specific role of these sites within established 
TSCs (Figure 3.8c-d). In contrast, the top 100 terms discovered in cluster 3 showed 
no enrichment for trophoblast-associated biological processes (Figure 3.8e), MGI 
mouse phenotypes (Figure 3.8f), nor trophoblast related lineages in the top 100 MGI 
expression terms (data not shown). As such, this analysis provided no distinct 
biological function for transdifferentiated TSC-like cell-specific (ADACHI) CDX2 
binding sites.  
 
One potential interpretation of these differential CDX2 binding sites is that CDX2 has 
different targets before and after trophoblast commitment, represented by embryo 
outgrowth-specific (C2) and transdifferentiated-specific (C3) sites, respectively. As 
Cdx2 has a reciprocal, repressive relationship with Oct4 (encoded by the Pou5f1 
gene) (Niwa et al., 2005) and Nanog (Chen et al., 2009b) during trophectoderm 
establishment, I examined the flanking regions of these gene loci for differences in 
CDX2 binding (Figure 3.9). Near the transcription start site (TSS) of both Pou5f1 and 
Nanog, there is a highly enriched CDX2 binding site in INX and XYO_R2 samples, 
with other peaks present in the vicinity. Corresponding peaks are present at these 
sites in TSC ATAC-seq libraries, showing that these sites are accessible. In contrast, 
CDX2 binding in the ADACHI (transdifferentiated TSC-like cells) was distinct from 
INX and XYO and those regions inaccessible in TSCs. Therefore, CDX2 remains 




bound around pluripotency genes even in established TSCs, but these sites are not 
all equivalent to those found in transdifferentiated cells generated by Oct4 removal.  
 
 
Figure 3.9: CDX2 binding around pluripotency genes. a) Integrative Genomics Viewer (IGV) tracks at 
pluripotency gene Nanog. B) IGV track for the Oct4 encoding gene Pou5f1 locus.   
  




3.5 Cdx2 may have different roles pre- and post-trophoblast 
establishment 
Pou5f1 and Nanog may be repressed by different CDX2 binding sites during and 
after trophoblast establishment. Alternatively, differences in CDX2 binding between 
embryo-derived TSCs (INX/XYO) and TSC-like cells transdifferentiated from mESCs 
(ADACHI) may be due to difference in global chromatin accessibility between TSCs 
and mESCs, respectively.  
 
ADACHI CDX2 ChIP-seq libraries were generated from transdifferentiated ZHBTc4 
mESCs. To determine if CDX2 binding in transdifferentiated TSC-like cells are 
accessible in ZHBTc4 mESCs, read density heatmaps were generated for published 
wild-type mESCs and 24-hours post-Oct4 knockout mESCs at C1, C2 and C3 sites 
(Figure 3.10a) (King and Klose, 2017). CDX2 binding sites in the ADACHI-specific 
cluster (C3) are not bound in these mESCs, nor one day after Oct4-knockout.  
 
 
Figure 3.10: Accessibility of CDX2 binding sites in mESCs. a) ATAC-seq read density heatmap at C1, 
C2 and C3 clusters (defined in Figure 3.5b) for ZHBTc4 mESCs and ZHBTc4 mESCs 24-hours post 
doxycycline treatment (ZHBTc4 +Dox) to delete Oct4. b) Normalised read density heatmap to show 
accessibility at peaks contained in C1 and C2, collectively called established trophoblast CDX2 binding sites 
(ETBS), in ZHBTc4 and ZHBTc4-Dox mESCs. K-means clustering was performed to generate three new 
clusters: ETBS-C1, ETBS-C2 and ETBS-C3. c) Bar charts to show -log(p value) of highest enriched motifs 
discovered in each ETBS cluster as determined by HOMER analysis using given peak sizes.   
 




Conversely, those CDX2 binding sites in embryo-derived TSCs, clusters C1 and C2, 
show high read density for mESC ATAC-seq data at some peaks, but negligible at 
others. At peaks contained in C1, overall read density increased after Oct4-knockout 
(summary plot, Figure 3.10a). Therefore, C1 sites may be those that CDX2 binds to 
in order to reinforce trophoblast fate.  
 
Does the accessibility of CDX2 binding sites in mESCs reveal information about their 
function? If sites are crucial for reinforcing the trophoblast fate, CDX2 would likely be 
recruited by its consensus motif and other known upstream co-factors. In contrast, 
CDX2 may bind opportunistically at regions of accessible chromatin in the absence 
of its consensus motif. As such, C1 and C2 peaks were combined to make an 
embryo-derived TSC CDX2 binding site (ETBS) peakset. K-means clustering was 
performed to separate ETBS sites into 3 new clusters based on their accessibility in 
mESCs: highly accessible, accessible and inaccessible sites (Figure 3.10b).  
 
Motif analysis revealed that highly accessible chromatin regions in mESCs (ETBS-
C1) show no enrichment for homeobox motifs (Figure 3.10c). Sites with lower-level 
accessibility in mESCs, ETBS-C2, show enrichment for the CDX2 consensus motif 
(contained in 32.2% of peaks) and other homeodomain motifs. However, the five 
most significantly enriched motifs were TEA(D) family motifs (Figure 3.10c). TEAD4 
is upstream of Cdx2 in trophoblast specification in vivo and directly interacts with 
CDX2 in established TSCs (Nishioka et al., 2009, Rayon et al., 2014, Latos et al., 
2015a). Motifs for other core TSC marker genes, including Esrrb and Sox2, were 
also enriched in this C2 cluster. The enrichment of these motif families indicates that 
TEAD4, ESRRB and SOX2 may be CDX2 co-factors in TSCs. As such, these peaks 
may represent sites crucial for reinforcing commitment to the trophoblast fate. In 
contrast, the top 7 enriched motifs found in inaccessible sites in mESCs (ETBS-C3) 
are homeobox motifs (Figure 3.10c). This cluster may therefore represent CDX2 
binding sites in the established trophoblast fate. The co-enrichment of Elf5 motifs, 
another key TSC marker, is also consistent with this function (Latos et al., 2015b). 
The enrichment of the POU motif Oct:Oct in the cluster C3 may suggest a small role 
for these sites in establishing the fate as a result of CDX2 antagonising OCT4 binding 
at these sites (Figure 3.10c). 




















































































































































































































































































Motif analysis suggested that separating ETBS based on accessibility in mESCs 
might generate distinct peaksets that reflect the differential roles of CDX2 binding. 
To address this, GO analysis was performed using the single closest gene to all 
peaks in each cluster using GREAT (McLean et al., 2010). CDX2 binding sites 
that are ‘highly accessible’ in mESCs (cluster ETBS-C1) are enriched around 
genes related to chromatin organization (Figure 3.11a) and those expressed in, 
and fundamental to, early developmental stages (Figure 3.11b-c). Therefore, 
unsurprisingly, these ‘highly accessible’ sites in mESCs likely play a key role 
during early embryonic development. CDX2 binding here is likely opportunistic.  
 
CDX2 binding sites that are ‘accessible’ in mESCs (ETBS-C2) are found near 
genes that important to the trophoblast lineage, including placental development 
(GO:0001890) and trophectodermal cell differentiation (GO:0001829) (Figure 
3.11d). Previous work has shown that Cdx2 is essential for TSC self-renewal 
(Strumpf et al., 2005, Niwa et al., 2005). In agreement, these ETBS-C2 sites are 
near genes associated with stem cell maintenance (GO:0019827) and various 
abnormal trophoblast phenotypes (Figure 3.11d-e). Similar to ETBS-C1, ETBS-
C2 CDX2 sites are concentrated around genes that are expressed at early 
embryonic stages (Figure 3.11f). Combined with the enrichment of TEAD motifs 
within these sites, these peaks may represent some of those that CDX2 binds 
during trophoblast establishment to reinforce commitment to the lineage.  
 
Unlike ‘highly accessible’ (ETBS-C1) and ‘accessible’ (ETBS-C2) sites, CDX2 
binding sites that are ‘inaccessible’ in mESCs (ETBS-C3) are not enriched near 
genes with an obvious trophoblast-related function (Figure 3.11g). Instead, ETBS-
C3 are enriched around genes associated with absent trophectoderm 
(MP:0012102) (Figure 3.11h) and those expressed in later trophoblast lineages 
(Figure 3.11i). In summary, CDX2 binding sites that are ‘inaccessible’ in mESCs 
are enriched at genes related to later trophoblast stages and consensus CDX2 
binding motifs are highly prevalent. This agrees with the hypothesis that these 
sites are unique to, and functional in, the established trophoblast lineage.      





In this chapter, I have characterised three trophoblast stem cell (TSC) lines. Whilst 
TSC markers such as Cdx2, Eomes and Gata3 decrease in expression as cell 
density and/or time increases, others, such as Tfap2c and Elf5, do not. This finding 
is intriguing given that precise ratios of Eomes, Elf5 and Tfap2c expression are 
required to maintain the stem cell fate. When Elf5 or Tfap2c expression increases 
and/or Eomes expression decreases, the balance between these factors are affected 
and TSC are driven to differentiate (Latos et al., 2015b). As well as informing the 
density at which cells were collected for CDX2 ChIP-seq, understanding Cdx2 
expression was crucial to design and control Cdx2 knockdown experiments 
performed later in this thesis (Chapter 4.1). 
 
Where CDX2 binds in TSCs is different depending on the way the cells were derived. 
K-means clustering separated CDX2 binding sites into three categories: universal, 
embryo-derived TSC-specific and transdifferentiated TSC-like cell-specific 
(mediated by Oct4 repression) binding sites. Whilst most universal and embryo-
derived TSC-specific binding sites are accessible in INX TSCs and an independent 
wild-type TSC line, TSC-like cell-specific peaks are not. Further, despite being 
generated by repressing Oct4 expression, TSC-like cell-specific peaks are also 
inaccessible in wild-type mESCs and in mESCs 24-hours after Oct4 repression. GO 
analysis of these transdifferentiated TSC-specific peaks showed no enrichment of 
any relevant trophoblast specific term, despite the high proportion of peaks 
containing the CDX2 consensus motif. Therefore, whether CDX2 binding sites in 
transdifferentiated TSC-like cells are biologically relevant or functional is unknown. 
 
CDX2 binding sites that were universal or specific to embryo-derived TSCs were 
located around genes enriched in absent or abnormal trophoblast GO terms. These 
sites were differentially accessible in mESCs and a subset of these sites increase in 
accessibility in mESCs after Oct4 repression. I therefore theorised that it might be 
possible to use the accessibility of CDX2 binding sites in mESCs to generate 
peaksets that reflected their functionality. All CDX2 binding sites in embryo-derived 
TSCs were separated into three new clusters based on their accessibility in mESCs: 
highly accessible, accessible and inaccessible. 





mESCs accessible CDX2 binding sites were enriched around genes expressed in 
the early embryo and trophoblast lineages and were enriched for TEAD, homeobox, 
ESRRB and SOX motifs. Tead4 is upstream of Cdx2 during trophectoderm 
establishment and may act as a co-factor for CDX2 during establishment (Nishioka 
et al., 2009, Rayon et al., 2014, Latos et al., 2015a). Therefore, I hypothesise that 
these mESC-accessible sites represent initial CDX2 binding targets in the 
trophoblast lineage that persist in established trophoblast stem cells. Additionally, 
the ESRRB motif enrichment at these sites agrees with previous work showing that 
the Cdx2 binding motif is enriched at ESRRB binding sites (Latos et al., 2015a).  
 
CDX2 binding sites that are inaccessible in mESCs are enriched around genes 
expressed in later trophoblast stages. These CDX2 binding sites are enriched for 
other transcription factors motifs, including the extraembryonic ectoderm marker 
ELF5, suggesting that these are later CDX2 binding targets (Latos et al., 2015b).  
 
Therefore, by integrating chromatin accessibility data with CDX2 ChIP-seq data, I 
have identified different CDX2 binding site subsets. These subsets are hypothesised 
to either represent those CDX2 binding sites involved in reinforcing commitment to 
the trophoblast lineage or distinct CDX2 binding targets within established TSCs. As 
such, my data suggest that Cdx2 has distinct targets and roles pre- and post-
trophoblast establishment.  
 
 




Chapter 4. Profiling the effects of short-term Cdx2 
knockdown on the transcriptome and chromatin 
landscape of Trophoblast Stem Cells 
Much work has been carried out over the last 15 years to understand the control of 
Cdx2 expression and its role in trophectoderm commitment. This has predominantly 
used the transdifferentiation of mESCs into TSC-like cells by Cdx2 overexpression 
as a model system (Niwa et al., 2005, Kuckenberg et al., 2010, Rhee et al., 2017), 
while other studies have aimed to understand Cdx2 in embryo-outgrowth derived 
TSCs. So far, it has been shown that Cdx2 is essential for maintaining 
undifferentiated TSC-like cells (Niwa et al., 2005), perhaps by regulating key TSC 
marker genes including Elf5, Eomes and Esrrb (Latos et al., 2015a). Much of the rest 
of the work to understand Cdx2 in the established trophoblast has centred on 
generating CDX2 ChIP-seq libraries (Adachi et al., 2013, Chuong et al., 2013). 
Unfortunately, as I show in Chapter 3, re-analysis of these data suggests that these 
published CDX2 ChIP-seq libraries are poor in quality and complexity. I also showed 
that CDX2 binding sites differ in TSC-like cells and embryo outgrowth-derived TSCs. 
These differences demonstrate why it is important to understand transcription factor 
binding in the context of the transcriptome and the chromatin landscape. 
 
CDX2 binding sites in TSC-like cells prove not to be accessible in TSCs or mESCs, 
despite being transdifferentiated from mESCs. In contrast, some, but not all, CDX2 
binding sites in embryo-derived TSCs are accessible in mESCs. When analysed 
based on this differential accessibility in mESCs, it was discovered that ‘accessible’ 
CDX2 binding sites in mESCs are located around genes expressed at earlier stages 
of embryonic development than ‘inaccessible’ binding sites. ‘Accessible’ and 
‘inaccessible’ CDX2 binding sites in mESCs are also enriched for different motifs, 
suggesting that at some sites CDX2 binding is opportunistic or occurs through 
recruitment by other factors, but at others CDX2 recognises its own consensus motif. 
With this in mind, I hypothesised that different CDX2 peaksets may reflect differential 
roles of Cdx2 during trophectoderm fate reinforcement and in established TSCs. 
Although the differential enrichment of both consensus motifs and GO terms at these 
sites is highly suggestive, the hypothesis that Cdx2 plays different roles at different 




trophoblast stages assumes that CDX2 binding near a gene is relevant to that gene. 
However, its binding near a gene, especially in distal regions, is neither indicative of 
its relevance nor function and requires functional validation (Inoue et al., 2017). 
 
In this chapter I explore the functionality of CDX2 binding in established embryo-
derived TSCs. To this end, I generated RNA-seq and ATAC-seq libraries in cells 
expressing wild-type and reduced levels of Cdx2 to determine the effect of Cdx2 loss 
on the transcriptome and chromatin landscape. By integrating chromatin landscape, 
transcriptome and CDX2 binding sites, I aimed to define the functional consequences 
of CDX2 binding. Multiple published histone ChIP-seq datasets were integrated into 
my analyses to complement libraries generated in-house. 
  




4.1 Optimisation of Cdx2 knockdown 
To minimise the effect of changes in Cdx2 expression during cell culture (Chapter 
3.2), all experiments were controlled for starting cell number and culture time. 
 
Previous work has shown that Cdx2-null embryos do not form trophoblast outgrowths 
(Strumpf et al., 2005) and Cdx2 expression is required to maintain proliferating TSC-
like cells (Niwa et al., 2005). As discussed in Chapter 3.4, CDX2 binding sites are 
enriched around genes associated with abnormal and absent trophoblast lineage GO 
terms. With these observations in mind, I concluded that the best approach to 
modulate Cdx2 transcript levels was to use short-hairpin RNAs (shRNAs). shRNAs 
are synthetic RNA molecules that are designed to mimic the hairpin precursors of 
short temporal RNAs used by the intrinsic RNA interference machinery (Paddison et 
al., 2002). For this, I tested the efficiency of five stem-loop-stem shRNA vectors 
(generated by The RNAi Consortium (TRC)) that target Cdx2 (Chapter 2, Table 2.1).  
 
Despite optimisation, the maximal transfection efficiency I achieved in TSCs was 
approximately 30%. To select for transfected cells, I cloned an mCherry-IRES-
puromycin cassette into these shRNA plasmids (Chapter 2.2.7.2). mCherry positive 
(transfected) and mCherry negative (untransfected) cells were sorted from the 
population by fluorescent activated cell sorting (FACS) (Figure 4.1a). As a control, a 
scrambled shRNA vector (SCR) was used in parallel with all shRNA knockdown 
experiments.  
 
When transfected with any single shRNA vector, Cdx2 knockdown efficiency was 
less than 50% (data not shown), but this was improved by co-transfection. When 
transfected together, shRNA1, shRNA4 and shRNA5 reproducibly knocked down 
Cdx2 expression at the transcript and protein level by 65% and 55%, respectively 
(Figure 4.1b-c).  
 





Figure 4.1: Optimisation of Cdx2 knockdown in TSCs. a) Dot plots showing the gating strategy to isolate 
cell populations based on mCherry expression by FACS. Three sequential gates were applied to stringently 
isolate single cells: ‘cells’, ‘single cells’ and ‘single cells 2’. mCherry expression was visualised against GFP 
(autofluorescence) and gates were drawn to isolate mCherry positive and mCherry negative populations. b) 
Cdx2 transcript levels in SCR mCherry negative (-ve), SCR mCherry positive (+ve) and shRNA 1,4,5 
mCherry positive (+ve) were analysed by qRT-PCR. Graphs shows fold change in Cdx2 expression 
(normalised to Gapdh) over untransfected (UT) cells. Significance was determined by one-way ANOVA 
statistical test: ** p<0.0021, **** p=<0.0001. Error bars show SD, n=5 biological replicate in INX TSCs. c) 
CDX2 protein level in SCR mCherry negative (-ve), SCR mCherry positive (+ve) and shRNA 1,4,5 mCherry 
positive (+ve) INX TSCs was analysed by flow cytometry. Graph shows fold change in geometric mean 
CDX2 expression over geometric mean in UT cells. Significance was determined by one-way ANOVA 
statistical test: ** p=<0.0021. Error bars show SD (n=3 biological replicates in INX TSCs). 
  




4.2 Approach, validation and library preparation 
To examine how the loss of Cdx2 affects the transcriptome and chromatin landscape 
of established TSCs, RNA-seq and ATAC-seq libraries were generated in wild-type 
and Cdx2 knockdown TSCs 48-hour post-transfection. To account for biological 
variability between samples and to allow for downstream statistical analyses, three 
biological replicate ATAC-seq and RNA-seq libraries were generated in the following 
conditions: untransfected (UT), mCherry positive Cdx2 shRNA knockdown (KD) and 




Figure 4.2: Summary of approach to generate HTS libraries in TSCs expressing wild-type and 
reduced levels of Cdx2. a) Schematic to illustrate the origins of each condition used to generate RNA-seq 
and ATAC-seq libraries. Cells were transfected with shRNA constructs for 4 hours approximately 16-hours 
post-plating. Cells were isolated by FACS based on their mCherry expression as outlined. UT = 
untransfected, KD = Cdx2 shRNA knockdown, SCR = scramble. b) qRT-PCR for Cdx2 expression in RNA 
samples for each library collected pre-library submission to confirm efficient Cdx2 knockdown. Error bars 
display SD for three technical replicates.  
 
Bearing in mind the substantial cost of generating these libraries, I decided to use 
one TSC line, the INX TSC line, as a core line for generating and validating ATAC-
seq and RNA-seq libraries. In Chapter 3, I showed that the INX, XYO and Rossant-
GFP TSC lines are similar in their expression of stem cell markers and in CDX2 
binding. The INX line was chosen because the XYO cell line had an increased 
propensity to spontaneously differentiate during culture and the Rossant-GFP TSCs 
did not have a passage number.  





A total of 50,000 cells was collected using FACS (outlined in Figure 4.2a) for each 
ATAC-seq and RNA-seq library. Biological replicate libraries were generated in 
parallel over three collections. qRT-PCR was performed for each RNA-seq sample 
to confirm efficient Cdx2 knockdown (Figure 4.2b). Cdx2 knockdown efficiency was 
over 65% for all libraries relative to control libraries. 
  




4.3 Cdx2 knockdown in established trophoblast stem cells 
perturbs the transcriptome 
As RNA-seq libraries were generated using a poly(A) enrichment kit, they only 
contain mature mRNA, rather than total RNA. Read quality and alignment efficiency 
for all libraries was high, with >98% of all reads mapped in each library (data not 
shown). An initial principal component analysis (PCA) was performed to assess 
similarities and differences between all libraries generated in an unbiased manner 
(Figure 4.3a). This revealed that most variance observed between libraries, as 
shown in PC1 (54%), is due to biological variation between replicates. Despite this 
biological heterogeneity, PC2 (24%) clearly separates the KD samples from all of the 
control samples. Therefore, Cdx2 knockdown perturbs the transcriptome of TSCs. 
 
Pairwise differential gene expression analysis using DESeq2 revealed that 1138, 
1370 and 964 genes were dysregulated (p<0.05) in KD versus UT, SCR NEG and 
SCR POS, respectively. The log2 fold change for the majority of these genes was 
low (all less than 2.8-fold) as shown in the MA plots in Figure 4.3b-c. Small fold 
changes in expression levels are unsurprising, bearing in mind that the overall 
knockdown efficacy is only 53-62% (Figure 4.3d). These low fold-changes make it 
more challenging to create a stringent list of genes dysregulated in Cdx2 knockdown.  
 
To make a list of dysregulated genes, I decided to overlap those genes that were 
differentially expressed (adjusted p<0.05) in KD versus control pairwise 
comparisons. Although SCR NEG samples cluster well with SCR POS and UT 
samples (Figure 4.3a), Cdx2 knockdown efficiency in KD versus SCR NEG (53%) 
was poorer than anticipated (Figure 4.3d). Therefore, genes that were differentially 
expressed in the same direction in KD versus SCR POS (herein after referred to as 
SCR) and UT were used to generate representative gene lists without SCR NEG. No 
fold change criteria were implemented to generate this final gene lists (Figure 4.3e). 
In total, 263 genes were downregulated and 363 genes were upregulated by Cdx2 
knockdown.   





Figure 4.3: 48-hour Cdx2 knockdown significantly perturbs the TSC transcriptome. a) Principal 
component analysis (PCA) of RNA-seq data generated using ggplot (version 2.2.1) within the R 
programming environment (version 3.3.1). Three biological replicates were generated for Cdx2 shRNA 
knockdown (KD), scramble transfected (SCR POS), scramble untransfected (SCR NEG) and untransfected 
(UT) TSC libraries. b-c) MA plot generated using ggplot (version 2.2.1) within the R programming 
environment (version 3.3.1) to show transcript fold change against normalised mean expression for all 
genes. In (b), the log2 fold changes of SCR (SCR POS) versus KD are shown and (c) shows the log2 fold 
changes of UT versus KD. Genes in grey are not differentially expressed. Genes in yellow and orange are 
only differentially expressed in SCR or UT versus KD, respectively. Purple genes are those that are 
differentially expressed in both pairwise comparisons. d) Fragments per kilobase of exon model per million 
reads mapped (FPKM) for Cdx2 in each library (n=3 per condition). Significance determined by one-way 
ANOVA: ** p=0.0019, *** p0.0002. e) Bar chart summarising differentially expressed genes in both SCR or 
UT versus KD pairwise comparison as outline in the MA plots in (c-d).  
 
Next, I compared the expression of dysregulated genes in all RNA-seq libraries. 
Although they were not used to make this gene list, SCR NEG replicates express 
high levels of downregulated genes and vice versa, validating both this gene list and 




the approach taken (Figure 4.4a). This heatmap also revealed that SCR R2 was an 
outlier, expressing lower levels of most genes downregulated in Cdx2 knockdown.  
Having defined what genes are affected by Cdx2 knockdown, I aimed to understand 
its effect on the whole transcriptome. As the lowest expressed dysregulated genes 
in the final gene list were 0.0825 transcripts per million (TPM) across all samples (for 
Cd93 and Nwd1), genes with an average TPM of 0.08 were deemed to be 
expressed (13418). By this definition, 4.7% of all genes expressed in TSCs are 
significantly perturbed as a result of Cdx2 knockdown (Figure 4.4b).  
 
 
Figure 4.4: Validation of genes differentially expressed by Cdx2 knockdown. a) Heatmap displaying 
log2 fold change in expression of differentially expressed genes over the average expression of each gene 
across all samples. Plot generated using ggplot (version 2.2.1) within the R programming environment 
(version 3.3.1). b) Pie chart to show the proportion of expressed genes, defined as being expressed on 
average at 0.08 TPM, that are up- and downregulated in Cdx2 knockdown. c) qRT-PCR analysis of 
differentially expressed genes known to be expressed in the trophoblast lineage. Graphs displayed as fold 
change (gene expression normalised to Gapdh) over UT samples. Significance determined by t-test: * 
p0.0332, ** p0.0021. Error bars show SEM. n=4 biological replicates. 
 
To validate RNA-seq findings, I performed qRT-PCR on a subset of differentially 
expressed genes. Only two trophoblast stem cell marker genes were affected by 




short-term Cdx2 knockdown: Gata3 and Tfap2c (Figure 4.4c). The upregulation of 
Gata3 and Tfap2c agrees with previous work suggesting that Cdx2 expression is 
downstream of these factors in established TSCs (Home et al., 2009, Kidder and 
Palmer, 2010). In contrast, Cdx2 is thought to be upstream of two other TSC marker 
genes, Eomes and Elf5, during trophoblast specification (Niwa et al., 2005, Ng et al., 
2008) and all three co-activate one another within established TSCs (Chuong et al., 
2013, Latos et al., 2015b). As neither Eomes nor Elf5 expression are affected by 
short-term Cdx2 knockdown, they are not direct targets of, or not responsive to, Cdx2 
in TSCs (Figure 4.4c). Other TSC markers such as Tead4, Ets2 and Sox2 were not 
differentially expressed as these were not included in the final gene list. Therefore, 
their expression was not assessed by qRT-PCR. Although few TSC marker genes 
are affected by Cdx2 knockdown, other trophoblast associated genes such as Plac1 
(Jackman et al., 2012), Htra1 (Nie et al., 2005), Cyr61 (Mo et al., 2002) and the 
trophoblast giant cell marker gene Hand1 (Riley et al., 1998) are perturbed by Cdx2 
knockdown (Figure 4.4c).  
 
To understand the potential functions of the genes dysregulated by Cdx2 
knockdown, gene ontology (GO) analysis was performed using MetaCore (Figure 
4.5). In contrast to Cdx2-null trophectoderm, which shows increased levels of 
apoptosis (Strumpf et al., 2005), short-term Cdx2 knockdown caused the 
downregulation of genes associated with apoptosis, inflammation and the immune 
response (Figure 4.5a). Reduced expression of two genes found in several of these 
GO terms, Mapk13 and Bak1, was validated by qRT-PCR (Figure 4.5b). Genes that 
were upregulated by Cdx2 knockdown are associated with GO terms related 
primarily to cell adhesion and other developmental terms (Figure 4.5c). Two genes 
that are found in several of these upregulated gene GO terms, Cdh5 and Itgb3, were 
validated as upregulated in KD cells (Figure 4.5d).  
 
I conclude that Cdx2 knockdown perturbs the transcriptome, but the biological 
relevance of the affected genes, whether upregulated or downregulated, is unclear. 
 





Figure 4.5: MetaCore cell processes enrichment analysis for upregulated and downregulated genes. 
a,c) MetaCore cell processes analysis for genes that are downregulated and upregulated genes resulting 
from Cdx2 knockdown respectively. b,d) qRT-PCR for key genes included in multiple differentially enriched 
terms in a and c. Significance was determined using t-tests: * p0.0032, ** p0.0021. Error bars display 
SEM, n=4 biological replicates. 
  
  




4.4 Cdx2 knockdown alters chromatin accessibility across 
the chromatin landscape 
To understand how Cdx2 knockdown affects the chromatin landscape I generated 
ATAC-seq data in parallel with the RNA-seq libraries discussed above. ATAC-seq 
uses a hyperactive Tn5 transposase that integrates adapter sequences preferentially 
in regions of open, accessible chromatin (Buenrostro et al., 2013). These regions 
can be PCR-amplified and sequenced to generate libraries that display overall 
chromatin accessibility within a relatively small starting pool of cells.  
 
To assess in an unbiased fashion the way in which UT, SCR, SCR NEG and KD 
ATAC-seq libraries relate to one another, principal component analysis was 
performed. There is some variation between libraries (PC2 = 15%), but most 
differences in the chromatin landscape are caused by Cdx2 knockdown (PC1 =72%) 
(Figure 4.6a). This effect of Cdx2 knockdown on the chromatin landscape must be 
at specific loci as the correlation between all samples was high, both genome-wide 
(Figure 4.6b) and at individual loci (Figure 4.6c).  
 
These ATAC-seq libraries have the characteristic visual profiles of ATAC-seq 
libraries, with peaks denoting regions of accessible chromatin around the Cdx2 locus 
(Figure 4.6c). Biological replicates for each sample were merged to generate overall 
alignment files for each condition (UT, SCR NEG, SCR and KD). As expected, all of 
these ATAC-seq libraries have a normal fragment length distribution, with the 
majority of sequenced reads either nucleosome-free or of mononucleosome-
associated lengths (Buenrostro et al., 2013) (Figure 4.6d). I conclude that all libraries 
are of good quality and can be used to assess the functional effect of Cdx2 
knockdown at the chromatin level.  
 





Figure 4.6: Quality control assessment of ATAC-seq libraries. a) Principal component analysis (PCA) 
generated using ggplot (version 2.2.1) within the R programming environment (version 3.3.1) for ATAC-seq 
libraries generated in biological triplicate. Those conditions assessed are Cdx2 shRNA knockdown (KD), 
scramble transfected (SCR POS), scramble untransfected (SCR NEG) and untransfected (UT) TSCs. Read 
quality and alignment efficiency was high, with less than 30% of all reads displaying mitochondrial 
contaminants and low duplication rates (data not shown). b) A correlation heatmap showing Pearson 
correlation coefficients. This was calculated using read density at 10,000bp intervals across the genome. c) 
IGV track displaying accessibility for each biological replicate sample individually around the Cdx2 locus. d) 
Insert size plot displaying the lengths of paired-end alignments in merged samples per condition.   
 
Regions of differential accessibility were determined by pairwise analysis for KD 
against SCR and UT. SCR NEG samples were discounted from this analysis 
because of lower Cdx2 expression in the corresponding RNA-seq libraries. To 
generate a consensus peakset of chromatin regions affected by Cdx2 knockdown, 
only peaks with p<0.01, fold change 0.25x and those present in both pairwise 
comparisons were included in the final peakset. Regions were discounted if they 
were found to differ between control (SCR and UT) samples.  
 
In total, there were 2313 (37.35%) and 3879 (62.65%) sites of lost accessibility (LA) 
and gained accessibility (GA), respectively (Figure 4.7a). Differences in accessibility 




at these sites between wild-type TSCs and Cdx2 knockdown TSCs were validated 
globally using heatmaps (Figure 4.7b) and locally around genes dysregulated by 
Cdx2 knockdown, including Cdh5, Plac1 and Cyr61 (Figure 4.4, Figure 4.7c-e) 
(Thorvaldsdottir et al., 2013). Overall, these data indicate that a short-term reduction 
in Cdx2 expression by only 53-62% alters the chromatin landscape at specific loci.  
 
 
Figure 4.7: Short-term Cdx2 knockdown causes significant changes to chromatin accessibility. a) 
Pie chart to show the relative proportion of lost accessibility (LA) and gained accessibility (GA) sites resulting 
from Cdx2 knockdown. b) Heatmap to show normalised read density of UT, SCR NEG, SCR and KD ATAC-
seq libraries at all LA and GA sites. c-e) IGV track to show sites of differential accessibility at the 
downregulated gene Cyr61 locus and upregulated genes Cdh5 and Plac1 loci. Boxes highlight those regions 
called as differentially accessible in KD libraries relative to WT libraries.  
 
To discover which transcription factors contribute to chromatin accessibility changes, 
I next performed motif and footprinting analyses. Transcription factors often bind to 
conserved DNA binding consensus motifs (Khan et al., 2018, Mathelier et al., 2016). 
There are several algorithms that can scan defined sets of chromatin intervals for 
consensus motifs and determine the transcription factors that may bind them  (Heinz 
et al., 2010, Khan et al., 2018, Bailey et al., 2009). Although not the case for all 
transcription factors, their binding to motif sequences can protect the region from 
enzymatic digestion  (Galas and Schmitz, 1978). In this way, the region can be locally 




protected, leading to a ‘footprint’ of decreased read coverage around motifs (Galas 
and Schmitz, 1978). However, not all transcription factors have a footprint and in, 
some cases, signatures arise from biases in cutting rather than transcription factor 
binding (He et al., 2014, Grontved et al., 2015, Sung et al., 2014, Swinstead et al., 
2016). To address and minimise the effect of these issues, the tool BaGFoot 
integrates two different transcription factor-DNA binding phenomena to perform 
differential footprinting analysis: footprinting and accessibility around motifs between 
conditions, referred to as flanking accessibility (Baek et al., 2017).  
 
 
Figure 4.8: Sites of lost and gained accessibility are attributable to CDX2 and TFAP2C, respectively. 
a-b) Bag plot depicting those motifs enriched as having a differential footprint depth (ΔFPD) and flanking 
accessibility (ΔFA) in KD versus SCR (a) and UT (b). Motifs that are statistically significant outliers are shown 
as red circles. c) Bar charts displaying the 30 most statistically significant enriched motifs in lost accessibility 
and gained accessibility peaksets as determined using HOMER. d) Fold change in TFAP2C protein 
expression in KD and SCR over UT as assessed by flow cytometry. Error bars show SD. n=3 biological 
replicates. Statistical significance determined by t-test: * = 0.0223. 
  




Footprinting analysis using BaGFoot attributed the loss and gain of accessibility in 
Cdx2 knockdown conditions over control conditions (SCR and UT) to the 
homeodomain CDX/HOX and AP2 motif families, respectively (Figure 4.8a-b) (Baek 
et al., 2017). The enrichment of these motifs was confirmed by conventional motif 
analysis using HOMER (Figure 4.8c) (Heinz et al., 2010). Overall, 69% and 76% of 
LA sites contained the CDX2 and CDX4 consensus motifs, respectively. This 
suggests the loss of accessibility in Cdx2 knockdown is a direct consequence of 
decreased CDX2 expression and its binding at these sites. The TSC marker gene 
Tfap2c, an AP2 transcription factor family member, is upregulated in Cdx2 
knockdown cells at both the transcript and protein levels (Figure 4.4c, Figure 4.8d) 
and is probably the main cause of gained accessibility in Cdx2 knockdown. 
 
I next determined where GA and LA sites are distributed across the genome (Heinz 
et al., 2010). Most GA and LA sites are located in introns or are intergenic (Figure 
4.9a-b). Using GREAT, I performed GO analysis using the single closest gene TSS 
to every LA and GA site (McLean et al., 2010). To make this as biologically relevant 
as possible, enrichment analysis was performed over a background file containing 
all accessible regions in all ATAC-seq libraries (Chapter 2.5.2).  
 
Limited GO terms were returned for LA sites (Figure 4.9c), perhaps because these 
sites are few in number and/or almost half are located over 10kb away from the 
closest gene. Of those GO terms enriched for LA sites, several were related to cell-
cell junctions: apical junction complex (GO:0043296) and tight junction 
(GO:0005923) (Figure 4.9d). This aligns with the in vivo phenotype of Cdx2-null 
embryos which show abnormal junctions by the late blastocyst stage (Strumpf et al., 
2005). Only one trophoblast lineage related MGI expression term was discovered in 
the top 50: E6.5 (TS5) trophectoderm (ID: 99, -log10(Hypergeometric p value) = 3.40) 
(Figure 4.9e). Instead, genomic intervals are near genes expressed in other Cdx2-
expressing tissues including the intestine and tail regions. As such, the functional 
relevance of LA sites for the trophoblast lineage is not immediately apparent. 
 
In contrast, gene ontology analysis for GA genomic regions suggest that sites are 
enriched around genes associated with trophoblast lineage derivatives from later 
stages of embryonic development, mainly E14 (TS22) (Figure 4.9f). The two most 




enriched GO biological processes terms are trophoblast giant cell differentiation 
(GO:0060707) and cell differentiation involved in embryonic placenta development 
(GO:0060706) (Figure 4.9g). This suggests that the biological function of sites that 
gain accessibility after Cdx2 knockdown might be to drive the cells to differentiate.  
 
 
Figure 4.9: Functional assessment of differentially accessible regions in Cdx2 knockdown by 
location and GO analysis. a-b) Location of LA and GA sites displayed as a percentage of the total regions 
as determined by HOMER annotation. c-g) Bar charts to show -log10 of the hypergeometric p-value GO 
terms called in LA (left) and GA (right) over total accessible sites in all samples. Analysis was performed 
using the single nearest gene association rule by GREAT. c,g = GO biological processes, d = GO cellular 
function, e,f = MGI expression. 
  




4.5 Library integration: ATAC-seq, ChIP-seq and RNA-seq 
To fully understand the role of Cdx2 in the established trophoblast lineage, the 
relationship between CDX2 binding and the effect of Cdx2 knockdown on the 
transcriptome and chromatin accessibility need to be integrated.  
4.5.1 To lose or not to lose: CDX2 binding, knockdown and changes in 
accessibility 
As shown in the previous section, sites of reduced accessibility in Cdx2 knockdown 
cells (LA) are enriched for the CDX2 homeodomain motif and footprint. In Chapters 
3.3 and 3.4, I discussed the generation and analysis of CDX2 ChIP-seq libraries in 
embryo-derived TSCs. Most, but not all, lost accessibility sites are bound by CDX2 
in these ChIP-seq libraries (Figure 4.10a). To quantify the number of CDX2 binding 
sites called in ChIP-seq libraries that overlap with sites of reduced accessibility in 
Cdx2 knockdown, these peaksets were intersected (Figure 4.10b). Overall, 92% of 
LA sites directly overlap CDX2 binding sites in one of the CDX2 ChIP-seq libraries. 
This suggests that only 7.6% of all reduced accessibility sites in Cdx2 knockdown 
are unrelated to CDX2 biding. 
 
 
Figure 4.10: Sites of lost accessibility show significant overlap with called CDX2 binding sites. a) 
Normalised read density heatmap to show enrichment of INX and XYO CDX2 ChIP-seq dataset at sites of 
lost accessibility (LA) by ATAC-seq in Cdx2 knockdown. b) UpSetR plot showing intersection of genomic 
intervals contained in LA, INX and XYO datasets.   
 
CDX2 binding sites in TSCs differ according to the way in which the cells were 
originally derived. In the previous chapter, I showed that CDX2 binding sites in 
embryo-derived TSCs (ETBS) can be separated based on their accessibility in 




mESCs (ETBS-C1, -C2 and -C3) (discussed in Chapter 3.5). Motif and GO analysis 
suggested that these different ETBS clusters may have different roles in the 
trophoblast lineage (Chapter 3.5). To discover whether one of these CDX2 binding 
site clusters is more affected by Cdx2 knockdown than the others, I generated profile 
plots that display how accessible they are, on average, in UT, SCR and KD 
conditions. This revealed that chromatin accessibility is reduced in all these clusters 
in KD samples relative to the wild-type controls, but there are also differences 
between SCR and UT (Figure 4.11a). This suggests that all ETBS peaksets may 
contain CDX2 binding sites that lose accessibility in Cdx2 knockdown. To determine 
if one ETBS cluster is more affected than the others, ETBS sites need to be directly 
overlapped with LA sites.  
 
To address this, I intersected LA peaks with those in the ETBS clusters (Figure 
4.11b). Of the sites that lose accessibility in Cdx2 knockdown cells, 78.4% are 
contained in cluster ETBS-C3 (Figure 4.11b). The high overlap between ETBS-C3 
and LA sites is unsurprising as this ETBS cluster showed the highest enrichment for 
homeobox motifs (Chapter 3, Figure 3.10c). However, despite this high enrichment 
for homeobox motifs, only 6.35% of all ETBS-C3 sites are affected by Cdx2 
knockdown. 
 
To understand why accessibility of CDX2 binding sites are only lost at specific sites, 
I removed CDX2 binding sites that lose accessibility in Cdx2 knockdown (LA) from 
each ETBS peaksets (ETBS-C1/2/3-minus LA (-mLA)). The read density heatmap in 
Figure 4.11c confirmed that the only CDX2 binding site peakset that significantly 
reduced chromatin accessibility between KD and UT/SCR conditions was LA sites 
(purple, Figure 4.11c). These LA sites are also those that are most enriched for CDX2 
binding in TSCs (green, Figure 4.11c), suggesting that the loss of CDX2 binding at 
these sites may be because this is where CDX2 binds the strongest. There are, 
however, many other sites where CDX2 binds robustly whose accessibility is 
unaffected by Cdx2 knockdown.  
 





Figure 4.11: Integration of ATAC-seq and CDX2 ChIP-seq libraries. a) Profile plot to show the average 
read density of UT, SCR and KD ATAC-seq libraries at embryo-derived TSC CDX2 binding site (ETBS) 
clusters generated in Chapter 3.5. b) Venn diagram displaying the number of unique and overlapping peaks 
between lost accessibility sites (LA) and ETBS clusters. c) Read density heatmap for UT, SCR and KD 
ATAC-seq libraries (purple) and ChIP-seq libraries (green) generated in INX and XYO cell lines at LA sites 
and ETBS clusters minus LA sites (-mLA). d) Bar chart showing the percentage of each ETBS cluster minus 
sites of reduced accessibility in Cdx2 knockdown (-mLA) that overlaps with a merged file of accessible 
chromatin across all ATAC-seq libraries, “merged all INX”.  
 
Next, I explored why chromatin accessibility did not change at most CDX2 binding 
sites by examining each ETBS cluster independently. In Chapter 3.5, it was 
hypothesised that Cluster ETBS-C1 represented opportunistic CDX2 binding sites 
due to the lack of homeobox motif enrichment and their high accessibility in mESCs 
(Chapter 3.5, Figure 3.10c). In agreement with this, only 1.6% of ETBS-C1 sites 
overlap with LA peaks (Figure 4.11b) and CDX2 binding (green, Figure 4.11c) is 
lower in ETBS-C1-mLA than in other clusters even though these sites are highly 
accessible in TSCs (purple, Figure 4.11c). The unchanging accessibility at ETBS-
C1-mLA sites after Cdx2 knockdown is, therefore, likely because CDX2 binding here 
is opportunistic. 
 
As with ETBS-C1, only 3.9% of ETBS-C2 sites overlap with LA sites (Figure 4.11b) 
and CDX2 binding (green, Figure 4.11c) is low relative to how accessible (purple, 




Figure 4.11c) ETBS-C2-mLA sites are. Chapter 3.5, I showed that ETBS-C2 sites 
are enriched for the TEAD family of motifs, suggesting that CDX2 may be recruited 
to these sites by TEAD4. The accessibility of ETBS-C2-mLA sites is, therefore, 
unaffected by Cdx2 knockdown because CDX2 binding here is likely recruited by 
other factors and is not required to maintain accessibility. 
 
Although 79.5% of LA sites overlap with CDX2 binding sites in cluster ETBS-C3, 
93.7% of ETBS-C3 sites do not show a significant reduction in accessibility after 
Cdx2 knockdown (Figure 4.11b). The ETBS-C3 sites are highly enriched for 
homeobox motifs (Chapter 3.5, Figure 3.10c) as are ETBS-C3 sites after LA sites 
are removed: ETBS-C3-mLA (data not shown). In contrast to other ETBS clusters, 
the strength of CDX2 binding (green, Figure 4.11c) in ETBS-C3-mLA sites correlated 
with how accessible the chromatin was (purple, Figure 4.11c). However, many 
ETBS-C3-mLA sites show negligible accessibility (Figure 4.11c) and 21.5% of ETBS-
C3-mLA sites were not called as accessible by MACS2 in any TSC ATAC-seq library 
(Figure 4.11d). In contrast,  0.6% and 3.5% of sites were inaccessible in TSCs for 
ETBS-C1-mLA and ETBS-C2-mLA, respectively (Figure 4.11d). 
 
Given the above, it is likely that the resistance of ETBS-C3-mLA sites to chromatin 
accessibility changes in Cdx2 knockdown may occur for different reasons. To 
address this, ETBS-C3-mLA sites were sub-divided into new clusters based on their 
accessibility in TSCs. Those 21.5% of ETBS-C3-mLA sites that were not deemed to 
be accessible by MACS2 peak calling on ATAC-seq libraries were considered to be 
a new, inaccessible subset. K-means clustering was subsequently performed with 
the remaining peaks to separate them into new clusters. In all, this generated three 
new sub-peaksets for ETBS-C3-mLA: highly accessible, accessible and inaccessible 
(Figure 4.12a). Next, I determined whether these ETBS-C3-mLA clusters were 
differentially enriched for motifs that may explain why they are unaffected by Cdx2 
knockdown. 
 


























































































































































































































































































































































































































































































































































































































‘Highly accessible’ ETBS-C3-mLA sites are most enriched for bZIP motifs (Figure 
4.12b) and several of these motifs, including JunB and AP-1, are also found in sites 
with increased accessibility as a result of Cdx2 knockdown (Figure 4.8c). Whilst 
homeobox motifs are poorly enriched in ‘highly accessible’ sites, motifs for other key 
TSC markers including Elf5, Ets2 (both ETS), Eomes and Tead4 (TEA(D)) are 
significantly enriched (Figure 4.12b). As both EOMES and TEAD4 are known to 
directly interact with CDX2 (Latos et al., 2015a), its binding at these sites is probably 
facilitated by other factors and/or is opportunistic. Unsurprisingly, bearing in mind 
their high accessibility in TSCs and the enrichment of TSC marker gene motifs, 
ETBS-C3-mLA ‘highly accessible’ sites are enriched around genes that are 
expressed in (Figure 4.12c) and critical to (Figure 4.12d) the trophoblast lineage. In 
sum, the accessibility of these ETBS-C3-mLA highly accessible sites is unaffected 
by Cdx2 knockdown because CDX2 binding here is recruited and/or opportunistic.  
 
‘Accessible’ ETBS-C3-mLA sites in TSCs are enriched for homeodomain, EOMES 
and EHF motifs (Figure 4.12b). This indicates that CDX2 binding at these sites may 
be predominantly driven by binding to its own consensus motif. However, the 
accessibility of these sites and the expression of Eomes and Elf5  are not affected 
by Cdx2 knockdown (Chapter 4.3), so the accessibility of ETBS-C3-mLA ‘accessible’ 
sites is probably dependent on EOMES and ELF5 binding rather than CDX2. 
Functionally, ETBS-C3-mLA accessible peaks are not enriched around genes that 
are expressed in the trophoblast lineage (Figure 4.12e), nor trophoblast-related 
mouse phenotypes (data not shown). Instead, the most enriched GO biological 
processes term is negative regulation of stem cell differentiation (Figure 4.12f).   
 
At ‘inaccessible’ ETBS-C3-mLA sites, 19 of the top 20 most enriched motifs are 
homeobox motifs (Figure 4.12b). As discussed in Chapter 3.4, it is not clear whether 
CDX2 is a pioneer factor, but its binding at ‘inaccessible’ ETBS-C3-mLA sites 
suggests that CDX2 can bind condensed chromatin. In addition to being 
‘inaccessible’, these CDX2 binding sites are not enriched around trophoblast-related 
genes (data not shown) and are instead located around genes associated with 
regulation of histone modifications and chromatin organisation (Figure 4.12g). In all, 
these sites are unaffected in Cdx2 knockdown because they inaccessible and, as a 
result, the biological relevance of CDX2 binding at these sites is unknown.  




4.5.2 Histone modifications are distinct at different CDX2 binding subsets 
To provide further context to these different CDX2 binding clusters, published histone 
ChIP-seq data was integrated into analyses (Chuong et al., 2013). Histone marks 
can be indicative of active or inactive gene function. H3K27ac is an active enhancer 
marker that is critical for controlling enhancer-regulated GRNs and the production of 
enhancer RNAs (Creyghton et al., 2010, Rada-Iglesias et al., 2011, Raisner et al., 
2018). H3K4me1 also marks enhancers, but not their activity, and is dispensable for 
enhancer function (Dorighi et al., 2017). The strength of H3K4me3 signal, present at 
the promoter-TSS of active genes, correlates with the strength of gene expression 
(Santos-Rosa et al., 2002, Heintzman et al., 2007, Bernstein et al., 2005, Okitsu et 
al., 2010, Benayoun et al., 2014). Both H3K27me3 and H3K9me3 are repressive 
markers (Rea et al., 2000). H3K27me3 is enriched on the inactive X chromosome 
and is responsible for long-term cell type-specific transcriptional repression (Plath et 
al., 2003, Silva et al., 2003, Lee et al., 2006, Boyer et al., 2006, Ezhkova et al., 2009). 
In contrast, H3K9me3 marks repeat-rich constitutive heterochromatin and is 
specifically concentrated at pericentric and centric heterochromatin (Nakayama et 
al., 2001, Peters et al., 2003). 
 
There are three CDX2 binding site peaksets outlined above in which CDX2 is 
probably recruited by its own consensus motif; LA, ETBS-C3-mLA accessible, and 
ETBS-C3-mLA inaccessible. At CDX2 binding sites in which Cdx2 knockdown 
causes a loss in chromatin accessibility, there is some enrichment for the generic 
enhancer marker H3K4me1 but not the active enhancer marker H3K27ac (Figure 
4.13). Similarly, most ‘accessible’ ETBS-C3-mLA sites are enriched for the enhancer 
marker H3K4me1, but are not marked as active (Figure 4.13). In contrast, few 
‘inaccessible’ ETBS-C3-mLA CDX2 binding sites show enrichment for both the 
enhancer markers H3K27ac and H3K4me3 (Figure 4.13). 
 
The homeobox motif was minimally enriched in all other CDX2 binding site clusters 
(ETBS-C1-mLA, ETBS-C2-mLA and ETBS-C3-mLA ‘highly accessible’), indicating 
that CDX2 binding here is recruited by other genes and/or is opportunistic because 
these sites are highly accessible. CDX2 binding sites that are highly accessible in 
mESCs, ETBS-C1-mLA, are primarily located at promoter-TSS as shown by the high 




enrichment of H3K4me3 reads (Figure 4.13). Some CDX2 binding sites that were 
less accessible in mESC, ETBS-C2-mLA, are found at promoter-TSS. However, 
ETBS-C2-mLA and ETBS-C3-mLA ‘highly accessible’ peaksets are mostly active 
enhancers (Figure 4.13).  
 
Overall, as well as the different enrichment of GO terms and motifs, CDX2 binding 
site subsets have distinct histone modification profiles, indicating that they have 
different functions in TSCs. 
 
 
Figure 4.13: Histone modifications at CDX2 binding site subsets. Read density heatmap for histone 
modification ChIP-seq data generated in TSCs at different CDX2 binding site subsets.  




4.5.3 Tfap2c, gained accessibility and histone modifications 
According to motif and footprinting analyses, increased accessibility under Cdx2 
knockdown conditions results from the upregulation of Tfap2c. A TSC marker gene, 
TFAP2C is upregulated during trophoblast differentiation and is the key driver of the 
global increase accessibility associated with this process (Latos et al., 2015b, Nelson 
et al., 2017). In agreement with the importance of Tfap2c to trophoblast 
differentiation, sites of gained accessibility are located around genes that are 
expressed in trophoblast differentiation (Figure 4.9g). To ask whether sites of gained 
accessibility in Cdx2 knockdown are bound by TFAP2C in TSCs or one day after 
differentiation by growth factor withdrawal (DD1), I compared my gained accessibility 
sites to published TFAP2C ChIP-seq datasets (Latos et al., 2015b).  
 
This analysis revealed that 52% of gained accessibility sites overlap with called 
TFAP2C binding sites in either TSCs, DD1 or both (Figure 4.14a). One possible 
explanation for the low overlap between these peaksets is that these sites are 
inaccessible in wild-type TSCs. To determine how TFAP2C binding correlates with 
accessibility in wild-type TSCs and Cdx2 knockdown TSCs, read density heatmaps 
were generated (Figure 4.14b). Most of these sites are poorly accessible in wild-type 
TSCs conditions but sites still show some enrichment for TFAP2C binding in one or 
both libraries (Figure 4.14b). In all, this suggests that TFAP2C does bind sites of 
gained accessibility, but there is no difference in its binding at these sites between 
TSCs and one day after growth factor withdrawal to differentiate cells.  
 
Next, I compared how similar TFAP2C binding sites are between TSCs and DD1 to 
assess how much TFAP2C binding changes over a short period of time. Although 
these libraries were only generated one day apart, TFAP2C is redistributed rapidly 
across the genome during differentiation, with 23.88% and 17.17% of TSC and DD1 
peaks unique, respectively (Figure 4.14a). However, TFAP2C binding at differential 
binding sites between TSCs and DD1 is weak compared to its binding at shared sites 
in both conditions (Figure 4.14c). In summary, TFAP2C binding is redistributed to 
different loci across the genome rapidly under differentiation conditions but the sites 
that TFAP2C binds most strongly to do not change between TSCs and one day after 
growth factor withdrawal.  





Figure 4.14: Integration of published TFAP2C and histone marker ChIP-seq data at gained 
accessibility sites in Cdx2 knockdown. a) UpSetR plot to show the intersection of TFAP2C ChIP-seq 
generated in TSCs and one day after initiation of differentiation by growth factor withdrawal (DD1) with sites 
of gained accessibility in Cdx2 knockdown (GA). b) Heatmap to show the read density of UT, SCR and KD 
ATAC-seq (purple) and TFAP2C TSC and DD1 ChIP-seq (green) libraries at sites of gained accessibility 
(GA). c) Read density heatmap showing chromatin accessibility (ATAC-seq, purple) and TFAP2C binding 
(ChIP-seq, green) at all TFAP2C binding sites. Peaks were separated into unique (TSC only, DD1 only) and 
overlapping (TSC and DD1) peaksets by intersecting peaks with HOMER. d) Read density heatmap of 
histone modification marker ChIP-seq data generated in TSCs at different GA sites in Cdx2 knockdown. 
 
The sites that gain accessibility in Cdx2 knockdown are different from gained 
TFAP2C binding sites in differentiation induced by growth factor withdrawal (Figure 
4.14a). To understand the significance of these sites, I next asked what histone 
modifications are enriched at sites of gained accessibility in Cdx2 knockdown (Figure 
4.14d). This revealed that these chromatin regions are strongly marked as enhancers 
by H3K4me1. As expected given that these are mostly inaccessible, few of these 
enhancers are marked as active (H3K27ac, Figure 4.14d). Further work is  required 
to determine if these sites subsequently become active in Cdx2 knockdown.  




4.5.4 Observed transcriptional and chromatin accessibility changes in Cdx2 
knockdown poorly correlate 
Most GA sites are highly enriched for H3K4me1, a general enhancer marker (Figure 
4.14d). To see if these regions may be enhancers, I asked whether changes in 
chromatin accessibility observed in Cdx2 knockdown resulted in dysregulated genes. 
For this, the closest lost (LA) or gained accessibility (GA) sites to the  transcription 
start site (TSS) of every differentially expressed gene was determined (Figure 4.15a). 
This revealed that the closest chromatin region showing any differential accessibility 
in Cdx2 knockdown was 50kb or away for 56.8% and 54.8% of all upregulated and 
downregulated genes, respectively. These sites, therefore, either represent distal 
enhancers or are unrelated to the genes dysregulated by Cdx2 knockdown.  
 
To determine if there is a trend that links the direction of chromatin accessibility and 
transcriptional changes in Cdx2 knockdown, the distance of the closest LA and GA 
site to each upregulated and downregulated gene TSS, respectively, was assessed 
(Figure 4.15b-c). GA sites are more commonly located within 50kb of the TSS of 
upregulated genes than LA sites (38.3% versus 8.27% LA sites) (Figure 4.15b). 
Similarly, LA sites are more commonly found within 50kb of the TSS of 
downregulated genes than GA sites (32.7% vs 17.9% total closest peak) (Figure 
4.15c). Whether these are biologically relevant observations is unclear. Overall, the 
relationship between chromatin accessibility and transcriptional changes is poor.  
 





Figure 4.15: Proximity of differentially accessible chromatin regions in Cdx2 knockdown to the TSS 
of dysregulated genes. a) Bar chart showing the closest differential accessibility site to the TSS of all down- 
and upregulated genes in Cdx2 knockdown. b) Bar chart to show the closest gained accessibility (GA, red) 
and lost accessibility (LA, blue) sites to the TSS of every upregulated gene. c) Bar chart to show the closest 
GA (red) and LA (blue) sites to the TSS of every downregulated gene  
  





Short-term Cdx2 knockdown perturbs both the transcriptome and the chromatin 
landscape of TSCs, with almost 5% of genes changing in their expression levels and 
6192 chromatin regions changing in accessibility. Fold changes of differentially 
expressed genes are small, perhaps because knockdown was only of the order of 
53-62%. Nevertheless, my results provide new insights into Cdx2 function in the 
trophoblast fate and new information about the gene regulatory network that 
underpins TSC maintenance. 
 
Upregulated genes account for 58% of all dysregulated genes and are enriched for 
GO terms related to cell adhesion and other differentiation pathways. Genes that are 
downregulated in Cdx2 knockdown are enriched for pathways related to the immune 
response and apoptosis. This is in direct contrast to the effect of Cdx2 knockdown in 
vivo, where trophectodermal cells show a significant increase in apoptosis (Strumpf 
et al., 2005). Therefore, Cdx2 knockout in the trophectoderm in vivo and Cdx2 
knockdown in TSCs in vitro have different transcriptional consequences. This 
provides further evidence that Cdx2 plays distinct roles during establishment of the 
trophoblast lineage and in maintaining the trophoblast stem cell status.  
 
Beyond this, the exact role of Cdx2 is difficult to ascertain given the poor correlation 
between transcriptional and chromatin landscape perturbations. Whilst sites that lose 
accessibility after short-term Cdx2 knockdown appear to be caused by a direct loss 
of CDX2 binding, they are low in number and their function is unclear. GO analysis 
reveals that these sites are localised around genes that are important in cell 
junctions. Whilst abnormal junctions are observed in Cdx2-null trophectoderm in vivo 
(Strumpf et al., 2005), these genes were not shown to be differentially expressed in 
RNA-seq analyses. Alternatively, sites of lost accessibility in Cdx2 knockdown are 
enriched around genes that are expressed in multiple Cdx2-related lineages, 
perhaps indicating that they represent core CDX2 binding sites irrespective of the 
cell type. This would provide an explanation as to why the direct biological function 
of lost accessibility sites is difficult to elucidate. 
 




Only 6% of CDX2 binding sites in embryo-derived TSCs (ETBS) lose accessibility 
after short-term Cdx2 knockdown. In Chapter 3.5, I separated CDX2 binding sites 
into clusters based on their accessibility in mESCs. Highly accessible (ETBS-C1) 
and accessible (ETBC-C2) binding sites are not enriched for the canonical 
homeobox motif. Instead, CDX2 binding at these regions is probably opportunistic or 
recruited by other transcription factors, such as TEAD4 and EOMES, binding to their 
canonical motifs. This is further substantiated by the previously established direct 
interaction between CDX2 and both TEAD4 and EOMES (Latos et al., 2015a). 
Accordingly, only 21.6% of decreased accessibility in Cdx2 knockdown overlap with 
peaks in both of these clusters. CDX2 binding sites that are inaccessible in mESCs, 
ETBS-C3, are highly enriched for the homeobox motif and binding at these regions 
are amongst the strongest of all sites in TSCs. However, when subdivided further 
based on their accessibility in TSCs, ETBS-C3 also generates peaksets that are 
poorly enriched for the homeobox motif.  
 
Therefore, the accessibility of CDX2 binding sites is largely independent of CDX2 
binding itself, and is instead dependent on binding of other transcription factors. 
Other than at those sites that showed reduced accessibility in Cdx2 knockdown, 
consensus homeobox motifs are most enriched in CDX2 binding sites at less 
accessible or inaccessible chromatin regions in TSCs. As these genomic regions 
remain inaccessible over successive passages, they do not represent active pioneer 
transcription factor (TF) sites. However, it is possible that these sites represent 
passive pioneer TF sites that facilitate binding of other unknown factor(s) that are not 
expressed within stable TSCs. If these are indeed passive pioneer TF binding sites, 
what factor(s) they recruit is undetermined and not represented by motif analysis.  
 
Given the small number of genes differentially expressed after Cdx2 knockdown, 
determining where Cdx2 fits into the TSC GRN is difficult. The expression of most 
TSC marker genes, including Eomes and Elf5, are unaffected by short-term Cdx2 
knockdown, revealing that they are not direct downstream targets of Cdx2. In 
contrast, TSC marker genes Gata3 and Tfap2c are upregulated in Cdx2 knockdown. 
Gata3 is upstream of Cdx2 in established TSCs, regulating Cdx2 expression using 
an enhancer within intron 1 of Cdx2 (Home et al., 2009). The observed upregulation 
of Gata3 in Cdx2 knockdown may be indicative of a feedback loop between Gata3 




and Cdx2 that controls both of their expression levels. However, the enhancer region 
within Cdx2 intron 1 shows no increase in accessibility in Cdx2 knockdown cells over 
wild-type controls (data not shown). As Gata3 is also upregulated in differentiation 
(Ralston et al., 2010), its upregulation may also indicate that Cdx2 knockdown cells 
are differentiating as predicted by GO analysis on sites of increased accessibility.   
 
Sites of gained accessibility, accounting for almost two thirds of all changes to the 
chromatin landscape in Cdx2 knockdown, were attributed to TFAP2C binding. As 
with Gata3, Tfap2c controls Cdx2 expression via an enhancer within Cdx2 intron 1 
(Cao et al., 2015). Therefore, its upregulation after Cdx2 knockdown may result from 
a feedback loop between these their expression. Tfap2c expression levels are also 
critical to balance the TSC GRN. When TSC are differentiated in vitro by growth 
factor withdrawal, the associated upregulation of TFAP2C drives differentiation and 
a global increase chromatin accessibility (Latos et al., 2015b, Nelson et al., 2017). In 
agreement with the importance of Tfap2c to TSC differentiation, sites of increased 
accessibility in Cdx2 knockdown are found around genes associated with placental 
differentiation, especially differentiation towards trophoblast giant cells (TGCs). 
Although GA sites are also enriched for the generic enhancer marker H3K4me1, 
these regions are over 50kb from most genes that are dysregulated in Cdx2 
knockdown indicating that these are distal enhancers or have minimal immediate 
effect on the transcriptome.  
 
The TGC marker Hand1 is also significantly upregulated in Cdx2 knockdown. It is 
well established that Hand1 overexpression alone is capable of inducing 
differentiation of TSCs into TGCs, albeit in only 30% of targeted cells (Scott et al., 
2000). Together with the gene ontology analysis of GA sites, the upregulation of 
three genes, Tfap2c, Hand1 and Gata3, indicates that long-term Cdx2 knockdown 
may drive differentiation towards the TGC lineage.  
 




Chapter 5. Long-term Cdx2 knockdown drives 
trophoblast stem cells to differentiate 
homogeneously into trophoblast giant cells 
Transient Cdx2 knockdown in TSCs perturbs gene expression and alters chromatin 
accessibility. At some CDX2 binding sites, loss of Cdx2 causes decreased 
accessibility, but elsewhere in the genome there is an increase in accessibility driven 
by the upregulation of Tfap2c. Genes whose expression is perturbed by loss of Cdx2, 
as well as those associated with a decrease in accessibility, are not enriched for 
trophoblast-related terms in gene ontology analyses. However, sites of increased 
accessibility are associated with genes that are involved in trophoblast differentiation, 
particularly towards trophoblast giant cells (TGCs). 
 
In vitro, removal of the growth factors that normally maintain cells as trophoblast stem 
cells causes them to differentiate into functional trophoblast derivates (Tanaka et al., 
1998). This process mimics in vivo differentiation, as cells move away from the niche 
environment of the extraembryonic ectoderm into the ectoplacental cone. Analysis 
of microarray, RNA-seq, ATAC-seq and ChIP-seq datasets derived from normal 
TSCs and those subject to growth-factor withdrawal (Nelson et al., 2017, Latos et 
al., 2015b, Chuong et al., 2013) confirm that Tfap2c and Gata3 are upregulated as 
TSCs differentiate (Latos et al., 2015b, Ralston et al., 2010). At the same time, Cdx2 
and other TSC markers genes, including Eomes and Esrrb, are downregulated 
(Donnison et al., 2015, Latos et al., 2015b). Recent work has shown that TSC 
differentiation is accompanied by increases in chromatin accessibility that are driven 
by TFAP2C (Nelson et al., 2017). However, Tfap2c drives Cdx2 expression during 
trophectoderm establishment, as does Tfap2c overexpression in mESCs (Cao et al., 
2015, Kuckenberg et al., 2010). Given that Cdx2 knockdown causes a global 
increase in TFAP2C-asscociated chromatin accessibility around genes associated 
with differentiation, the relationship between Tfap2c and Cdx2 in established cells is 
likely different from that in trophoblast establishment.      
 
In this chapter, I use genetic selection to maintain Cdx2 knockdown for over 48 hours, 
and use these cells to explore the long-term effects of lack of CDX2 on TSC 




maintenance and potency. As predicted by GO analyses, sustained reduction of 
Cdx2 expression proved to drive homogeneous differentiation into TGCs. In contrast, 
differentiation by growth factor withdrawal, the standard method to differentiate TSCs 
in vitro, generated a heterogeneous population of trophoblast derivatives. To 
understand why growth factor withdrawal and Cdx2 knockdown have such different 
outcomes, I made use of published growth factor withdrawal ATAC-seq and RNA-
seq datasets and compared them to my INX datasets. Given the observed long-term 
Cdx2 knockdown phenotype, I focused enhancer activity assays on sites of 
increased chromatin accessibility in the vicinity of the TGC marker gene Hand1.  
  




5.1 Maintained Cdx2 knockdown differs from differentiation 
by growth factor withdrawal and drives parietal 
trophoblast giant cell formation  
Loss of Cdx2 in transdifferentiated TSC-like cells causes them to differentiate (Niwa 
et al., 2005, Kuckenberg et al., 2010). In INX TSCs, Cdx2 returns to wild-type levels 
without selection and cell morphology comes to resemble that of normal TSCs (data 
not shown). Therefore, changes to the transcriptional and chromatin landscape after 
transient Cdx2 knockdown are not sufficient to change TSC potency. 
 
To obtain effective long-term knockdown of Cdx2 I used RNAi vectors carrying an 
mCherry-IRES-puromycin (mCIP) cassette, allowing me to select for transfected 
cells that continue to express the mCIP cassette. The XYO and Rossant-GFP cell 
lines were resistant to puromycin and could not be used in these experiments, but 
experiments on INX TSCs showed that 32-hour treatment with 0.7 µg/mL puromycin 
was sufficient to kill all untransfected cells (data not shown). 
 
INX TSCs were therefore transfected with KD or SCR constructs and puromycin 
added 48 hours post-transfection to select for transfected cells. These cells were 
also compared with INX TSCs induced to differentiate in a heterogeneous manner 
by growth-factor withdrawal (-GF) (see 2.1.1.4). Puromycin was removed after 32 
hours of treatment, and all cells analysed six days after transfection. 
 
By five days after transfection (1.5 days post-puromycin removal), there were clear 
differences in the phenotypic appearances of SCR, KD and -GF cells. At six days, 
SCR cells formed wild-type colonies, with only sporadic differentiation perhaps 
caused by the stress of puromycin selection (Figure 5.1a). In contrast, KD cells 
resembled TGCs; they were larger and more irregularly shaped than SCR cells with 
prominent nuclei (Figure 5.1a). A few phenotypically normal TSC colonies were 
present in KD cells at seven days, potentially due to silencing of the shRNA and 
continued expression from the antibiotic resistance cassette (data not shown). After 
growth factor withdrawal, cultures appeared heterogeneous, with some cells 
resembling TGCs (Figure 5.1a). 





Figure 5.1: Long-term Cdx2 knockdown drives homogenous differentiation into TGCs. a) Brightfield 
images taken of SCR and KD six days post-transfection and six days post-growth factor (-GF) withdrawal. 
At 48-hours post-transfection, cells positively transfected with SCR and KD vectors were selected using a 
32-hour treatment with puromycin. b) Immunofluorescence staining of HAND1, actin fibres (Phalloidin) and 
DAPI in SCR, KD and -GF cells six days post-transfection/growth factor withdrawal. 
 
TGCs have large nuclei, prominent actin stress fibres, and express HAND1 (Parast 
et al., 2001). KD cells exhibit these characteristics in a homogeneous manner, while 
SCR cells fail to express HAND1 and actin is localised at the cell membrane. Growth 
factors withdrawal caused a subset of cells to exhibit the characteristics of TGCs 
(Figure 5.1b) (Tanaka et al., 1998).  
 




Previous work has shown that Elf5, Eomes and Esrrb are downregulated after five 
days of Cdx2 knockdown (Latos et al., 2015a). qRT-PCR demonstrated that the 
same is true in KD and -GF conditions compared with SCR controls (Figure 5.2). 
 
 
Figure 5.2: Differentiation induced by Cdx2 knockdown and growth factor withdrawal are distinct. 
qRT-PCR analysis of trophoblast lineage markers in SCR, KD and -GF samples 6 days post-transfection or 
growth factor withdrawal. Those trophoblast lineages assayed are trophoblast stem cells, progenitors, 
spongiotrophoblast, syncytiotrophoblast and trophoblast giant cell. Data are normalised to Gapdh. n=3 
biological replicates per cell line. Significance determined by one-way ANOVA statistical test: * = <0.0332, 
** = <0.0021, *** = <0.0002, **** = <0.0001. Error bars display SD. 
 
Other markers of differentiation were also studied. Gata3 and Tfap2c, both TSC 
markers, are upregulated during growth factor withdrawal differentiation (Latos et al., 
2015b, Ralston et al., 2010) and the same was true in KD and -GF cells (Figure 5.2). 
Interestingly, the ectoplacental cone marker Ascl2 is upregulated in -GF cells but not 
in KD cells, suggesting that KD cells do not follow a typical TSC differentiation route 
(Figure 5.2). Tpbpa, a marker of the ectoplacental cone and spongiotrophoblast 
fates, is upregulated in -GF conditions compared with SCR and KD (Figure 5.2). 
Similarly, Snai1, a marker of the syncytiotrophoblast lineage, was significantly 




upregulated only in -GF cells. Unexpectedly, Syna, another syncytiotrophoblast 
marker, was expressed at low levels under all three conditions (Figure 5.2).  
 
I also analysed markers specific for trophoblast giant cell sub-types. The transcription 
factor Hand1 is expressed in all four TGC sub-types (Simmons et al., 2007). Prl3d1 
(Pl1) is exclusively found in parietal TGCs (p-TGCs). Ctsq is expressed in sinusoidal 
TGCs (s-TGCs) and channel TGCs (Ch-TGCs) (Simmons et al., 2007, Rawn et al., 
2015). Prl3d3 (Plig) is expressed in both p-TGC and Ch-TGCs subtypes (Rawn et 
al., 2015). Prl2c2 (Plf) is expressed in spiral-artery associated TGCs (SpA-TGCs), in 
canal TGCs (c-TGCs), s-TGCs and p-TGCs.  
 
Expression of Hand1 proved to be upregulated in Cdx2 KD cells, as was expression 
of Prl3d1, Prl2c2 and Prl3d3. None of these markers was significantly upregulated in 
-GF cells compared with SCR, perhaps because SCR cells underwent spontaneous 
differentiation. The s-TGC and Ch-TGC marker Ctsq was only upregulated in -GF 
samples (Figure 5.2). These results indicate that long-term Cdx2 knockdown drives 
cells to differentiate into p-TGCs. 
  




5.2 Distinct chromatin landscape changes in Cdx2 knock-
down and differentiation by growth factor withdrawal 
In Chapter 4, GO analysis correctly predicted that long-term Cdx2 knockdown would 
drive trophoblast stem cells to differentiate into trophoblast giant cells (Chapter 4, 
Figure 4.9g). This is an indirect effect, driven by an increase in expression and 
binding of TFAP2C. Previous analyses of the effect of growth factor withdrawal on 
TSCs indicate that heterogeneous differentiation is similarly accompanied by a global 
increase in chromatin accessibility, driven by TFAP2C (Nelson et al., 2017). What, 
then, underlies the differences in TSC differentiation following long-term Cdx2 
knockdown and growth factor withdrawal? 
 
One possibility is that TFAP2C binds differently under the two conditions. To test this 
idea, I compared the INX ATAC-seq libraries to those generated in the Robertson 
Lab (RL): one made in TSCs (herein named ‘TS RL’) and another made from cells 
two days after growth factor withdrawal (herein named ‘-GF RL’) (Nelson et al., 
2017). These datasets were available as processed data files aligned to the mm10 
genome, the same genome used for INX libraries, from the NCBI GEO depository 
(GSE94694) (Nelson et al., 2017) (see 2.5.1, Table 2.2).  
 
There are two potential reasons for differences between RL and INX libraries: 
biologically relevant differences related to different the cell lines and/or condition 
used, and biologically irrelevant differences resulting from the analysis pipelines. If 
biologically irrelevant differences are present between these libraries, this would 
compromise any future analysis. To address the possibility of biologically irrelevant 
differences between INX and RL libraries, regions of open chromatin in ‘TS RL’, ‘-GF 
RL’ and all INX TSCs (‘merged all INX’) were compared to see how similar they were 
(Figure 5.3a). In total, 84.81% of open chromatin in ‘TS RL’ libraries and 73.52% of 
‘-GF RL’ were also open in ‘merged all INX’ (Figure 5.3a). Although the profiles of 
RL and INX peaks were different in height and shape, their positions were similar 
across the genome (Figure 5.3b-c) (Thorvaldsdottir et al., 2013). Therefore, neither 
the cell line nor the analysis pipeline changed the overall chromatin landscape and 
TFAP2C driven differences between these libraries can be directly compared.  
 





Figure 5.3: 'TS RL', '-GF RL' and INX ATAC-seq libraries are similar despite the use of different cell 
lines and analysis pipelines. a) Venn diagram displaying the overlap of the total accessible regions called 
for ‘TS RL’, ‘-GF RL’ and ‘merged all KB’. ‘Merged all KB’ represent all chromatin regions called as accessible 
in at least one the UT, SCR NEG, SCR or KD ATAC-seq libraries. The discrepancy in peak number between 
‘TS RL’ (57,019) and ‘merged all INX’ (210,088) are perhaps due to a difference in the number of libraries 
or the stringency of analysis itself. b-c) IGV tracks to display the UT, SCR, KD, ‘TS RL’ and ‘-GF RL’ libraries 
around two core TSC marker genes: Cdx2 and Eomes. As ‘TS RL’ and ‘-GF RL’ were downloaded as pre-
analysed datasets, these are displayed on a different scale to INX libraries. 
 
In total, 7378 and 3879 regions of chromatin were shown to gain accessibility after 
two days of growth factor withdrawal (d2DARs) (Nelson et al., 2017) or Cdx2 
knockdown (GA, Chapter 4.3), respectively. To compare these peaksets, I found the 
closest d2DARs peak to every GA peak (Figure 5.4a). Although 12.76% of GA peaks 
have a d2DAR peak within 100bp, the closest d2DAR peak to 76.54% of GA sites 
are over 10kb away. Therefore, sites of gain accessibility in Cdx2 knockdown (GA) 
are distinct from those that result from growth-factor removal mediated differentiation 
(d2DARs).  
 
GA and d2DAR peaks were next intersected to determine which sites were shared 
or unique to Cdx2 knockdown and growth factor withdrawal conditions. However, GA 
(507.5bp  195.1bp) and d2DARs (193.9bp  97.3bp) peaks varied in size because 
of the different analysis pipelines used. To overcome this, all peaks were made to be 
700bp total around their centre point, making them similar in size to the largest GA 
peaks. When these were intersected, peaks were classified as overlapping (515), 
GA only (3330) and d2DARs only (6522) (Figure 5.4b). Whilst both Cdx2 knockdown 




(KD) and growth factor withdrawal (‘-GF RL’) conditions showed increased 
accessibility over TSCs at overlapping sites, only KD or ‘-GF RL’ increased in 
accessibility at GA only and d2DARs only sites, respectively (Figure 5.4c). 
Differences in accessibility were also confirmed locally (Figure 5.4d-e). There is a 
shared peak at the Plac1 transcription start site (TSS) (orange box, Figure 5.4d), a 
gene upregulated after transient Cdx2 knockdown (Chapter 4.3, Figure 4.4c), as well 
as multiple d2DARs peaks (black box, Figure 5.4d). In contrast, the Tfap2c locus is 
surrounded by unique sites (Figure 5.4e). Gained accessibility is higher under growth 
factor withdrawal conditions than Cdx2 knockdown conditions, both globally (Figure 
5.4c) and locally (Figure 5.4d-e). Therefore, these peaksets accurately reflect 
overlapping and unique sites of gained accessibility between these conditions.    
 
 
Figure 5.4: Sites of gained accessibility are distinct between short-term Cdx2 knockdown and 
differentiation induced by growth factor withdrawal. a) Histogram displaying the closest d2DARs peaks 
to every GA site. b) The centre of every GA and d2DAR peak was determined, extended by 350bp on either 
side and intersected using HOMER (Heinz et al., 2010). This chart summaries the proportion of overlapping, 
GA only and d2DARs only peaks. c) The average read density of UT, SCR and KD or ‘TS RL’ and ‘-GF RL’ 
ATAC-seq data at overlapping, GA only and d2DAR only peaksets. d-e) IGV track displaying UT, SCR, KD, 
‘TS RL’ and ‘-GF RL’ ATAC-seq data around the Plac1 and Tfap2c locus. Black boxes denote d2DAR only 
peaks, red boxes represent GA only peaks and orange boxes denote overlapping peaks.  





Figure 5.5: Differential TFAP2C binding in Cdx2 knockdown and growth factor withdrawal induced 
differentiation might be caused by different co-factors. Bar charts displaying the 24 most statistically 
significant enriched motifs in overlapping (left), GA only (middle) and d2DARs only (right) peaksets as 
determined using HOMER.  
 
Next, I re-confirmed that TFAP2C is the main driver of gained accessibility at shared 
and unique sites, with AP-2γ and AP-2α the two most enriched motifs in all peaksets 
(Figure 5.5). Beyond this, however, enriched motifs in GA only and d2DARs only 
peaksets are very different. Whilst GA only peaks are enriched for AP-1 transcription 
factor components and SOX motifs, d2DARS are enriched for GATA, C/EBP, PPAR 
and E-box bHLH, such as ASCL1, motifs (Figure 5.5). Intriguingly, transcription factor 
family members for some of these motifs have previously been associated with 
different trophoblast derivates. Whilst Sox15 is known to drive TGC formation, Pparb 
and Ppard are required to maintain the ectoplacental cone and spongiotrophoblast 
(Yamada et al., 2006, Nadra et al., 2006, Wang et al., 2007). 
  




5.3 Genes perturbed in Cdx2 knockdown and differentiation 
by growth factor withdrawal overlap 
The differential motif enrichment between GA only and d2DAR only peaks may be 
driven by differential expression of transcription factor family members between 
conditions. To test this idea, published RNA-seq libraries from TSCs and two growth 
factor withdrawal time points, day 1 (DD1) and day 3 (DD3), were incorporated into 
analyses (Latos et al., 2015b). These libraries were re-analysed using the same 
pipeline as for INX libraries.  
 
 
Figure 5.6: Those genes perturbed by Cdx2 knockdown highly correlate with those affected when 
TSCs are differentiated by growth factor withdrawal. a) Bar charts summarising the number of genes 
significantly up- and downregulated by Cdx2 knockdown (KD), one day after growth factor withdrawal (DD1) 
or three days after growth factor withdrawal (DD3), over TSCs. b) Venn diagram summarising the number 
differentially expressed genes between KDvsTSC, DD1vsTSC and DD3vsTSC that overlapped.  
 
Despite the short timeframes, 5821 and 9133 genes were differentially expressed 
one day or three days after growth factor withdrawal, respectively (Figure 5.6a). 
Although fewer genes are affected by transient Cdx2 knockdown (626, Chapter 4.3), 
86.74% of these overlap with those genes differentially expressed after growth factor 
withdrawal (Figure 5.6b). Of these overlapping genes, 56.35% are differentially 
expressed in the same direction (cluster 1 and 2, Figure 5.7a) and 30.94% in 
opposite directions (clusters 3 and 4, Figure 5.7a) at one or both growth factor 
withdrawal time points. No GO analysis was performed as this would have provided 
little insight into the potential functional relevance of such a small number of genes. 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































qRT-PCR revealed that Tfap2c is significantly upregulated in -GF over both the SCR 
and KD conditions, but is less so in KD over SCR (Figure 5.7b). Whilst TSC marker 
genes Gata3 and Elf5 are upregulated after short-term growth factor withdrawal 
(Latos et al., 2015b, Ralston et al., 2010), only Gata3 is after Cdx2 knockdown 
(Figure 5.7b).  
 
 
Figure 5.8: Jun and Ascl2 are differentially expressed and show differential sites of gained 
accessibility under Cdx2 knockdown and differentiation by growth factor withdrawal conditions. a,c) 
qRT-PCR analysis of Jun (a) and Ascl2 (c). Graphs displayed as fold change (gene expression normalised 
to Gapdh) over UT samples. Significance determined by one-way ANOVA: * p0.032, ** p0.0021. Error 
bars show SEM. n=4 biological replicates. b,d) IGV track displaying KD, SCR, ‘TS RL’ and ‘-GF RL’ ATAC-
seq data (purple), TFAP2C ChIP-seq generated in TSCs and DD1 (dark green), and CDX2 ChIP-seq (light 
green) generated in TSCs around the Jun (b) and Ascl2 (d) loci. 
 
Multiple AP-1 transcription factor family motifs are enriched in GA only sites, 
including AP-1, JunB, Fra1, Fra2 and Jun-AP1 (Figure 5.5). qRT-PCR confirmed that 
AP-1 transcription factor family members Junb and Fosb are uniquely upregulated in 
Cdx2 knockdown (Figure 5.7b). In contrast, Jun, is significantly more upregulated 
after growth factor withdrawal than Cdx2 knockdown (Figure 5.8a). Despite this, the 
only changes in accessibility around the Jun locus are GA sites (Figure 5.8b). The 




HAND2 motif is also specifically enriched in the GA only peakset, but Hand1 is 
upregulated in both KD and -GF conditions (Figure 5.7b).  
 
In contrast, d2DAR only peaks are uniquely enriched for a variety of motifs including 
CEBP, PPAR and ASCL1 (Figure 5.5). Ppard shows an upregulated trend in KD 
and -GF conditions over SCR. In contrast, Cebpa is upregulated after growth factor 
withdrawal but is downregulated after Cdx2 knockdown (Figure 5.7b). Ascl2 
expression is low in TSCs and remains low in Cdx2 knockdown, but is significantly 
upregulated in -GF conditions by more than 200-fold over UT, SCR and KD (Figure 
5.8c). There are two d2DARs around the Ascl2 locus, one upstream and one 
downstream of the gene, but no differentially accessible regions in Cdx2 knockdown 
cells (Figure 5.7d). This may reflect the observed unchanging expression of Ascl2.  
 
In all, this suggests that genes whose family motifs are differentially enriched 
between GA only and d2DAR only peaksets are also differentially expressed 
between Cdx2 knockdown and differentiation by growth factor withdrawal conditions.  
  




5.4 Long-term Cdx2 knockdown avoids progression through 
a progenitor fate 
Previous work has shown that cells can differentiate into TGCs in vivo without 
progressing through a Tpbpa-positive outer ectoplacental cone (EPC) progenitor fate 
(Simmons et al., 2007). Ascl2, a gene that marks the entire EPC, is not upregulated 
at either 48-hours (Figure 5.8d) nor six days (Figure 5.2) after Cdx2 knockdown, 
suggesting that these cells may not progress through a progenitor fate as they 
differentiate. Hand1 and Ascl2 expression overlaps in the ectoplacental cone where 
they antagonise one another (Scott et al., 2000). Ascl2 is essential for maintaining 
the progenitor fate and, when overexpressed, can prevent differentiation into TGCs. 
In contrast, Hand1 overexpression can drive TSCs to differentiate into TGCs, 
although this is less efficient than by Cdx2 knockdown (Scott et al., 2000). Unlike 
Ascl2, Hand1 is upregulated at both the transcript (Figure 5.7b) and protein (Figure 
5.9a) level after short-term Cdx2 knockdown, providing an early indication that Cdx2 
knockdown drives TGC formation. 
 
To determine when morphological difference can first be observed between KD and 
SCR, live cell imaging was performed immediately after 32-hour puromycin selection. 
Figure 5.9b shows the same example SCR and KD colonies every 5 hours over a 
40-hour time period. In SCR conditions, cells show highly dynamic movement, 
undergo clear cell divisions and form colonies with characteristic TSC morphology 
(Figure 5.9b). Whether KD cells undergo cell division after selection is unclear, but 
they show morphological differences to SCR cells within 5-10 hours of puromycin 
removal (Figure 5.9b). Giant cell characteristics and endoreduplication are present 
within 25 hours (Figure 5.9b). In all, this suggests that KD cells, unlike SCR cells, 
have minimal proliferative capacity and are committed to differentiate into TGCs 
within 24-hours after they are selected by puromycin treatment. 














































































































































































































































































































































































































5.5 Validation of potential enhancer regions around the 
Hand1 locus 
The upregulation of Hand1 after short-term Cdx2 knockdown is a key indicator that 
long-term Cdx2 knockdown drives homogeneous TGC differentiation. There are 
multiple sites of increased accessibility after short-term Cdx2 knockdown upstream 
of the Hand1 locus that are unaffected by growth factor withdrawal. These genomic 
loci may, therefore, represent enhancers that are unique to Cdx2 knockdown. 
Despite these differences in sites of gained accessibility around its locus, Hand1 is 
also upregulated at the transcript level after growth factor withdrawal (Figure 5.7b). 
As such, the Hand1 locus represents a model system for determining whether 
differentially accessible chromatin regions between short-term Cdx2 knockdown and 
growth factor withdrawal differentiation conditions are functional.  
 
Whether two loci are likely to interact with one another can be predicted based on 
how the genome is structured in 3D. Chromosomes themselves occupy distinct and 
pre-defined nuclear territories (Cremer and Cremer, 2010). Within these territories, 
the genome is organised into domains known as topologically associated domains 
(TADs) (Nora et al., 2012, Szabo et al., 2019). As chromatin inside TADs interact 
more frequently than chromatin in different TADs, gene loci and their 
enhancer/repressor elements are usually contained in the same TAD domain. Our 
understanding of the 3D chromatin landscape comes from technological 
advancements to assay chromatin organisation (reviewed in Sati and Cavalli, 2017).  
 
While circular chromosomal conformation capture (4C) examines how frequently all 
genomic loci interact with a specific region of interest, Hi-C examines how frequently 
genomic loci interact with all other genomic loci (Zhao et al., 2006, Belton et al., 
2012). Figure 5.10 is a ‘virtual 4C plot’, generated using the 3D Genome Browser, to 
displays how frequently genomic regions in this window interact with the Hand1 locus 
in mESCs (Figure 5.10) (Wang et al., 2018, Bonev et al., 2017). Hand1, on the 
reverse strand, frequently interacts with genomic regions approximately 100kb 
upstream and 50kb downstream (Figure 5.10). Six sites of increased accessibility in 
Cdx2 knockdown are found in the highly interactive upstream region.  
 





Figure 5.10: Visualising Hand1 interactions with surrounding chromatin. A virtual 4C plot generated 
by the tool ‘3D Genome Browser’. This tool enables the most frequent interactions between any locus and 
the surrounding genome to be visualised from a choice of published Hi-C datasets. This plot displays 
Hand1’s interaction with chromatin 200kb upstream and downstream in mESCs. The higher the Hi-C Read 
Value, the more frequently two genomic loci interact.   
 
To determine whether these GA sites are enhancer regions for Hand1, I performed 
enhancer validation assays. These were to be tested on the Hand1 promoter itself. 
As such, I tested the baseline activity and responsiveness of three Hand1 ‘promoters’ 
of different lengths, containing different promoter elements (Figure 5.11a). The 
smallest ‘promoter’, 209bp in length (P1), contains a TATA box but not the Hand1 
TSS, whereas the 283bp ‘promoter’ (P2), contains both. A larger 673bp ‘promoter’ 
region (P3) contained a CAAT box and a second TATA box (Figure 5.11a). The 
activity of each vector was tested in TSCs as these contain all the transcription 
factors and co-factors that are required to drive the Hand1 promoter in TSCs.  
 
Each of these promoter constructs (containing Firefly luciferase) was co-transfected 
with the pRL Renilla Luciferase vector to control for transfection efficiency between 
biological replicates and produce a normalised luciferase readout. Several pGL3 to 
pRL ratios and acquisition times were tested to determine which were the most 




appropriate (Figure 5.11b). All promoter constructs responded similarly, regardless 
of the condition tested (Figure 5.11b). Therefore, it was decided that 120 ng of pRL 
Renilla Luciferase and a one second acquisition time were to be used for subsequent 
experiments as this resulted in the highest Firefly:Renila ratios.  
 
 
Figure 5.11: Comparison of different Hand1 promoters for enhancer validation assays. a) Schematic 
representing the different promoter constructs tested for their activity in the dual luciferase assay. b) The 
baseline activity (promoter only) and responsiveness to the SV40 enhancer was tested for each promoter 
(P1-3). Different ratios of renilla (pRL) and promoter vectors (firefly) were assayed: either 1:19 (60ng renilla 
to 1140ng firefly) or 1:9 (120ng renilla to 1080ng firefly). Different acquisition times were also tested: either 
five seconds or one second.   
 
Whilst the 209bp promoter (P1) responds to the SV40 enhancer, its baseline activity 
is poor (Figure 5.11b). In contrast, the baseline activity of the 283bp promoter (P2) 
is similar to the SV40 promoter (pGL3-promoter vector) and increases three- to five-
fold when activated by the SV40 enhancer (Figure 5.11b). P3, the largest Hand1 
promoter region tested (673bp), is slightly more active than P2 but is similarly 
responsive to the SV40 enhancer (Figure 5.11b). As the luciferase activity of P2 was 
most similar in activity to the pGL3-promoter vector, prospective enhancer constructs 
were cloned onto this vector. 
 


























































































































































































































































































































































































































































































































































































































































































































































Regions that were tested in this enhancer validation assay are outlined in Figure 
5.12. Regions A-F all show increased accessibility after short-term Cdx2 knockdown. 
Only one of these regions, F, also showed increased in accessibility two days after 
growth factor withdrawal (Nelson et al., 2017). Two control regions, C1 and C2, were 
also included in analyses. C1 is inaccessible in TSCs, whereas C2 is bound by 
TFAP2C and shows minimal difference in accessibility between conditions (Figure 
5.12). Whilst regions C-F contain the AP-2 and/or AP-2 consensus motif, neither 
A nor B contain either. Despite this, TFAP2C binds to regions A-F in both TSCs and 
one day post-growth factor withdrawal (dark green, TFAP2C ChIP-seq, Figure 5.12). 
 
The most biologically relevant condition to test these enhancers would be after short-
term Cdx2 knockdown in TSCs, but it is unfeasible to co-transfect five vectors. 
Instead, validation was performed in the presence (+GF) or absence (-GF) of growth 
factors to see how enhancer constructs to respond to different levels of transcription 
factors. Routinely, cells are cultured overnight (16 hours) before they are transfected. 
If TSCs were cultured overnight without growth factors, there was high cell death 
after transfection (data not shown). To reduce cell death, growth factor withdrawal 
and transfection were performed at the same time. Although cell death was greater 
in the -GF conditions than +GF conditions, transfection efficiency was higher in -GF 
than in +GF (Figure 5.13a). Cells were collected 24-hours after transfection.  
 
Although regions A, C and F have no effect, regions B, D and E significantly 
upregulate Hand1 promoter activity in the presence and absence of growth factors 
(Figure 5.13b-c). Region D is the most active Hand1 enhancer, but can only increase 
Hand1 promoter activity 2.3-fold in the presence of growth factors; significantly less 
than the 5-fold increase in Hand1 promoter activity driven by the SV40 enhancer 
(Figure 5.13b-c). Therefore, regions B, D and E are not strong enhancers for the 
Hand1 promoter alone, but may behave synergistically with other Hand1 enhancers. 
Surprisingly, both control regions significantly repress the Hand1 promoter (Figure 
5.13b-c). Although this effect from the inaccessible C1 region is difficult to explain, 
C2 was chosen because it is accessible in TSCs and is bound by TFAP2C (Figure 
5.12). TFAP2C binding at C2 appears to decrease after growth factor withdrawal 
(dark green, DD1 TFAP2C ChIP-seq, Figure 5.12) and may therefore increase 
Hand1 expression after growth factor withdrawal indirectly.  










































































































































































































































































































































































































































































































































































































Next, I determined whether the activity of these confirmed enhancers or repressors 
changed under different growth factor conditions. Both regions D and E were 
significantly less active under growth factor withdrawal conditions (Figure 5.14a). As 
the activity of other enhancer-promoter constructs did not change, this decrease in 
activity is unique to these two enhancers. Unlike region B, both D and E contain the 
consensus AP-2 motif (Figure 5.12).  
 
To understand why these enhancers are less efficient after growth factor withdrawal, 
qRT-PCR was performed on samples collected concurrently with the dual luciferase 
experiments (Figure 5.14b). Tfap2c expression did not change 24 hours after growth 
factor withdrawal (Figure 5.14b). Therefore, the decline in regions D and E enhancer 
activity in the absence of growth factors cannot be explained by a change in TFAP2C 
expression directly. Cdx2 expression was significantly reduced after growth factor 
withdrawal and Ascl2 expression was significantly upregulated. Whilst both Hand1 
and Gata3 expression increased when growth factors were removed from cultures, 
this was not statistically significant. In all, this suggests that undetermined factors 
other than TFAP2C help drive the activity of these enhancers and that these are 
differentially expressed in the presence or absence of growth factors. 











































































































































































































































































































































































































































































































































































































































































































Sustained Cdx2 knockdown drives TSCs to homogeneously differentiate into parietal 
trophoblast giant cells (p-TGCs). Hand1, a pan-TGC marker gene, is upregulated in 
response to short-term Cdx2 knockdown. Ectopic expression of Hand1, even in the 
presence of TSC maintenance factors, can drive TGCs differentiation, but less 
efficiently than that observed in Cdx2 knockdown (Scott et al., 2000, Hughes et al., 
2004). Whilst validating my data, I attempted to replicate the findings of Scott et al 
(2000) and Hughes et al (2004) by overexpressing Hand1 in the INX cell line. 
Although I could transiently upregulate Hand1, I could neither maintain its expression 
nor generate a phenotype (data not shown). It is therefore unlikely that sustained 
overexpression of HAND1 alone is sufficient to drive the homogeneous differentiation 
observed in Cdx2 knockdown, at least in the INX cell line. 
 
Instead, the observed homogeneous differentiation is likely driven by upregulation of 
both Hand1 and Tfap2c. Tfap2c, upregulated during differentiation by growth factor 
withdrawal in vitro, drives a global increase in accessibility (Latos et al., 2015b, 
Nelson et al., 2017). However, these sites of gained accessibility in growth factor 
withdrawal are distinct from those in Cdx2 knockdown conditions despite both being 
attributed to TFAP2C. Further work is required to confirm that TFAP2C binding at 
these unique sites differs between these conditions. I performed ChIP-qPCR 
experiments to address this, but they were unsuccessful because of difficulties in 
obtaining sufficient numbers of cells by cell sorting (data not shown).  
 
Other than AP-2γ and AP-2α motifs, there was no overlap in the motifs enriched at 
unique sites of gained accessibility in Cdx2 knockdown and growth factor withdrawal 
induced differentiation. This indicates that differential TFAP2C binding between 
Cdx2 knockdown and growth factor withdrawal conditions might be driven by the use 
of different co-factors. Indeed, SOX and AP-1 family members motifs were enriched 
in peaks unique to Cdx2 knockdown. Sox15 and various AP-1 family members have 
previously been implicated in driving trophoblast differentiation, especially towards 
the TGC lineage (Yamada et al., 2006, Shaulian and Karin, 2002, Renaud et al., 
2014, Kubota et al., 2015, Lee et al., 2018). In contrast, PPAR and ASCL1 motifs are 
only enriched in sites of gained accessibility unique to growth factor withdrawal. 




Associated genes Ascl2, Pparb and Ppard are known to be expressed in those 
progenitor cells derived from the stem cell niched in vivo: the ectoplacental cone and 
spongiotrophoblast (Scott et al., 2000, Nadra et al., 2006, Wang et al., 2007). 
 
Surprisingly, there was a large overlap in the genes perturbed by Cdx2 knockdown 
and differentiation by growth factor withdrawal, but the direction in which these genes 
changed was not always maintained. This disparity in direction of differential gene 
expression was confirmed for several genes whose motifs were also differentially 
enriched at TFAP2C binding sites between these two conditions. This re-affirms that 
differential binding of TFAP2C between Cdx2 knockdown and growth factor 
withdrawal are likely influenced by transcriptional differences.  
 
One potential fundamental difference between these TFAP2C-inducing conditions is 
the unique and rapid upregulation of Ascl2, a marker of the progenitor cell-containing 
ectoplacental cone, after growth factor withdrawal (Cross et al., 1995, Guillemot et 
al., 1994). The ASCL1 motif is uniquely enriched in sites of increased chromatin 
accessibility in growth factor withdrawal differentiation. Ascl2 antagonises Hand1 
expression, maintaining proliferative trophoblast cells and inhibiting giant cell 
formation (Scott et al., 2000). As such, the lack of Ascl2 expression may explain why 
Cdx2 knockdown cells commit to the TGC fate so rapidly and homogeneously. 
Indeed, qRT-PCR and live cell imaging experiments suggests that these cells do not 
progress through a progenitor fate. Previous work shows that Ascl2 is significantly 
upregulated within 6-12 hours of growth factor withdrawal, indicating that it is a direct 
target of the growth factors that maintain TSCs (Donnison et al., 2015). As a result, 
Ascl2 upregulation may not occur under Cdx2 knockdown because these growth 
factors are present.  
 
Beyond this, the importance of these signalling pathways and the genes under their 
control was confirmed by the differential activity of two Cdx2 knockdown-associated 
Hand1 enhancers in the presence and absence of exogenously supplied growth 
factors. Both enhancers contain the AP-2γ and AP-2α consensus motifs and 
TFAP2C binds to these loci under both TSC maintenance conditions and after one 
day of differentiation by growth factor withdrawal (Latos et al., 2015b). However, 
further work is required to confirm the importance of TFAP2C binding to these 




enhancer regions. One approach to this would be to mutate the AP-2 consensus 
binding motifs and then re-examine the efficiency of these enhancers in dual 
luciferase assays. Indeed, Tfap2c expression was the same whether growth factors 
were exogenously supplied or not, but activity of both enhancers decreased 
significantly when growth factors were removed. Given this, the underlying cause of 
this change in responsiveness is likely related to the differences in transcriptional 
profiles based on the presence and absence of growth factors. The transcription 
factors that underlie this difference are currently unknown.  
 
In all, this chapter confirms that there are differences in the sites that increase in 
accessibility between Cdx2 knockdown and growth factor withdrawal-induced 
differentiation that are likely critical for their different long-term outcomes. Although 
the number of sites tested in enhancer validations were small, they confirm that some 
sites of increased accessibility after Cdx2 knockdown are functional and responsive 
to transcriptional changes.  
 




Chapter 6. Validating the long-term Cdx2 knockdown 
phenotype by CRISPR-Cas9 genome editing 
I have shown that both the trophoblast stem cell transcriptome and the chromatin 
landscape are affected by short-term Cdx2 knockdown. Without selection, Cdx2 
expression reverts to wild-type levels and TSCs are morphologically normal. Yet, if 
Cdx2 knockdown is sustained for an extra 32 hours by puromycin selection, INX 
TSCs are driven homogeneously to differentiate into parietal TGCs (p-TGCs). Thus, 
although the changes driven by short-term Cdx2 knockdown are insufficient to 
commit TSCs to the TGC fate, extension beyond this time, albeit brief, leads to their 
irreversible commitment to this fate.  
 
Whether these Cdx2 knockdown cells progress through a progenitor fate as they 
differentiate into p-TGCs is unclear. All mural trophectoderm and some 
extraembryonic ectoderm differentiate into p-TGCs without progressing through a 
progenitor fate (Dickson, 1966, Simmons et al., 2007). Ascl2, a key marker of the 
ectoplacental cone progenitor fate, is not required for primary p-TGC formation 
(Rossant et al., 1998). Similarly, Ascl2 is not expressed after 48-hour nor 144-hour 
Cdx2 knockdown. Other key trophoblast genes are also affected differently after 
transient Cdx2 knockdown; whilst Elf5, Esrrb and Eomes are unaffected by transient 
Cdx2 knockdown, their expression is negligible a mere four days later.  
 
The critical events that commit Cdx2 knockdown TSC to differentiate into TGCs 
occur during or immediately after puromycin selection. Limited material is available 
during this time period and selection itself is a source of exogenous stress (Moran et 
al., 2009). Furthermore, both the XYO and Rossant-GFP cell lines characterised in 
Chapter 3.1 are puromycin resistant, preventing the validation of the Cdx2 
knockdown phenotype in other TSC lines. Therefore, although informative, this 
knockdown approach is not appropriate for studying these intermediate stages of 
TGC commitment.  
 
To address this, I decided to knock out Cdx2 function in both the INX and Rossant-
GFP lines. Recent advancements in CRISPR-Cas9 genome editing approaches 




allow specific genomic loci to be targeted using guide RNAs (gRNAs) and a human 
coding optimised version of Cas9 (reviewed in (Doudna and Charpentier, 2014)).  In 
cell culture systems, targeted cells can be maintained as polyclonal or clonal 
populations if mutations are not lethal. However, the phenotype of gene knockout 
and knockdown studies are not necessarily the same (De Souza et al., 2006, Daude 
et al., 2012). Such differences may arise from genetic compensation in knockout 
approaches (Rossi et al., 2015, El-Brolosy et al., 2019) or off-target side effects in 
knockdown approached, including the upregulation of the innate immune response 
(Gentsch et al., 2018).  
 
In this chapter, I use CRISPR-Cas9 genome editing to generate polyclonal and clonal 
Cdx2 mutant TSCs. Using these Cdx2 mutant TSCs, I validated the importance of 
Cdx2 in maintaining the TSC fate by preventing spontaneous TGC formation. 
Subsequent analysis of clonal Cdx2 mutant cells provided further understanding of 
the TSC gene regulatory network.  
  




6.1 CRISPR design and efficacy optimisation 
Long-term Cdx2 knockdown drives TSCs to terminally differentiate into p-TGCs 
(Chapter 5.1) and Cdx2-null TSCs cannot be maintained in culture (Niwa et al., 
2005). This indicates that it should not be possible to use conventional CRISPR-
Cas9 editing approaches to generate clonal populations. Instead, polyclonal Cdx2-
null TSCs were generated and maintained only in the short term. To achieve this, 
mutations had to abolish CDX2 function (through frameshifts or large deletions) and 
efficacy had to be high. By using wild-type Cas9 and no repair template, I aimed to 
increase the indel rate by favouring non-homologous end-joining (NHEJ) (Yang et 
al., 2013). Multiple guide RNAs (gRNAs) were designed to target the Cdx2 
homeobox domain and boost disruption of CDX2 function in mutants (Figure 6.1a) 
(Ran et al., 2013).   
 
 
Figure 6.1: Mutation efficiency of single gRNAs targeting the Cdx2 homeobox is insufficient. a) 
Schematic outlining the position of each gRNA designed to target the Cdx2 homeobox domain in exon 2. b) 
Bar chart showing the mutagenic efficiency of each single gRNAs. Transfected cells were isolated by FACS, 
the target region amplified from bulk gDNA and sequenced using MiSeq. Using this data, it is possible to 
determine any allele variants generated by CRISPR targeting and their frequency within the population. 
Alleles were classified as the following genotypes: wild-type or substitution (WT/SUB), frameshift, indels that 
were multiples of three (MO3) that were less than 15bp in length and MO3 indels that were larger than 15bp.  




Most of the Cdx2 homeobox domain is located in exon 2 (Figure 6.1a). Six gRNAs 
(G2a-f) targeting this region were identified using the MIT CRISPR Designer and 
were predicted to have low off-target effects (Figure 6.1a) (Cong et al., 2013). Each 
guide was cloned into a plasmid (px330) containing a human-coding optimised 
spCas9, a trans-activating crRNA element and an mCherry cassette. To determine 
their efficiency, TSCs were transfected with a gRNA-containing plasmid or with an 
empty plasmid as a control. I aimed to mutate >75% of alleles in each polyclonal 
population as this would imply that over 50% of cells were homozygous for a mutation 
within a diploid population.  
 
Transfected cells were isolated based on their mCherry expression 24-hours post-
transfection using FACS as previously described (Chapter 4.1, Figure 4.1) and they 
were genotyped by MiSeq sequencing. Cas-Analyzer was used both to classify the 
different allele variants based on the type of mutation and to determine their 
frequencies (Park et al., 2017). This tool categorises point mutations as ‘substitute’ 
and groups them with wild-type alleles (WT/SUB). As the effect of a point mutation 
would be difficult to predict, it was decided that only deletion and insertions would be 
considered as mutations during analyses. As expected, INX controls samples 
contained 99.9% WT alleles (data not shown). No gRNA induced mutations in >75% 
of alleles as desired, but G2a, G2c, G2d and G2f were the most mutagenic (Figure 
6.1b). 
 
To increase the mutation efficiency, cells were co-transfected with two gRNA vector 
combinations; G2a + G2c (A+C) and G2a + G2c (A+D) (Figure 6.2a). Both 
combinations reproducibly increased mutagenic efficiency, although the A+D 
combination was less efficient in Rossant-GFP TSCs (27.5% WT/SUB) than INX 
TSCs (15% WT/SUB) (Figure 6.2a-b). These gRNA combinations also reproducibly 
induced the same type of mutations, generating two common mutations that 
accounted for 44.2-59.1% of total A+C alleles (Figure 6.2c) and 57.2-71.1% of total 
A+D alleles (Figure 6.2d) across cell lines and biological replicates. Therefore, both 
gRNA combinations were sufficiently mutagenic to proceed with validating the effect 
of Cdx2 mutations on polyclonal populations. 
 





Figure 6.2: A+C and A+D gRNA combinations generate reproducible mutations and are sufficiently 
mutagenic. a-d) TSCs were transfected with gRNA pairs G2a and G2c (A+C) and G2a and G2d (A+D). 
Positively transfected cells were isolated by FACS 24-hours post-transfection and genotyped by MiSeq. 
Each bar represents one biological replicate. a-b) Bar charts displaying allele variants generated by A+C (a) 
and A+D (b) classified into the following genotypes: wild-type or substitute (WT/SUB), frameshift, indels that 
were multiples of three (MO3) less than 15bp in length and MO3 indels that were larger than 15bp. c-d) Bar 
charts to represent proportion of reads attributed to the three most common alleles in A+C (c) and A+D (d) 
polyclonal populations. e-f) Fold change in geometric mean expression of CDX2 (e), TFAP2C (f) and HAND1 
(g) expression in A+C and A+D over px330. Analysis performed by flow cytometry (n=3 biological replicates 
per cell line). Error bars display SD. Statistical significance was determined by two-way ANOVA tests: * 
p0.0332, ** p0.0021, *** p0.0002. h-i) Robust coefficient of variation (CV) of CDX2 (h), TFAP2C (i) and 
HAND1 (j) expression in A+C, A+D and px330 determined by FlowJo. n=3 biological replicates per cell line. 
Error bars display SD. Two-way ANOVA test: * p0.0332. 
 
  




Next, I aimed to determine how efficiently Cdx2 mutations reduce CDX2 expression 
48-hours post-transfection (Figure 6.2e). CDX2 expression was reduced by 
approximately 49% in all INX mutant experiments (Figure 6.2e); a level similar to that 
observed in knockdown experiments (55%, Chapter 4.1, Figure 4.1c). In line with the 
increased presence of WT/SUB alleles in these samples, CDX2 expression was less 
reduced in Rossant-GFP TSCs than INX TSCs for both the A+C (36.4%) and A+D 
(43%) combinations (Figure 6.2e). How efficiently Cdx2 mutant populations reduced 
CDX2 expression changed between biological replicates for both Rossant-GFP and 
INX TSCs, perhaps because some cells in these populations retain WT alleles. To 
assess variability in the expression of CDX2 in cells of the same sample, I measured 
the coefficient of variation (CV): the dispersion of the data around the mean (Figure 
6.2h). Although the variation was similar between different INX conditions, Rossant-
GFP A+C and A+D samples were generally more variable than px330 control 
samples. In all, this suggests that the reduction in CDX2 expression in Cdx2 mutant 
polyclonal cells can be heterogeneous and is probably related to the efficiency of 
inducing Cdx2 mutations.  
 
In Chapters 4 and 5, I showed that HAND1 and TFAP2C upregulation are key drivers 
of aberrant TSCs differentiation in long-term Cdx2 knockdown. Whilst Cdx2 mutant 
polyclonal lines showed a trend in upregulating TFAP2C and HAND1 expression 48-
hours post-transfection, this was not statistically significant in most experiments 
(Figure 6.2f-g). The observed variability in both HAND1 and TFAP2C expression 
may be related to the differences in Cdx2 mutation efficiency between biological 
replicates. Therefore, I measured the robust CV of both proteins (Figure 6.2f-g). 
HAND1 expression is particularly variable between cells in Cdx2 mutant conditions, 
suggesting that some cells do upregulated its expression, whilst others do not. 
Overall, HAND1 and TFAP2C expression are upregulated when Cdx2 is mutated, 
but their expression is variable between cells in polyclonal population.  
  




6.2 Mutated alleles are outcompeted by wild-type alleles in 
bulk Cdx2 mutant populations  
To assess the long-term effect of Cdx2 mutations on TSCs, transfected A+C, A+D 
and px330 cells were isolated using FACS 24-hours after transfection to generate 
polyclonal cell lines. By 144-hours, there was a small increase in the number of TGCs 
in A+C and A+D cultures (data not shown), but this did not recapitulate the 
homogeneous phenotype observed after long-term Cdx2 knockdown (Chapter 5.1). 
At 24-hours post-transfection, up to 25% of alleles in these polyclonal populations 
were WT/SUB alleles (Figure 6.2a-b). To determine whether this lack of long-term 
phenotype reflected a selective advantage for cells containing wild-type alleles, the 
frequency of mutations in polyclonal populations was determined at 96-hours and 
144-hours post-transfection (Figure 6.3a-b).  
 
In A+C polyclonal populations, the proportion of WT/SUB alleles increased between 
each successive time point in both INX and Rossant-GFP polyclonal populations 
(Figure 6.3a). In contrast, the proportion of WT/SUB alleles did not change between 
24-hours and 96-hours after transfection in A+D Rossant-GFP (27.6% versus 27.6%) 
and A+D INX (15.6% versus 18.1%) polyclonal populations (Figure 6.3b). However, 
by 144-hours after transfection, 47.7% and 44.2% of total alleles in A+D Rossant-
GFP and INX polyclonal cell lines were WT/SUB, respectively (Figure 6.3b). 
 
To discover whether specific mutations were being outcompeted in the polyclonal 
populations, I assessed the percentage of reads attributed to the three most common 
alleles over time (Figure 6.3c-d). In A+C polyclonal cultures, the 42bp and 41bp 
deletion alleles were lost in similar proportions to the ‘rest’ of the edited alleles in 
both cell lines over time (Figure 6.3c). In the A+D polyclonal lines, there was a 32.7% 
and 38.8% reduction in the proportion of the most dominant allele, the 31bp deletion, 
between 24-hours and 144-hours post-transfection for Rossant-GFP and INX TSCs, 
respectively (Figure 6.3d). Perhaps because of their lower overall contribution, 
changes to the proportion of the 32bp deletion and ‘rest’ alleles in A+D populations 
were smaller and less consistent (Figure 6.3d). In all, it appears that Cdx2 mutant 
alleles are outcompeted from polyclonal populations by WT alleles at similar rates.  
 





Figure 6.3: Wild-type alleles outcompete mutant alleles in Cdx2-targeted polyclonal populations. a-
d) Positively transfected TSCs with gRNA pairs A+C or A+D were isolated by FACS 24-hours post-
transfection. Cells were either used for genotyping by MiSeq immediately (24 hours) or replated in bulk and 
collected for genotyping at 96-hour or 144-hours post-transfection. n=2 biological replicates for 24-hour 
genotypes; n=1 biological replicate for 96-hour and 144-hour genotypes. a-b) Bar charts displaying allele 
variants frequencies A+C (a) and A+D (b) polyclonal populations classified into the following genotypes: 
wild-type or substitute (WT/SUB), frameshift, indels less than 15bp in length that were multiples of 3 (MO3) 
and MO3 indels that were larger than 15bp. c-d) Bar charts represent proportion of reads attributed to the 
three most common alleles found within A+C (c) and A+D (d) populations. e) Fold change in geometric mean 
expression of CDX2 in Cdx2 mutant A+C and A+D polyclonal populations (n=1 biological replicate per cell 
line) over the relevant cell line px330. Analysis was performed by flow cytometry. Error bars display SD. f) 
Robust CV of CDX2 expression in Cdx2 mutant A+C and A+D and px330 polyclonal populations determined 
by FlowJo. (n=1 biological replicate A+C, A+D and px330 per cell line.) Error bars display SD. Significance 
determined by one-way ANOVA: * p0.0332.  
 
Given the increase in WT alleles in all polyclonal edited populations over time, I next 
examined the expression of CDX2 in these cells at 144-hours post-transfection. 
Although CDX2 expression remained up to 32% lower in mutant clones than in px330 
controls (Figure 6.3e), this still represented an overall increase in CDX2 expression 
compared to its expression 48-hours post-transfection, where it was 36-55% lower 
than px330 controls (Figure 6.2e). Further, there was significant variation in CDX2 
expression between cells in Cdx2 targeted populations at 144-hours (Figure 6.3f). In 
all, this confirms that there is a significant increase in the number of cells in polyclonal 
populations expressing higher levels of CDX2 by 144-hours post-transfection.  




6.3 Clonal Cdx2 mutant TSCs can be maintained for several 
passages but are inherently unstable 
Cdx2-mutant alleles are outcompeted by WT alleles in polyclonal populations. To 
determine the effect of Cdx2 mutations on TSCs, clonal analysis was performed.  
6.3.1 Generation, characterisation and genotyping of single-cell CRISPR 
clones 
To generate clonal lines, INX and Rossant-GFP TSCs were transfected with either 
the optimised gRNA combinations (A+C, A+D) or an empty vector control (px330). 
Positively transfected cells were single-cell sorted into 96 well plates 24-hours after 
transfection. Clones were categorised based on their appearance seven days after 




Figure 6.4: Cdx2-targeted TSCs can form clonal trophoblast outgrowths. a) Representative brightfield 
images taken of clonal outgrowths classified as ‘Colony’, ‘Colony differentiating’ and ‘Trophoblast giant cell 
(TGC)’ 7 days post-single cell sort. Colonies that showed morphological characteristics of TSCs with low 
levels of visible differentiation were categorised as ‘colony’. Colonies that showed substantial differentiation, 
including large colonies of TGCs, were categorised as ‘colony differentiating’ so as to allow for the possibility 
of surviving stem cells. When wells only contained a few TGCs, they were categorised as ‘TGCs’. b) Bar 
chart to display the total number of outgrowths and how they were classified as described in (a). c) To enable 
classification of colonies to be compared between conditions and cell lines, the number of clones in each 
category is displayed as a proportion of the total for each cell line and condition.  
  




In total, I picked between 14 and 83 clones per condition and cell line across two 
experiments (Figure 6.4b). Increased exogenous stress, such as transfection and/or 
cell sorting, can result in spontaneous TSC differentiation. Thus, it was unsurprising 
to see ‘differentiating colony’ or ‘TGCs’ clones in control px330 clonal experiments 
(~30%). Despite this, the proportion of clones categorised as ‘TGC’ or ‘colony 
differentiating’ was higher in all Cdx2-targeting conditions (55.4-65.9%) relative to 
the px330 control regardless of the cell line used (Figure 6.4c). 
 
Attempts to expand clones over multiple passages to generate clonal cell lines were 
not successful for all clones (Figure 6.5a-d). Only one TGC clone (striped yellow 
bars, Figure 6.5a-d) and a large proportion of ‘colony differentiating’ clones (50-94%, 
yellow bars, Figure 6.5a-d) survived to passage three. This initial segregation of 
clones into ‘TGC’ or ‘colony differentiating’ categories was, therefore, predictive of 
their reduced survival rate. In contrast, the majority of wild-type colony clones 
survived to passage three (72-90.9%, Figure 6.5a-d).  
 
It was noted that some wild-type clones changed in morphology over several 
passages, indicating that they were differentiating. These clones may be edited 
clones whose phenotype is less pronounced in early passages. Therefore, the clones 
were re-classified based on their appearance at passage three (Figure 6.5e). This 
analysis revealed that a large number (72-86.7%) of clones derived from gRNA 
edited populations show some level of differentiation by passage three (Figure 6.5e).  
 
  





Figure 6.5: 'Colony' and some 'colony differentiating' Cdx2-targeted clonal populations can be 
expanded over multiple passages. a-d) Attempts were made to passage all clonal outgrowths, but many 
clones were lost over successive passages. To assess which classification of clones were most frequently 
lost, the number of clones that contained any cells at passage two (P2) and passage three (P3) were 
determined. These bar charts display the total number of clones that remained in culture for each of the 
original categories from passage 1 (P1) to P3. e) The majority of clones classified as ‘colony’ at P1 were 
successfully passaged to P3, but their appearance changed. This bar chart displays the fate of all clones 
categorised as ‘colony’ at P1 and their re-classification at P3.  
 
I next focused on genotyping these characterised clones. Sanger sequencing 
revealed that many of these clones contained compound mutations and some were 
either polyploid or polyclonal because they possessed three alleles. Whilst TSC lines 
are diploid in early passages, most TSC lines tested display some form of aneuploidy 
after passage 40 regardless of the culture conditions (Kubaczka et al., 2014). All 
experiments in this thesis used INX TSCs at passage 55 and above and the passage 
number of the Rossant-GFP TSC line was unknown. Whole exome sequencing 
(WES) for these TSCs lines confirmed that they both are aneuploid (data not shown, 
personal correspondence with Daniel Snell).  
 
To precisely characterise the mutations and their ratios in each clone, genotyping 
was performed using a multiplexed MiSeq approach with three primer sets (see 
2.2.10.1 and Figure 6.6a). Clones were grouped into categories according to the type 
of mutation: wild-type, frameshift or large deletions. When a clone contained two 
different alleles in equal proportions, it was classified as compound heterozygous. If 
the difference between the frequencies of two alleles was greater than 10%, or if a 
clone contained more than two alleles, it was classified as >2N.  





Figure 6.6: Genotyping of Cdx2-targeted clones reveals that they can be expanded in the absence of 
wild-type Cdx2 alleles. a) A schematic outlining the multiplex MiSeq approach used to genotype clonal 
lines. gDNA from each clone was PCR amplified using one of the three MiSeq primer sets outlined. PCR 
amplicons from one of each primer set were combined for MiSeq library preparation and sequencing. b-f) 
MiSeq was used to genotype clones. Genotypes are provided using overall categories: wild-type (WT), 
Homozygous (hom), multiple of 3 (MO3), heterozygous (het). Compound hets were clones with two alleles 
in approximate 50:50 proportions. Over 2N (>2N) represents clones where difference between the 
frequencies of two alleles was greater than 10% or where there were more than two alleles detected. Failed 
clones were those whose sequencing was poor or the reads number was insufficient due to low gDNA 
amounts extracted from clones. Genotypes are provided with information as to the phenotypic appearance 
of clones at P3 according to the criteria outlined in Figure 6.4a. 
  




In line with the poorer mutation efficacy observed in Rossant-GFP TSCs compared 
with INX TSCs (Figure 6.3), a higher proportion of Rossant-GFP clones were wild-
type when compared to INX clones (Figure 6.6b-e). Across both cell lines and gRNA 
pairs, 75.4% of clones that were classified as morphologically normal TSCs ‘colonies’ 
at passage three (Figure 6.5e) were genotyped as wild-type and 79% contained least 
one wild-type allele (Figure 6.6f). In contrast, only 10.6% of clones that were 
classified as ‘colony differentiating’ contained wild-type alleles (Figure 6.6f). 
Therefore, the morphological appearance of clones could be used to accurately 
predict between wild-type and edited clones. There was insufficient genomic material 
to genotype 25.5% of the ‘differentiating colony’ clones and all the ‘TGC’ terminally 
differentiated clones (black bars, Figure 6.6b-f). These ‘failed’ clones were lost during 
subsequent passages due to differentiation (data not shown), suggesting that Cdx2 
mutations destabilised the cells and resulted in terminal differentiation.  
6.3.2 Not all clones are born equal: the same mutation does not affect TSCs 
the same way 
Unlike Cdx2 knockdown cells, clones containing only Cdx2 mutant alleles can be 
maintained, although they are prone to differentiate. The rate at which Cdx2 mutant 
clones differentiate and/or are lost from the population is different. One potential 
explanation for these phenotypic differences is that different mutations compromise 
CDX2 function differently. With this in mind, I next asked if specific phenotypes were 
associated with unique genotypes (Table 6.1).  
 





Table 6.1: Most Cdx2-mutant clones that show no visible phenotype at passage three contain an in-
frame mutation. This table summarises all of the unique genotypes found for clones in both A+C and A+D 
gRNA combinations in the INX and Rossant-GFP cell lines. The phenotypic appearance of each clone at 
passage 3 was classified as colony or colony differentiating as described in Figure 6.4a. All genotypes are 
categorised as in-frame or frameshift.  
 
CDX2 contains a highly conserved 60 amino acid homeobox domain (Kissinger et 
al., 1990, Dragan et al., 2006, Burglin and Affolter, 2016). These 60 amino acids 
encode three helices and it is the third and longest helix that interacts with DNA 
(Burglin and Affolter, 2016). Recent work has shown that the human CDX2 protein 
preferentially binds methylated DNA using suitably positioned hydrophobic residues, 
Ile232 and Ala239, within this third helix (Yin et al., 2017).  
 
The two most common alleles in surviving clones were a 42bp deletion and a 31bp 
deletion, generated through editing with A+C or A+D gRNA combinations, 
respectively (Table 6.1). Both deletions are predicted to start 81bp into the homeobox 
domain, at amino acid 27. The 42bp deletion is predicted to cause an in-frame 
mutation that would result in deletion of the subsequent 14 amino acids. This 14 
amino acid region contains all of helix two and the loop region to helix 3 (Kissinger 
et al., 1990, Burglin and Affolter, 2016). It is unlikely, although not impossible, that 
CDX2 could function without such a large and important structural compartment of 
Number Genotype Colony Colony Differentiating Predicted effect
1 103bp del + 78bp del (3:1) 1 Frameshift and in-frame
2 110bp del homozygous 1 Frameshift
3 31bp del + 1bp ins (3:2) 1 Frameshift
4 31bp del homozgous 2 5 Frameshift
5 32bp del + 31bp del (1:3) / (3:1) 3 Frameshift
6 32bp del homozygous 1 Frameshift
7 33bp del homozygous 1 In-frame
8 35bp del + 3bp del (3:2) 1 In-frame
9 38bp del + 35bp del (3:1) 1 Frameshift and in-frame
10 3bp del homozygous 1 In-frame
11 41bp del + 37bp del (1:1) 1 Frameshift
12 41bp del homozygous 1 Frameshift
13 42bp del + 33bp del (1:1) 1 In-frame
14 42bp del + 35bp del (1:1) 1 In-frame
15 42bp del + 37bp del (1:1) 2 Frameshift and in-frame
16 42bp del + 37bp del + 41bp del (1:1:1) 1 Frameshift and in-frame
17 42bp del + 38bp del (1:1) / (3:1) 1 1 Frameshift and in-frame
18 42bp del + 39bp del (1:1) 1 In-frame
19 42bp del + 40bp del (1:1) 1 Frameshift and in-frame
20 42bp del + 41bp del (1:1) / (1:2) / (3:1) 3 Frameshift and in-frame
21 42bp del + 45bp del (1:1) 1 In-frame
22 42bp del homozygous 2 3 In-frame
23 WT + 1bp ins (4:1) 1 WT and frameshift
24 WT + 32bp del + 6bp del (3:3:2) 1 WT and inframe
25 WT + 35bp del (2:1) 1 WT and inframe




this highly conserved domain. The 31bp deletion is predicted to cause a frameshift 
that would result in a premature stop codon in exon 3 and reduce the protein size by 
42 amino acids. This, as with all frame-shift mutations listed in Table 6.1, would alter 
the amino acid sequence of the third helix of the homeodomain and affect the DNA 
binding function of CDX2.  As such, clones with large deletions or with frameshift 
mutations were predicted to have a complete loss of CDX2 function. In addition to 
these mutations, only a few clones had small in-frame deletions of only a few amino 
acids in length (8, 10 and 24, Table 6.1). Whether these are sufficient to disrupt CDX2 
function is unclear.  
 
In all, a diverse range of phenotypes were observed in Cdx2 mutant clones 
irrespective of their genotype (Table 6.1). There was no visible differentiation in both 
clones where over 60% of alleles are wild-type (23 and 24, Table 6.1), suggesting 
that Cdx2 expression over a certain threshold maintains undifferentiated TSCs. 
However, many clones had no wild-type alleles and showed no obvious increased 
differentiation. Interestingly, 71.4% of these morphologically normal Cdx2 mutant 
clones (8, 16, 17 and 22, Table 6.1) contained at least one copy of an in-frame 
mutation, either 42bp, 35bp or 3bp deletion, suggesting that in-frame mutations might 
generate a functional CDX2 protein. Beyond this, despite containing identical 
homozygous mutations, 28.6% of 31bp deletion clones (4, Table 6.1) and 40% of 
42bp deletion clones (22, Table 6.1) showed no obvious increase in differentiation at 
passage three. Therefore, the same mutation in the same cell lines does not 
necessarily induce the same phenotype.  
6.3.3 Spot the difference: linking genotype to phenotype 
The different phenotypes of Cdx2 mutant clones with the same homozygous 
mutations are intriguing. I next validated the genotype of multiple wild-type and edited 
(compound heterozygous (CH), frameshift (FS) and large deletion (LD)) clones by 
sequencing their full-length Cdx2 cDNA (Table 6.2). Several RNA samples had low 
yields of RNA and were excluded from analysis. Sanger sequencing of these cDNAs 
revealed that some clones contained more than one Cdx2 transcript. Where more 
than one transcript was detected, PCR products were TA cloned and re-sequenced.  
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Some INX clones contained alternatively spliced Cdx2 transcripts (Table 6.2). In 
total, 50% (8/16) of all INX mutant clones analysed contained an alternative spliced 
transcript in which exon 2 was skipped. To model the loss of Cdx2 in vivo, mouse 
models have been generated whereby exon 2 is floxed and can be removed by Cre 
recombination. The resulting transcript is the same as observed here (van de Ven et 
al., 2011), indicating that this generates a non-functional CDX2 protein. Other 
alternative splicing Cdx2 variants were also found in clones INX-CH-3, INX-LD-1 and 
INX-LD-2. No alternative splicing was observed for INX clones containing a 31bp or 
a 32bp deletion, suggesting that only mutations larger than these affect splicing.  
 
Interestingly, no mutant Rossant-GFP clones showed any alternative splicing, even 
for deletions larger than 32bp. Overall, Rossant-GFP Cdx2 mutant clone survival 
was poorer than INX clones, with only one validated Rossant-GFP mutant clone 
reaching passage six (Table 6.2). The lack of alternative splicing in Rossant-GFP 
mutant clones may represent a biological difference in the ability of INX and Rossant-
GFP cell lines to compensate for Cdx2 loss. 
 
Previous work has shown that CRISPR-Cas9 genome editing can cause exon 
skipping, probably as a result of mutations in splice-regulatory sequences (Kapahnke 
et al., 2016, Mou et al., 2017). Exonic splicing enhancers (ESE), which represent 
binding sites for highly conserved splicing factors (serine/arginine (SR) proteins), are 
common in exons and are important for regulating alternative splicing (Cartegni et 
al., 2003). At these sites, SR proteins recruit the splicing machinery and/or 
antagonise repressive elements in the vicinity (Cartegni et al., 2002, Graveley, 2000).  
 
Therefore, I next examined the distribution of putative ESE motifs across Cdx2 exon 
2 using the online tool ‘ESE finder 3.0’ (Figure 6.7) (Cartegni et al., 2003, Smith et 
al., 2006). As expected, ESE motifs are common across exon 2, many of which would 
be unaffected in Cdx2 mutant clones. At least one motif for every SR protein 
assessed, except SRSF6, was present in the region known to be affected by the two 
most common mutations generated in Cdx2 mutant clones: the 31bp deletion and 
the 42bp deletion. Furthermore, there are specific motifs that would be uniquely 
affected in mutations larger than the 31bp deletion (Figure 6.7). Therefore, the lack 




of one or more of these putative motifs at the end of exon 2 may be responsible for 
the alternative splicing seen in edited clones with mutations larger than 31bp.  
 
 
Figure 6.7: Positioning of exonic splicing enhancers (ESEs) across Cdx2 exon 2. The positions of 
conserved motifs for SR proteins within exon 2 of Cdx2 as determined by ‘ESE finder 3.0’. The distribution 
of these motifs is shown relative to the positions of the highly prevalent 31bp and 42bp deletions.  
 
6.3.4 Characterising the gene regulatory network of Cdx2-mutant clones 
In contrast to Cdx2 knockdown cells, some Cdx2 mutant clones can be maintained 
for a few passages. However, cell morphology indicates that some clones are 
unstable and contain terminally differentiated cells. One potential explanation for the 
longer survival of mutant clones, especially those with frameshift and larger 
deletions, is that these clones use transcriptional adaptations. Upon knockout of a 
gene, it is known that homologous genes can become misregulated in an apparent 
attempt to compensate for the loss of the mutated gene (reviewed in Kafri et al., 
2009). However, as these characterised mutations either do not introduce 
frameshifts or do not induce a premature termination codon until the last exon, it is 




unlikely that Cdx2 transcripts would undergo nonsense mediated decay (NMD) 
(Lindeboom et al., 2016). NMD is thought to be required for transcriptional adaptation 
(El-Brolosy et al., 2019).  
 
Nonetheless, Cdx2 has two homologs: Cdx1 and Cdx4. Although neither homolog is 
expressed in the trophoblast lineage, work completed by Niwa et al (2005) 
demonstrated that overexpression of Cdx4, but not Cdx1, can transdifferentiate 
mESCs to TSC-like cells (Niwa et al., 2005). Given this, it is possible that Cdx2 
mutant clones may survive because of genetic compensation. To test this 
hypothesis, I examined the expression of Cdx2, using primers upstream or 
downstream of exon 2 in order to pick up alternative spliced variants, as well as Cdx1 
and Cdx4 (Figure 6.8).  
 
 
Figure 6.8: Relative expression of Cdx2 in Cdx2-mutant clones is similar to wild-type expression. 
qRT-PCR analysis of Cdx2 5’ and 3’ of exon 2 and Cdx1 in compound heterozygous (CH), frameshift (FS) 
and large deletion (LD) Cdx2-mutant clones and 5 wild-type (WT) control clones, outlined in Table 6.2. Each 
data point represents a single clone. Gene expression was normalised to Gapdh. Significance determined 
by two-way ANOVA test: * p0.0332. Error bars show SD.  
 
Cdx2 expression in edited clones was largely consistent with that observed for wild-
type clones (Figure 6.8a-b). Given the absence of nonsense mediated decay for 
Cdx2 transcripts in mutant clones, it was unlikely that transcriptional adaptation 
would occur (Lindeboom et al., 2016). In keeping with this, Cdx1 expression was 
negligible and unchanged between wild-type and mutant clones (Figure 6.8c) and no 
Cdx4 transcripts were detected in either wild-type or mutant clones (data not shown). 
It is possible, although unlikely, that other untested homeobox transcription factors 
may be upregulated to compensate for the absence of Cdx2 instead.  
 





Figure 6.9: Trophoblast stem cell marker gene expression in Cdx2-mutants. qRT-PCR analysis for 
TSC marker genes in compound heterozygous (CH), frameshift (FS) and large deletion (LD) Cdx2-mutant 
clones and 5 wild-type (WT) control clones, outlined in Table 6.2. Each data point represents a single clone. 
Gene expression was normalised to Gapdh. Significance determined by two-way ANOVA test: * p0.0332, 
** p0.0021, *** p0.0002, **** p0.0001. Error bars show SD.  
 
Next, I asked whether the expression of other trophoblast stem cell markers was 
altered. Elf5 was significantly downregulated in all mutant clones over WT controls 
(Figure 6.9a). All Rossant-GFP mutants, irrespective of the mutation type, showed a 
significant reduction in Eomes expression, but INX mutant clones did not (Figure 
6.9b). Esrrb expression was unchanged in all mutant clones (Figure 6.9c). Gata3 
and Tfap2c are upregulated after both short-term (Chapter 4.3, Figure 4.4c) and 
long-term Cdx2 knockdown (Chapter 5.1, Figure 5.2) and, although not significant in 
most cases, the same is true for most Cdx2 mutant clones, irrespective of their 
mutation (Figure 6.9c,d). In sum, several core TSC marker genes change in 
expression, but only Elf5 expression is universally affected in all clones. 
 
To confirm that Cdx2 mutations drive TSCs to differentiate into parietal trophoblast 
giant cells (p-TGCs), as in Cdx2 knockdown, I examined the expression of TGC 
markers (Figure 6.10). The pan-TGC marker Hand1 and mature TGC markers 
Prl3d1, Prl3d3 and Prl2c2 were upregulated in most mutant clones. However, this 
was not statistically significant because their expression was highly variable between 
mutant clones (Figure 6.10a-d), probably caused by the diverse range of phenotypes 




between clones (Table 6.2). Ctsq, a marker of sinusoidal TGCs (s-TGCs) and 
channel TGCs (Ch-TGCs), was significantly upregulated in both ‘large deletion’ 
Rossant-GFP clones, but its expression was low in comparison to other TGC marker 
genes (Figure 6.10e). Therefore, the upregulation of Ctsq in these clones may not 
be biologically relevant. Overall, the co-expression of all p-TGC marker genes and 
absence of Ctsq expression indicates that Cdx2-mutants differentiate into p-TGCs.  
 
 
Figure 6.10: Parietal trophoblast giant cell markers are upregulated in Cdx2-mutant clones. qRT-PCR 
analysis for TGC marker genes in compound heterozygous (CH), frameshift (FS) and large deletion (LD) 
Cdx2-mutant clones and wild-type (WT) control clones. Co-expression of Prl3d1, Prl3d3, and Prl2c2 and 
absence of Ctsq expression marks p-TGCs. Each data point represents a single clone. INX clones are shown 
in blue and Rossant-GFP are shown in red. Gene expression was normalised to Gapdh. Significance 
determined by two-way ANOVA test: **** p0.0001. Error bars show SD.  
 
Next, I asked whether the expression levels of other trophoblast lineage markers 
were dysregulated in Cdx2 mutant clones. Both the syncytiotrophoblast-I (Syn-I) 
progenitor marker Snai1, and Syn-I marker Syna, were upregulated in some, but not 
all, Cdx2 mutant clones (Figure 6.11a-b). This upregulation was more consistent and 
statistically significant in Rossant-GFP mutant clones than in INX mutant clones. 
Both Syna and Snai1 expression increased to a level comparable to that observed 
in Cdx2 knockdown TSCs and in growth factor withdrawal differentiated cells (Figure 
6.11, Figure 5.2). This data suggests that mutant clones may have acquired some 
Syn-I fate, but the TGC phenotype was more prominent.  





Figure 6.11: Cdx2-mutant clones do not progress through a progenitor fate as they differentiate. qRT-
PCR analysis of Syncytiotrophoblast-I (Syn-I) marker genes Snai1 and Syna, progenitor marker Ascl2 and 
spongiotrophoblast and progenitor marker Tpbpa. Analysis was performed in compound heterozygous (CH), 
frameshift (FS) and large deletion (LD) Cdx2-mutant clones and 5 wild-type (WT) control clones, outlined in 
Table 6.2. Each data point represents a single clone. Gene expression was normalised to Gapdh. 
Significance determined by two-way ANOVA: ** p0.0021, *** p0.0002, **** p0.0001. Error bars show SD.  
 
In Chapter 5, I showed that the progenitor marker genes Ascl2 and Tpbpa were not 
upregulated after short-term nor long-term Cdx2 knockdown (Chapter 3, Figure 5.2, 
Figure 5.8c). This suggests that Cdx2 knockdown cells do not progress through a 
typical progenitor fate as they differentiate. In contrast to Cdx2 knockdown, several 
Rossant-GFP Cdx2 mutant clones, upregulated Ascl2 over WT levels (Figure 6.11c). 
Tpbpa, also a marker of the spongiotrophoblast lineage, was not expressed in WT 
clones of either cell line. Almost all Cdx2 mutant clones upregulated Tpbpa, but this 
was low and not statistically significant in most cases. However, both Rossant-GFP 
large deletion (LD) mutant clones significantly upregulated Tpbpa expression (Figure 
6.11d). These Rossant-GFP LD clones were also those that uniquely upregulated 
Ctsq expression (Figure 6.10e) indicating that there may be something unique about 
these clones. In all, given the low expression of Tpbpa and Ascl2 in most Cdx2-
mutant clones and the high levels of differentiation, it can be concluded that TSCs 
lacking Cdx2 do not progress through a progenitor fate during TGC differentiation.  






Figure 6.12: Expression of potential TFAP2C co-factors in Cdx2 mutants. qRT-PCR analysis was 
performed in compound heterozygous (CH), frameshift (FS) and large deletion (LD) Cdx2 mutant clones 
and 5 wild-type (WT) control clones, outlined in Table 6.2. Each data point represents a single clone. 
Significance determined by two-way ANOVA: * p0.0332, ** p0.0021. Error bars show SD. 
 
Sites of increased accessibility, which was attributed to TFAP2C binding, are 
different between short-term Cdx2 knockdown and growth factor withdrawal induced 
differentiation (-GF). Motif analysis attributed this to different transcription factor 
and/or co-factor binding. Two such motifs, the Jun-AP1 and CEBP motifs, are 
uniquely enriched in Cdx2 knockdown and growth factor withdrawal conditions, 
respectively (Chapter 5.2, Figure 5.5). Cebpa, also a marker of the 
syncytiotrophoblast-II (Syn-II) lineage, was upregulated in the absence of growth 
factors but downregulated in transient Cdx2 knockdown (Chapter 5.3, Figure 5.7) 
(Simmons et al., 2008). Few INX Cdx2 mutant clones expressed Cebpa beyond the 
range observed in WT cells (Figure 6.12a). In Rossant-GFP Cdx2 mutants, Cebpa 
was upregulated in one clone from each genotype, but its expression is also more 
variable in Rossant-GFP WT clones (Figure 6.12a). In contrast, Jun is upregulated 
after both short-term Cdx2 knockdown and differentiation by growth factor withdrawal 
(Chapter 5.3, Figure 5.8). All Cdx2 mutant clones upregulated Jun expression over 
wild-type clones, but this was not significant (Figure 6.12b). Further work is required 
to determine whether other transcription factors, whose motifs are differentially 
enriched in sites of gained accessibility between Cdx2 knockdown and growth factor 
withdrawal conditions, are also differentially expressed in Cdx2 mutant clones.  
  




6.4 CRISPR clones reveal the importance of Cdx2 to the 
trophoblast stem cell gene regulatory network 
The work described above shows that the transcriptional profiles of Cdx2 mutant 
clones and long-term Cdx2 knockdown are similar. In both cases, the TSC marker 
genes Elf5 and Eomes are downregulated, whereas Gata3, Tfap2c and several TGC 
markers are upregulated. However, the expression of these dysregulated genes 
varied between Cdx2 mutant clones, perhaps reflecting their heterogenous 
morphological appearance (Table 6.2). I next explored whether there are any 
correlations between the changes in expression of analysed genes that could explain 
why some clones continue to proliferate whilst others differentiate (Figure 6.13).  
 
Those Cdx2 mutant clones that expressed small amounts of Cdx1 are not those that 
downregulated Cdx2, nor those that expressed alternative splicing variants of Cdx2 
(underlined, Figure 6.13). Therefore, the continued survival of Cdx2 mutant clones 
cannot be explained by genetic compensation from another Cdx family member.  
 
Rossant-GFP Cdx2 mutant clones that most significantly downregulated Elf5 tended 
to downregulate Eomes more, downregulate Esrrb less and upregulate Gata3 and 
Tfap2c the most (Figure 6.13). This trend is either not present or is less obvious in 
INX clones, perhaps representing biological difference between these TSC lines. 
Furthermore, those mutant clones that downregulated Elf5, Eomes, and Esrrb the 
most also showed the strongest upregulation of markers of differentiation, including 
p-TGC markers Prl3d1, Prl2c2 and Prl3d3, the spongiotrophoblast marker Tpbpa 
and Syn-I associated markers Syna and Snai1 (Figure 6.13). Jun upregulation is also 
predictive of TGC marker upregulation (Figure 6.13), perhaps indicating that its 
expression required during TGC differentiation as predicted in Chapter 5. 
 
Given that most TSC marker genes are not expressed in differentiating cells, this 
observed correlation in gene expression is not surprising. Cdx2 mutant clones are, 
therefore, heterogeneous populations in which the expression of TSC marker genes 
and differentiation marker genes changes depending on the rate at which they are 
differentiating.  





Figure 6.13: Patterns in differential gene expression between Cdx2-mutant and WT clones may 
explain the observed heterogeneity in their differentiation. qRT-PCR data for core trophoblast genes 
displayed as Log2 fold change in normalised expression over average expression in the corresponding cell 
line WT clones. Those trophoblast lineages assayed are trophoblast stem cells (blue), progenitors (purple), 
spongiotrophoblast (orange), syncytiotrophoblast-I (red) and trophoblast giant cell (green). Motifs for Cebpa 
and Jun are differentially enriched at sites of gained accessibility after short-term Cdx2 knockdown and 
differentiation by growth factor withdrawal. Log2 fold change is displayed on different scales for different 
marker groups. 




As the TSC markers Elf5, Eomes and Esrrb are not expressed in differentiated TSCs, 
it is difficult to know whether their downregulation in Cdx2 mutant clones occurred in 
all cells or just those that were differentiating. To examine this, immunofluorescence 
was performed for multiple TSC marker genes on an exemplar Cdx2 mutant clone 
(INX-FS-5) and a wild-type clone (INX-WT-2) (Figure 6.14).  
 
The expression of CDX2 was determined in these clones using two antibodies in 
immunolabelling assays. Clone INX-FS-5 is homozygous for a 31bp deletion and 
does not express an alternatively spliced variant (Table 6.2). The first CDX2 
antibody, used to generate ChIP-seq libraries in Chapter 4 (A300-691A, Bethyl), 
recognises an epitope of CDX2 between residues 250 and 300 of human CDX2. As 
this epitope is downstream of the 31bp deletion in INX-FS-5, it would be unlikely to 
recognise the frameshift downstream of this deletion. Low-level signal was observed 
using the CDX2 Bethyl antibody (Figure 6.14). Although predicted to recognise a 
specific epitope, the CDX2 Bethyl antibody is a polyclonal antibody, and may 
recognise other epitopes with lower efficiency. The epitope recognised by the second 
CDX2 antibody (CDX2-88, Abcam) is not disclosed by any distributor. No signal was 
seen when using this CDX2-88 antibody (Figure 6.14).   
 
To mark differentiated cells, clones were stained for the TGC marker HAND1. Like 
all other TGC marker genes, Hand1 expression was highly variable between clones 
(Figure 6.10a). No Cdx2 mutant clone upregulated Hand1 more than 20-fold over 
WT controls and only half upregulated Hand1 over 5-fold (Figure 6.10a). Despite the 
modest increase in Hand1 expression (1.7-fold more than in WT control cells), INX-
FS-5 contained many cells resembling TGCs: HAND1 expressing cells with large 
nuclei and prominent actin stress fibres. In contrast, the wild-type control, INX-WT-
2, did not express HAND1, nor did this clone possess any other phenotypic hallmarks 
of TGCs (Figure 6.14). 
 





Figure 6.14: TSC marker gene expression is significantly perturbed at the protein level in Cdx2-
mutants. Immunofluorescence was performed for TSC marker genes (GATA3, CDX2, EOMES, TFAP2C) 
and the TGC marker gene HAND1 in a Cdx2-mutant clone (INX-FS-5) and wild-type control (INX-WT-2). 
Phalloidin staining was used to assess the presence of actin stress fibres, a phenotypic hallmark of TGCs.  




Interestingly, the expression of TSC markers at the transcript level does not reflect 
their protein expression. In contrast to its 2.3-fold upregulation at the transcript level 
in INX-FS-5, GATA3 is downregulated in all cells relative to INX-WT-2 (Figure 6.13, 
Figure 6.14). Tfap2c is upregulated 1.7-fold in INX-FS-5 over WT cells (Figure 6.13). 
Cdx2 mutant cells that resemble TGCs expressed more TFAP2C than other cells, 
indicating that it is upregulated during the differentiation of Cdx2 mutant cells as in 
Cdx2 knockdown conditions. However, TFAP2C is lower in all other cells in this Cdx2 
mutant population than in INX-WT-2 cells, suggesting its expression is lower in 
proliferating Cdx2 mutant cells than wild-type cells (Figure 6.14). Eomes mRNA 
expression in most INX mutant clones was within the range of expression observed 
in WT control cells (Figure 6.9b). However, EOMES is almost completely lost in all 
INX-FS-5 cells (Figure 6.14). In all, the data suggests that the expression of core 
TSC genes at the protein level are significantly affected when Cdx2 is targeted. 
  





CRISPR-Cas9 gene targeting at the Cdx2 locus using two gRNAs in combination 
was efficient and reproducible, generating consistent mutations between 
experiments and cell lines. Cdx2 mutant alleles were outcompeted by WT alleles in 
polyclonal populations, probably due to an increase in the number of wild-type cells 
at the expense of clones containing mutations. Unexpectedly, given the phenotype 
in long-term Cdx2 knockdown, it was possible to maintain Cdx2-mutant clonal lines 
in culture for several passages. Despite this, the outcome of Cdx2 knockdown and 
knockout are comparable, with both driving differentiation into p-TGCs without 
progressing through a progenitor fate in both the INX and Rossant-GFP cell lines.  
 
It is possible to predict which clones contain Cdx2 mutations by their phenotypic 
appearance, with most mutant clones showing sporadic differentiation within the first 
few passages. Of those clones that were successfully genotyped, 59% of clonal lines 
contained two or more Cdx2 mutant alleles in different ratios, suggesting that some 
populations were either not clonal or not diploid. Although normal karyotypes have 
been found in TSC lines at early passages, aneuploidy is prevalent in TSC lines over 
passage 40 (Tanaka et al., 1998, Kubaczka et al., 2014), as are both the INX and 
Rossant-GFP TSC lines used in this thesis (personal correspondence with Daniel 
Snell). Cdx2 mutant populations also differentiate into TGCs and are, therefore, 
undergoing endoreduplication. Proportions of the genome are commonly under- or 
over-replicated as a result of endoreduplication, although such copy number variants 
have not been reported for the Cdx2 locus (Hannibal and Baker, 2016, Hannibal et 
al., 2014). Whether clonal or otherwise, the mutants used for subsequent qRT-PCR 
and IF analyses contained no WT Cdx2 alleles.  
 
The two most common mutations in polyclonal populations were also found in 71% 
of all successfully genotyped clones: a 42bp deletion and a 31bp deletion. The 42bp 
deletion would result in the loss of 14 amino acids from the conserved homeobox 
domain, namely the second helix and loop immediately adjacent to the DNA binding 
third helix. In contrast, the 31bp deletion results in a frameshift and is predicted to 
generate a truncated protein 42 amino acids smaller than wild-type CDX2 that is non-
functional. All of the clones validated express Cdx2 transcripts to similar extents as 




WT clones. Immunofluorescence on a 31bp deletion mutant using two different anti-
CDX2 antibodies validated that CDX2 expression is significantly reduced or absent 
and that 31bp deletion homozygous mutant clones are Cdx2 knockout TSC lines.  
 
Given that all validated Cdx2 mutant clones largely contain these two mutations, the 
heterogeneity in the rate at which they differentiate is surprising. Rossant-GFP Cdx2 
mutant clones cannot be maintained for the same number of passages as INX for 
the same mutation. This suggests that they cannot compensate for loss of Cdx2 to 
the same extent. One observed difference between the cell lines is that half of all 
INX Cdx2-mutant clones express at least one alternatively spliced variant of Cdx2, 
whereas no Rossant-GFP clones do. Alternative splicing may occur due to disruption 
of exonic splicing enhancers in the regions deleted in mutants. Yet, why this only 
occurs in INX clones and what the function and/or significance of this observation is 
remains unclear.  
 
Another potential explanation is that Eomes expression was shown to be more 
consistently and significantly downregulated in Rossant-GFP clones than INX 
clones. A core TSC marker gene, Eomes is known to work in tandem with Elf5 and 
Tfap2c to maintain a subsection of TSC gene regulatory network (Latos et al., 
2015b). In combination with the significant downregulation in Elf5 observed in both 
cell lines, this difference in Eomes expression may explain why Rossant-GFP clones 
are inherently less capable of maintaining proliferation in the absence of Cdx2. 
Despite this apparent difference in Eomes transcript expression between INX and 
Rossant-GFP clones, EOMES protein staining was negligible in a homozygous 31bp 
deletion INX clone.  
 
Both Gata3 and Tfap2c are upregulated in most mutant clones, in agreement with 
published literature showing that they are upregulated in differentiation (Latos et al., 
2015b, Ralston et al., 2010). Although Gata3 transcript increased, GATA3 protein 
was significantly reduced in an INX Cdx2-mutant clone. TFAP2C staining was lower 
in the proliferating cells in the INX Cdx2-mutant clone, but its expression is similar or 
higher in cells displaying morphological characteristics of differentiation. This may 
indicate an essential role of TFAP2C in driving differentiation towards TGCs as 




observed in Cdx2 knockdown. In all, this shows that the GRN of Cdx2 mutant clones 
is significantly affected.  
 
Although Elf5 and Eomes may not be immediately downstream of Cdx2, given that 
their expression is unaffected in transient Cdx2 knockdown, the loss of Cdx2 has a 
significant effect on their expression. However, given the heterogeneity of transcript 
expression levels and morphological appearance of clones, further immunostainings 
on other mutant clones are required to confirm that differences in the GRN are 
universal to TSCs when Cdx2 is deleted.  
 
Given the described changes to multiple TSC marker genes described above, how 
Cdx2-mutant cells compensate and continue to self-renew for several passages is 
unclear. One potential hypothesis tested was that transcriptional adaptation, known 
to occur when mutant transcripts are expressed and rapidly undergo nonsense 
mediated decay, might be important in driving compensation (El-Brolosy et al., 2019). 
As Cdx2 transcripts do not undergo nonsense mediated decay, it was unsurprising 
that Cdx1 and Cdx4 expression was negligible or absent. Whilst there was no link 
between reduction in Cdx2 transcript expression and an upregulation of Cdx1, there 
are other genes with similar sequence homology to Cdx2 that were not tested. 
However, genetic compensation is unlikely to be the reason for the prolonged 
survival of Cdx2 mutant clones. 
 
Due to the high heterogeneity in differentiation phenotype, I have not been able to 
conclude how Cdx2-mutant clones compensate for the loss of Cdx2 and subsequent 
changes to the TSC GRN. To more accurately assess this, an unbiased screen of 
the entire transcriptome is required.  
 




Chapter 7. Discussion 
In this thesis I have examined the short- and long-term consequences of reduced 
Cdx2 expression in trophoblast stem cells. I have also addressed the role of Cdx2 
within the established trophoblast gene regulatory network. The key finding of my 
work is that Cdx2 plays a significant role in maintaining the balance of the TSC gene 
regulatory network and that it prevents direct TSC differentiation into parietal 
trophoblast giant cells. Cdx2 is, therefore, a gatekeeper of mouse TSC potency.  
 
Cdx2 and the trophoblast stem cell gene regulatory network 
Transient Cdx2 knockdown in trophoblast stem cells, to about 60% of control levels, 
perturbs the chromatin landscape and transcriptome but has no effect on the 
expression of most TSC marker genes. To some extent, this lack of effect is 
unsurprising, because even in normal TSCs, expression of Cdx2, as well as that of 
Eomes and Gata3, declines with time in culture. One possibility is that Cdx2 
knockdown causes TSCs to adopt a more differentiated cell type only transiently 
(Frias-Aldeguer et al., 2019).  
 
In contrast, long-term reduction or loss of Cdx2 expression affects the expression of 
most TSC marker genes (Latos et al., 2015a) and drives differentiation into parietal 
trophoblast giant cells. Both Elf5 and Eomes are downregulated after prolonged 
Cdx2 loss, while Tfap2c and Gata3 are upregulated. These results suggest that Cdx2 
is important for long-term maintenance of the TSC gene regulatory network. 
 
Despite their upregulation at the transcript level, TFAP2C and GATA3 proteins are 
expressed at lower levels in proliferating cells of surviving Cdx2 mutant clones than 
in their wild-type counterparts. What allows Cdx2 mutant clones to survive? It is 
possible that they adopt a distal extraembryonic ectoderm fate (Cdx2 is not 
expressed in distal extraembryonic ectoderm), but the lack of Elf5 and Eomes 
expression in Cdx2 mutant clones suggests this is unlikely (Donnison et al., 2015). 
Another possibility is based on the observation that Esrrb expression fails to be 
downregulated in these surviving mutant clones. ESRRB blocks the expression of 
differentiation markers (Latos et al., 2015a), and this may enable Cdx2 mutant clones 
to self-renew. More work is required to explore the role of ESRRB in Cdx2 mutants. 




Not all Cdx2 mutant clones are the same  
TSCs are heterogeneous and can adopt a range of trophoblast stem cell fates (Frias-
Aldeguer et al., 2019). Cdx2 mutant clones, even those with the same mutations in 
the same TSC line, differ with respect to their ability to self-renew or differentiate. 
The behaviour of a Cdx2 clone may depend on the type of TSC that has been 
mutated, with one trophoblast fate responding differently to Cdx2 loss than another. 
If the proportions of TSC subpopulations are different between different cell lines, 
this may provide an explanation of why clones from the INX cell line survive longer 
than Rossant-GFP clones. To address this, RNA-seq analysis might be required to 
provide a global insight into clone heterogeneity and their compensatory 
mechanisms for the loss of the TSC GRN. 
 
Trophoblast giant cells differentiated by Cdx2 loss are not derived from a 
progenitor population 
When they move away from growth factor signals in the extraembryonic ectoderm, 
TSCs differentiate as spongiotrophoblast and TGCs via progenitors in the 
ectoplacental cone (EPC) that are marked by Ascl2 and Tpbpa (Guzman-Ayala et 
al., 2004, Hughes et al., 2004, Latos and Hemberger, 2016). However, 50% of 
secondary parietal trophoblast giant cells come from non-Tpbpa expressing cells 
(Simmons et al., 2007) and embryos lacking Ascl2 are nevertheless able to form p-
TGCs (Guillemot et al., 1994). This indicates that p-TGCs can form in vivo without 
progressing through an EPC fate. 
 
Ascl2 and Tpbpa are not significantly upregulated when Cdx2 expression is reduced 
or abolished, suggesting that the TSCs that differentiate as a result of Cdx2 loss do 
not progress through an EPC progenitor fate. The absence of Ascl2 expression is of 
particularly significance because Ascl2 antagonises the pan-TGC marker Hand1 
(Scott et al., 2000), which itself is upregulated after transient Cdx2 knockdown. When 
overexpressed in TSCs, Hand1 causes about 30% of cells to differentiate towards 
TGCs (Scott et al., 2000), but this differentiation is significantly less efficient than the 
homogeneous differentiation observed in long-term Cdx2 knockdown. Furthermore, 
HAND1 is not expressed in proliferating Cdx2 mutant cells, indicating that Hand1 
upregulation is not the driver of direct TGC differentiation when Cdx2 expression is 
reduced. Instead, I propose that a relationship between CDX2 and TFAP2C, direct 




or otherwise, is essential to modulate this direct differentiation into p-TGC. Cdx2 
knockdown in TSCs provides an in vitro model system to characterise this 
relationship and direct p-TGC differentiation.  
 
Tfap2c: the multipurpose trophoblast transcription factor  
TFAP2C is a versatile transcription factor that has distinct roles at different stages of 
trophoblast development (Kuckenberg et al., 2012, Choi et al., 2012, Cao et al., 
2015, Latos et al., 2015b, Nelson et al., 2017). It is a core TSC transcription factor 
that is expressed in stoichiometric ratios with Eomes and Elf5 in TSC. In TSCs, 
interaction is stronger between ELF5 and EOMES proteins, but all three transcription 
factors bind together around TSC marker genes (Latos et al., 2015b). During 
differentiation by growth factor withdrawal in vitro, Tfap2c and Elf5 are upregulated, 
whilst Eomes is downregulated (Latos et al., 2015b). As a result, during 
differentiation ELF5 preferentially interacts with TFAP2C, globally increasing 
chromatin accessibility by binding near differentiation-associated genes (Latos et al., 
2015b, Nelson et al., 2017). Interestingly, CDX2 also directly interacts with EOMES 
in TSCs (Latos et al., 2015a), but how relevant this is to the balance between 
stemness and differentiation is unclear.  
 
As is observed following growth factor withdrawal, chromatin accessibility increased 
after transient Cdx2 knockdown. Increased accessibility in both cases is attributed to 
TFAP2C, but the sites themselves differ between Cdx2 knockdown and growth factor 
withdrawal differentiation. Motif analysis suggested that these differences are driven 
by different co-factors. In keeping with this, although most of the genes dysregulated 
by Cdx2 knockdown are affected by growth factor withdrawal, 31% of these genes 
changed in opposite directions. Interestingly, neither of the known TFAP2C 
interactors, Elf5 and Eomes, were dysregulated in transient Cdx2 knockdown cells 
and their motifs were not identified in sites of gained accessibility. Instead, Cebpa 
and Jun were identified as candidate TFAP2C co-factors under growth factor 
withdrawal and Cdx2 knockdown conditions, respectively. In all, TFAP2C appears to 
be repurposed depending on what co-factors are available, either maintaining 
undifferentiated cells or driving differentiation into different fates.   
 




I confirmed that half of those sites that gained accessibility upstream of the Hand1 
locus in Cdx2 knockdown cells are functional enhancers for the Hand1 promoter. 
TFAP2C binds to these sites, as shown by published TFAP2C ChIP-seq data (Latos 
et al., 2015b), but its functional requirement for the activity of these enhancers 
requires further validation. As several of these enhancers behave differently in the 
presence and absence of growth factors, context is essential for regulating TFAP2C 
behaviour. Therefore, I hypothesise that both the transcriptional changes that occur 
after Cdx2 knockdown and the change in the balance of CDX2 and TFAP2C 
expression alters the behaviour of TFAP2C. As a result, reduced Cdx2 expression 
drives the observed direct differentiation towards p-TGCs. To understand why 
TFAP2C behaviour changes in different trophoblast contexts, one could use mass 
spectrometry to determine the factors that TFAP2C interacts with under stem cell, 
Cdx2 knockdown and growth factor withdrawal differentiation conditions.  
 
CDX2 is repurposed from pre- to post-trophoblast establishment 
Cdx2-null embryos are incapable of forming trophoblast outgrowths (Strumpf et al., 
2005), confirming that Cdx2 is essential for reinforcing commitment to the trophoblast 
fate. As shown in this thesis, Cdx2 is essential for maintaining undifferentiated TSCs, 
suggesting that Cdx2 also plays a key role in the established trophoblast fate.  
 
By combining CDX2 ChIP-seq data with ATAC-seq data in TSCs, I showed that most 
CDX2 binding sites are located in regions of open chromatin in TSCs, suggesting 
that CDX2 is not a pioneer factor. There are, however, a small number of CDX2 
binding sites which are inaccessible in TSCs. Bearing this in mind, it is possible that 
CDX2 is a pioneer factor in TSCs, although this is unlikely given that TSCs are a 
stable cell type and Cdx2 is downregulated as TSCs differentiate.  
  
To address the possibility that CDX2 plays different roles pre- and post-trophoblast 
commitment, I separated CDX2 binding sites in established TSCs based on their 
accessibility in mESCs. CDX2 binding sites that are ‘accessible’ in mESCs were 
found around genes expressed in early development and are highly enriched for 
multiple TEAD family of motifs as well as SOX, ESRRB and homeobox. TEAD4 
regulates Cdx2 expression during trophectoderm establishment (Nishioka et al., 
2009, Rayon et al., 2014) and directly interacts with CDX2 in TSCs (Latos et al., 




2015a). Since mESC-accessible sites are unaffected by Cdx2 knockdown, CDX2 
binding here is likely recruited by TEAD4. I, therefore, hypothesise that these sites 
represent binding targets of CDX2 during trophectoderm establishment that remain 
bound in TSCs.  
 
CDX2 binding sites that were inaccessible in mESCs were located around genes 
expressed in later embryonic development. Although they are highly enriched for the 
homeobox motif, the accessibility of most of these sites is unaffected by Cdx2 
knockdown. This is largely due to the enrichment of other TSC maker gene motifs at 
sites that are accessible in TSCs and the enrichment of homeobox motifs at poorly 
accessible or inaccessible sites in TSCs. In all, by separating CDX2 binding sites 
based on their accessibility in mESCs and TSCs, I have shown that CDX2 binding is 
highly opportunistic or recruited by other factors, perhaps explaining why so few 
CDX2 binding sites lose accessibility in Cdx2 knockdown. Therefore, while a subset 
of CDX2 binding sites may be critical to maintain stemness in TSCs, more work is 
required to understand the relevance of CDX2 binding at most of its binding sites. 
 
Further work is also required to understand whether CDX2 has different binding sites 
at different stages of trophoblast lineage development in vivo that can explain its 
different role pre- and post-trophoblast commitment. Although there are no ATAC-
seq libraries available for the trophectoderm and the extraembryonic ectoderm, these 
would be invaluable if we are to better understand the trophoblast lineage. Using 
these libraries, differentially accessible chromatin regions that overlap with CDX2 
binding sites could be validated using previously established ChIP-qPCR protocols 
for mouse blastocysts (Home et al., 2009).  
 
TSC-like cells are not real TSCs 
Whether transdifferentiation of mESCs generates bona fide TSCs is contentious 
because the resulting TSC-like cells have distinct transcriptomes, DNA methylation 
patterns and chromatin landscape profiles from bona fide TSCs (Cambuli et al., 
2014, Rhee et al., 2017). Bona fide TSC have highly similar chromatin accessibility, 
even when different cell lines and analysis pipelines are used (Nelson et al., 2017). 
Therefore, comparing the chromatin landscape is a robust approach to validate TSC 
identity.  




In this thesis, I re-analysed published CDX2 ChIP-seq libraries from TSC-like cells 
made by repressing Oct4 in mESCs (Adachi et al., 2013) and compared them to 
libraries I made from embryo outgrowth-derived TSCs. CDX2 binding in TSC-like 
cells was different to that in embryo-outgrowth derived TSCs. Furthermore, the 
unique CDX2 binding sites in TSC-like cells were inaccessible in both bona fide 
TSCs and in the mESC line from which TSC-like cells were derived from. 
Additionally, over 78% of CDX2 binding in TSC-like cells derived by overexpressing 
Cdx2 in mESCs are unique from any other CDX2 ChIP-seq library analysed in this 
thesis (Rhee et al., 2017). Whilst it is possible that some CDX2 binding sites in TSC-
like cells are uniquely bound in trophectoderm specification, the majority are likely 
biologically irrelevant. As such, caution must be taken in drawing conclusions from 
TSC-like cells.  
 
Conclusion 
In summary, my work confirms previous observations that loss of Cdx2 expression 
in TSCs increases differentiation towards parietal trophoblast giant cells (Latos et al., 
2015a, Niwa et al., 2005). However, in contrast to previous work, I show that this 
differentiation is homogenous, avoids the progenitor fate, and is mediated by the 
upregulation of Tfap2c and other co-factors. To the best of my knowledge, this is the 
first time Tfap2c and Cdx2 have been associated with the direct differentiation of 
stem cells into parietal trophoblast giant cells. The direct differentiation of TSCs to 
TGCs had been previously shown in vivo, both from the mural trophectoderm and 
extraembryonic ectoderm, but is poorly understood. Here, I provide a potential 
mechanism for this phenomenon. As the behaviour of TFAP2C when Cdx2 
expression is perturbed is different to others contexts, I have provided new insight 
into the importance of the balance of CDX2 and TFAP2C expression and shown that 
this dynamic represents one of the main functions of CDX2 in TSCs. This is distinct 
from the role of CDX2 in repressing the pluripotency network during trophectoderm 
establishment, a role CDX2 probably exerts by its interaction with TEAD4. Finally, I 
showed that Cdx2 mutant clones can be maintained in vitro for several passages but 
are heterogeneous and predisposed to differentiate into p-TGCs. Cdx2 mutant 
clones may be used to further our understanding of the plasticity in the trophoblast 






Appendix A: Cell Culture Media and Solutions 
 
Table A-1: Components of cell culture media used in this thesis 
 
  
Medium Component Source Product Code Volume Final Conc. 
































Peprotech 100-31 1.5 μg/mL






























Table A-2: Components of the solutions used in this thesis  
  
Solution Component Concentration Chapter
KT lysis buffer Tris-HCl (pH9.1) 67 mM 2.2.1
(NH4 )2 SO4 15 mM
MgCl2 3.5 mM
Bovine serum albumin 150 μg/mL
Proteinase K 800 μg/mL
Triton-X100 0.50%
ChIP Cell lysis buffer Tris-HCl (pH8.0) 10 mM 2.4.1.1
NaCl 10 mM
IGEPAL CA-630 0.20%
CEWB1 buffer Tris-HCl (pH8.0) 10 mM 2.4.1.1
EDTA 1 mM









TEN buffer Tris-HCl (pH8.0) 10 mM 2.4.1.1
EDTA 1 mM
NaCl 150 mM
SDS Elution buffer Tris-HCl (pH8.0) 50 mM 2.4.1.1
EDTA 1 mM
Sodium dodecyl sulphate (SDS) 1%








Appendix B: Oligonucleotide Sequences 
 
  
Chapter Oligo Sequence Application
2 mCIP_ F CTCCCCAGGGGGATCCACGCCGCCACCATGGCCATCATCAAGGAG Cloning
2 mCIP_R GGTCTTAAAGGTACCTCAGGCACCGGGCTTGCGGG Cloning
2 Hand1_Prom_209bp_F GATCCTCGAGATAAAACTTGGGACCGCCAC Cloning
2 Hand1_Prom_209bp_R GATCAAGCTTAGGCTGGAGATGACACGAAG Cloning
2 Hand1_Prom_283bp_F GATCCTCGAGAGAGGGGAGGGACATAGGC Cloning
2 Hand1_Prom_283bp_R GATCAAGCTTAGGCTGGAGATGACACGAAG Cloning
2 Hand1_Prom_673bp_F GATCCTCGAGCTGAAGCAGGGGACCTAAAG Cloning
2 Hand1_Prom_673bp_R GATCAAGCTTAGGCTGGAGATGACACGAAG Cloning
2 Hand1_Enh-A_F GATCGTCGACATAATGGGTGGCCCTTTCC Cloning
2 Hand1_Enh-A_R GATCGTCGACGCCTCCTATCAACCAGGCTAC Cloning
2 Hand1_Enh-B_F TAAGGATCCGTCGACGCATTCTAAGGGATTTTGATGG Cloning
2 Hand1_Enh-B_R AGGGCATCGGTCGACTCAGGGCTGCGAAAACTC Cloning
2 Hand1_Enh-C_F GATCGTCGACTAGAGAGACCACCCCCTGAG Cloning
2 Hand1_Enh-C_R GATCGTCGACCAGTGGAATGCCATGCAG Cloning
2 Hand1_Enh-D_F TAAGGATCCGTCGACGCACTCCTGTCCTTTGTAGGTC Cloning
2 Hand1_Enh-D_R AGGGCATCGGTCGACGAGGAAGAACCTGAAATAAGC Cloning
2 Hand1_Enh-E_F GATCGTCGACAGGAAAGTGGGTTGGTGCT Cloning
2 Hand1_Enh-E_R GATCGTCGACCTTCTATCAGGCTGGGTTGG Cloning
2 Hand1_Enh-F_F GATCGTCGACTGCTTGCCAGAGTTGTGTTT Cloning
2 Hand1_Enh-F_R GATCGTCGACCCTCAGTGTCCCAAAATGGT Cloning
2 Hand1_Enh-C1_F GATCGTCGACGGAGAATCTTCTAGGTCTGTCTGG Cloning
2 Hand1_Enh-C1_R GATCGTCGACCGGGGAGAGAGGAGTAGAATG Cloning
2 Hand1_Enh-C2_F GATCGTCGACCAGAACACGGAAACGAGTTG Cloning
2 Hand1_Enh-C2_R GATCGTCGACTCGGGACCAGCTGTTAATTC Cloning
2 sgRNA_G2a_F CACCGTTAGTCGATACATCACCATC Cloning
2 sgRNA_G2a_R AAACGATGGTGATGTATCGACTAAC Cloning
2 sgRNA_G2b_F CACCGTACACAGACCATCAGCGGC Cloning
2 sgRNA_G2b_R AAACGCCGCTGATGGTCTGTGTAC Cloning
2 sgRNA_G2c_F CACCGCCACACTTGGGCTCTCCGAG Cloning
2 sgRNA_G2c_R AAACCTCGGAGAGCCCAAGTGTGGC Cloning
2 sgRNA_G2d_F CACCGCCTCTCGGAGAGCCCAAGTG Cloning
2 sgRNA_G2d_R AAACCACTTGGGCTCTCCGAGAGGC Cloning
2 sgRNA_G2e_F CACCGTCGATACATCACCATCAGG Cloning
2 sgRNA_G2e_R AAACCCTGATGGTGATGTATCGAC Cloning
2 sgRNA_G2f_F CACCGATGGTCTGTGTACACCACC Cloning
2 sgRNA_G2f_R AAACGGTGGTGTACACAGACCATC Cloning
2 pGL2-Basic_F GGCCTCTTCGCTATTACGC Sanger Sequencing
2 LucNrev CCTTATGCAGTTGCTCTCC Sanger Sequencing
2 RVprimer4 GACGATAGTCATGCCCCGCG Sanger Sequencing
2 EnForKB TGGGAGGTTTTTTAAAGCAA Sanger Sequencing
2 hU6 GACTATCATATGCTTACCGT Sanger Sequencing
2 5to3_Cdx2_F GTCCCTCGCCACCATGTA Sanger Sequencing
2 5to3_Cdx2_R TCCACTCATCTTCTGTCCTCAA Sanger Sequencing
3,4,5,6 Cdx2_5'_F AAACCTGTGCGAGTGGATG qRT-PCR
3,4,5,6 Cdx2_5'_R GCCGCTGATGGTCTGTGTA qRT-PCR
3,4,5,6 Elf5_F GGACTCCGTAACCCATAGCA qRT-PCR
3,4,5,6 Elf5_R TACTGGTCGCAGCAGAATTG qRT-PCR
3,4,5,6 Eomes_F GGAAGTGACAGAGGACGGTG qRT-PCR
3,4,5,6 Eomes_R GGAAGTGACAGAGGACGGTG qRT-PCR
3,4,5,6 Esrrb_F AACAGCCCCTACCTGAACCT qRT-PCR
3,4,5,6 Esrrb_R CTCATCTGGTCCCCAAGTGT qRT-PCR
3,4,5,6 Gata3_F GGGTTCGGATGTAAGTCGAG qRT-PCR
3,4,5,6 Gata3_R CCACAGTGGGGTAGAGGTTG qRT-PCR
3,4,5,6 Tfap2c_F TGCACACAGGGTATTGAAAC qRT-PCR
3,4,5,6 Tfap2c_R CGTCACCCACACAAACTAAA qRT-PCR
3,4,5,6 Ascl2_F TAAGGGCTGAGCACCAGGAC qRT-PCR
3,4,5,6 Ascl2_R CGTACCAGTCAAGGTGTGCTT qRT-PCR







Chapter Oligo Sequence Application
3,4,5,6 Hand1_F CAAGATCAAGACTCTGCGCC qRT-PCR
3,4,5,6 Hand1_R TTAATCCTCTTCTCGCCGGG qRT-PCR
3,4,5,6 Tpbpa_F CCAGCACAGCTTTGGACATCA qRT-PCR
3,4,5,6 Tpbpa_R AGCATCCAACTGCGCTTCA qRT-PCR
3,4,5,6 Snai1_F CACGCTGCCTTGTGTCTG qRT-PCR
3,4,5,6 Snai1_R AGACTCTTGGTGCTTGTGGA qRT-PCR
3,4,5,6 Gapdh_F AATGTGTCCGTCGTGGATCT qRT-PCR
3,4,5,6 Gapdh_R CCTGCTTCACCACCTTCTTG qRT-PCR
4 Cyr61_F AGCAGCCTAAAAAAGGGCA qRT-PCR
4 Cyr61_R GGTATTTCTTGACACTGGAGCA qRT-PCR
4 Htra1_F ACGCCAAGACCTACACCAAC qRT-PCR
4 Htra1_R TCTCCACCACATCAGCAATAA qRT-PCR
4 Plac1_F GCACAAAGCCACGTTTCA qRT-PCR
4 Plac1_R GCATGAAGGCGACTAAGACAG qRT-PCR
4 Mapk13_F AAGCGGACAGGGGAGAAG qRT-PCR
4 Mapk13_R AGGGGTGAAGACATCCAGAA qRT-PCR
4 Bak1_F CAACCCCGAGATGGACAA qRT-PCR
4 Bak1_R TGTGGGCTGAAGCTGTTCT qRT-PCR
4 Cdh5_F ATGAGCCCCCTGTCTTCC qRT-PCR
4 Cdh5_R TGGTCTTGCGGATGGAGT qRT-PCR
4 Itgb3_F GTGGAAGAGCCTGAGTGTCC qRT-PCR
4 Itgb3_R TCCAGATGAGCAGAGTAGCAAG qRT-PCR
4,6 Cdx2_3'_F TCCTGCTGACTGCTTTCTGA qRT-PCR
4,6 Cdx2_3'_R CCCTTCCTGATTTGTGGAGA qRT-PCR
5 Junb_F GCAGCTACTTTTCGGGTCAG qRT-PCR
5 Junb_R TTCATCTTGTGCAGGTCGTC qRT-PCR
5 Fosb_F GCAACCCACCCTCATCTCT qRT-PCR
5 Fosb_R GGGCAGACACAGGTCCAC qRT-PCR
5 Ppard_F AGGAGCTGGGGGATTCTG qRT-PCR
5 Ppard_R CCGTGGGTTTGTCTTCATCT qRT-PCR
5,6 Syna_F CCTCACCTCCCAGGCCCCTC qRT-PCR
5,6 Syna_R GGCAGGGAGTTTGCCCACGA qRT-PCR
5,6 Prl3d1_F GGAGCCTACATTGTGGTGGA qRT-PCR
5,6 Prl3d1_R TCCCTATACACATCTGCGGC qRT-PCR
5,6 Prl3d3_F GGCTCCGGAATGCAATTGTT qRT-PCR
5,6 Prl3d3_R TCCCTATACACATCTGCGGC qRT-PCR
5,6 Prl2c2_F TGCTCCTGGATACTGCTCCT qRT-PCR
5,6 Prl2c2_R TGAGACAAACTGCCGGCTAA qRT-PCR
5,6 Ctsq_F AATTGGCTATGGTTATGTGGGA qRT-PCR
5,6 Ctsq_R TCACACAGTAGGGTATTGGG qRT-PCR
5,6 Cebpa_F ACTAACGGCTGGGGGAAG qRT-PCR
5,6 Cebpa_R CTCTGGGAGGCAGACGAA qRT-PCR
5,6 Jun_F ACGACCTTCTACGACGATGC qRT-PCR
5,6 Jun_R CCAGGTTCAAGGTCATGCTC qRT-PCR
6 MiSeq_Cdx2ex2_1_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAAATGACTCCTGGGTTAGGG MiSeq
6 MiSeq_Cdx2ex2_1_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCATTGAAAGAGCGGCAAAA MiSeq
6 MiSeq_Cdx2ex2_2_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCAAAACTTCTCCTTCCTCCA MiSeq
6 MiSeq_Cdx2ex2_2_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCGCTCTTTCTCTGTCCAAGTG MiSeq
6 MiSeq_Cdx2ex2_3_F TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTGTGAGTGGATATTGTCAACCTG MiSeq









Enhancer Validation Vectors Location in mm10 Size in mm10 Deviation in sequence from mm10
pGL3-basic + 209bp Promoter Chr11:57832121-57831913 209bp Point mutation T→C at position Chr11:57832019
pGL3-enhancer + 209bp Promoter Chr11:57832121-57831913 209bp Point mutation T→C at position Chr11:57832019
pGL3-basic + 283bp Promoter Chr11:57832195-57831913 283bp Point mutation T→C at position Chr11:57832019
pGL3-enhancer + 283bp Promoter Chr11:57832195-57831913 283bp Point mutation T→C at position Chr11:57832019
pGL3-basic + 673bp Promoter Chr11:57832585-57831913 673bp
Point mutation T→C at position Chr11:57832019
Loss of 'acacacacac' prior to Chr11:57832397
pGL3-enhancer + 673bp Promoter Chr11:57832585-57831913 673bp
Point mutation T→C at position Chr11:57832019
Loss of 'acacacacac' prior to Chr11:57832397
283bp Hand1 promoter + Region A Chr11:57850827-57851433 607bp
Insertion of 'GAAG' after position Chr11:57850851
Point mutation T→C at position Chr11:57851044
283bp Hand1 promoter + Region B Chr11:57857626-57857998 373bp
Point mutation G→A at position Chr11:57857662
Point mutation T→C at position Chr11:57857704
Point mutation G→T at position Chr11:57857726
Point mutation C→T at position Chr11:57857731
Point mutation T→C at position Chr11:57857749
Point mutation G→A at position Chr11:57857949
Point mutation G→A at position Chr11:57857961
283bp Hand1 promoter + Region C Chr11:57864343-57865008 666bp
Point mutation C→T at position Chr11:57864754
Point mutation G→A at position Chr11:57864769
Point mutation G→A at position Chr11:57864774
Point mutation A→T at position Chr 11:57864715
Gain of 'CTCTCTCTCTCTCTCT' after Chr 11:57864715 
in string of repetitive TCs
Point mutation T→A at position Chr11:57864508
283bp Hand1 promoter + Region D Chr11:57869180-57869527 349bp
1bp deletion at position Chr11:57869202
Point mutation T→C at position Chr11:57869352
Point mutation G→T at position Chr11:57869478
283bp Hand1 promoter + Region E Chr11:57894913-57895360 448bp
Point mutation A→G at position Chr11:57894978
Point mutation A→Gat position Chr11:57895282
Point mutation T→C at position Chr11:57895125
Point mutation T→C at position Chr11:57895282
Point mutation T→C at position Chr11:57895285
Point mutation T→C at position Chr11:57895310
Point mutation A→C at position Chr11:57895315
Point mutation G→A at position Chr11:57895327
283bp Hand1 promoter + Region F Chr11:57896662-57897162 501bp Point mutation T→C at position Chr11:57896849
283bp Hand1 promoter + Region C1 Chr11:57881044-57881573 538bp
Point mutation A→G at position Chr11:57881130
Point mutation T→A at position Chr11:57881284
1bp deletion at position Chr11:57881285
Point mutation T→C at position Chr11:57881324
Point mutation A→G at position Chr11:57881362
Point mutation G→A at position Chr11:57881433
Point mutation G→T at position Chr11:57881496
283bp Hand1 promoter + Region C2 Chr11:57915883-57916496 589bp
Point mutation A→T at position Chr11:57915930
1bp deletion at Chr11:57916007
Point mutation G→A at position Chr11:57916372
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